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Abstract 
 
Cough is an important protective reflex. Sensory nerve activity mediating cough may 
be enhanced during disease. Current antitussives possess little clinical efficacy, 
therefore research is needed to investigate the modulation of airway sensory nerves in 
order to understand the mechanisms driving chronic cough.  
 
A conscious guinea-pig cough model using different tussive stimuli, known to elicit 
cough in man, was established. Corresponding in vitro effects of these tussive agents 
on sensory nerve activation were characterised. These agents were also characterised 
into sub-types as they produced distinct patterns of response.  
 
Cigarette smoke (CS) exposure elicited distinct effects on the cough reflex in 
conscious guinea-pigs and on sensory nerve activity measured in vitro; CS enhanced 
responses to citric acid (CA), capsaicin (CAPS) and bradykinin, inhibited a 
prostaglandin E2 (PGE2)-induced response and had no effect on the response to 
hypertonic saline. The CS model demonstrated neutrophilia and increased mucus in 
the airways. Focussing on mechanisms driving enhanced cough, revealed that nerve 
growth factor (NGF) and brain derived neurotrophic factor (BDNF), may play a role 
in cough reflex sensitisation. An in vitro bioassay confirmed that NGF and BDNF 
exhibited bioactivity and the anticipated species cross-reactivity.   
 
CS exposure augmented the expression of transient receptor potential vanilloid 1 
(TRPV1) in vagal sensory nerve ganglion. Pharmacological modulation of guinea-pig 
and human vagus nerve activation showed that TRPV1 antagonists, capsazepine and 
SB366791, abolished CAPS-induced depolarisation, partially inhibited low pH, 
bradykinin and PGE2-induced responses and had no effect on hypertonic saline. 
Despite positive in vitro and pharmacokinetic analyses, TRPV1 antagonists did not 
inhibit CAPS-induced cough in vivo. Further work is required to expand upon these 
findings. 
 
This thesis contains an assessment of the effects of sensory nerve modulation in 
guinea-pig models of cough. Understanding the neural mechanisms associated with 
this research may help to guide the development of novel antitussive therapies.  
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1.1. What is cough?    
 
Cough is defined in layman’s terms as “to expel air from the lungs with a sudden 
sharp sound”. This protective defence mechanism is vital to remove foreign material 
and secretions from the airways. However, the underlying mechanisms of reflex 
cough production are complex and involve a network of events, which are not fully 
understood. Furthermore, modulation of the cough reflex pathway in disease can lead 
to inappropriate coughing, which also demands further investigation to elucidate the 
mechanisms surrounding this phenomenon. 
 
1.1.1. Overview of the cough reflex   
The cough reflex response can be divided into three components; the first initiates the 
reflex through a sensory nerve input, the second is a complex central nervous network 
which processes the information and the third part is stimulation of the efferent limb 
and the motor output to produce a cough. Cough can be initiated in humans and 
animals by a variety of stimuli including citric acid (CA) (Bickerman and Barach, 
1954; Lalloo et al., 1995; Usmani et al., 2005; Morice et al., 2007), capsaicin (CAPS) 
(Collier and Fuller, 1984; Lundberg et al., 1991; Trevisani et al., 2004; Davenport et 
al., 2007), bradykinin (Fuller et al., 1987; Ichinose et al., 1992; Bergren, 2001b; 
Canning et al., 2004), prostaglandins (Kawakami et al., 1973; Costello et al., 1985; 
Gardiner and Browne, 1984) and hypertonic saline (Lalloo et al., 1995; Fahy et al., 
1995; Lowry et al., 1988; Gatti et al., 2006). Cough can also be initiated by airways 
obstruction, mechanical irritation (Canning et al., 2004), dust, cigarette smoke (CS) 
(Bergren, 2001b), chemical fumes, or a change in ion concentration or osmolarity of 
the airway surface liquid (Koskela et al., 2005). These stimuli trigger specialised 
cough receptors, which are located in or under the airway epithelium. Stimulation of 
these peripheral sensory nerve endings results in afferent fibres, which are innervated 
by the vagus nerve, relaying the information to a specific area within the brainstem. 
This area is as yet undefined in terms of the exact mechanism of output (Bonham et 
al., 2006). The subsequent reflex stimulation of the efferent limb results in somatic 
innervations causing contraction of the skeletal muscle of the abdomen and thorax 
which further results in the production of cough. 
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1.1.2. Physiology of cough 
Physiologically, cough is a reflex, forced expiratory event, which clears irritant 
material up and out of the airways. The first stage of a cough is a rapid deep 
inspiration through a widely open glottis. This inspiration results in a large lung 
volume and the airways are now open for the subsequent expiratory phase. There is a 
reflex increase in expiratory effort and contraction of muscles producing an expiratory 
effort against a closed glottis. During this compressive phase of cough there is a rapid 
generation of intrapulmonary pressure. Sudden opening of the glottis causes explosive 
expiration and a high linear velocity of gas flow, removing irritant material from the 
airways (Widdicombe, 2002). A cough is more effective with greater elastic recoil of 
the lungs. A bout of coughing is defined as a number of repetitive coughs in 
succession and the classical bout of coughing is believed to begin with the first 
coughs removing foreign particles from the larger bronchi. Successive coughs cause 
compression of smaller bronchi, sweeping secretions towards the trachea. 
Interestingly, even though coughing is an involuntary reflex, a cough can be 
mimicked voluntarily and accurately.   
 
The nature of a cough response can be termed either productive or non-productive. A 
productive cough can be voluntary or involuntary and is efficient at clearing sputum, 
mucus, noxious substances and foreign particles from the airways. A non-productive 
cough, which is also classified as a ‘dry cough’, can be a prolonged, persistent and 
troublesome symptom.  
 
1.2. Cough in man 
 
Clinically, the aetiology and treatment of cough can be broadly classified into acute 
and chronic as deduced from the length of time cough persists. The cough reflex is an 
important defence mechanism, which in the normal state serves its function 
appropriately. However, cough is a symptom that often presents in conjunction with a 
number of diseases including chronic obstructive pulmonary disease (COPD), asthma, 
post-nasal drip syndrome and gastro-oesophageal reflux disease (GORD) (Morice et 
al., 2004). The modifications to the cough reflex in the disease state can result in a 
greatly augmented cough response. Chronic coughers can suffers for months or years 
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from this debilitating symptom, which if left untreated can seriously affect quality of 
life. Correlations between chronic cough and deterioration in the patients quality of 
life have been documented (French et al., 1998).  Although the cause of chronic 
cough can be delineated as a symptom of specific diseases,  often the cause of the 
cough may be unknown and the incidence of  ‘idiopathic cough’ may be as high as 
20% or more of patients seeking treatment at specialist cough clinics (O'Connell et 
al., 1994; McGarvey et al., 1998).  
 
1.2.1. Prevalence of cough 
Cough is the most common condition for which patients seek consultation from a 
doctor (Schappert and Burt, 2006). Furthermore, antitussives are available without 
medical prescriptions and are among the most widely used over-the-counter (OTC) 
remedies. A US survey of over 8000 subjects reported that more than half of pre-
school children were given OTC remedies and that cough medicines composed 67% 
of the OTC medications used (Kogan et al., 1994). However, a recent review of trials 
involving over 2100 participants determined OTC cough remedies to possess little 
clinical efficacy (Schroeder and Fahey, 2002).  
 
The prevalence of chronic cough is difficult to determine but is estimated to occur in 
up to 40% of the population (Cullinan, 1992; Janson et al., 2001; Morice and 
Kastelik, 2003). Despite the incidence of chronic cough being uncertain, information 
has been gathered from large population surveys. In 2001, the European Community 
Respiratory Health survey of 18,277 subjects from 16 countries worldwide reported 
that the occurrence of nocturnal cough occurred in 30% of the population, non-
productive cough occurred in 10% and productive cough in 10% of subjects (Janson 
et al., 2001). The incidence of chronic cough also appears to differ between the sexes 
as a higher proportion of females are referred to cough clinics than males (Morice and 
Kastelik, 2003). Cough caused by angiotensin converting enzyme (ACE) inhibitors is 
also more frequent in women than in men (Gibson, 1989). Furthermore, healthy 
females have a heightened sensitivity to inhalation of tussive agents and an 
augmented cough response compared to healthy males (Fujimura et al., 1990; 
Dicpinigaitis and Rauf, 1998). This gender difference in cough reflex sensitivity has 
also been described in patients with chronic cough (Kastelik et al., 2002).  
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1.2.2. Cough of recent onset or acute cough 
Acute cough is classified as lasting less than three weeks (Irwin et al., 1998) and 
although transient, acute cough can be very troublesome to normal daily life. The 
most common causes of acute cough are viral or bacterial upper respiratory tract 
infections such as the common cold, acute bacterial sinusitis, rhinitis and 
exacerbations of COPD (Curley et al., 1988; Irwin et al., 1998). Therefore, acute 
cough generally arises from stimulation of the upper respiratory tract such as post-
nasal drip and mucus accumulation. Furthermore, patients presenting with acute 
cough will often have accompanying symptoms such as fever, sore throat, sneezing 
and nasal discharge (Irwin and Madison, 2000).  Since chronic cough is classified as 
persisting for longer than 8 weeks, there lies a grey area of classification and cough 
presenting between 3 and 8 weeks is termed sub-acute or post-infectious (Braman, 
2006).  
 
1.2.3. Chronic cough 
Cough that persists for longer than 8 weeks is classified as chronic and can result in 
both elevated frequency and intensity of the cough (Morice et al., 2004).  However, 
chronic cough is not always clear to diagnose as sufferers may present with repetitive 
mild spells of coughing that may be of unrecognised origin. Furthermore, it is 
important to determine whether an acute episode of cough is a new symptom or 
actually represents an exacerbation or manifestation of an existing chronic condition 
such as COPD. Although there are a number of different causes of chronic cough, it is 
notable that patients may present with multiple diseases that contribute to the 
symptom (Irwin and Madison, 2002).  
 
There are many conditions that can give rise to chronic cough. However, assessment 
of patients investigated at specialist cough clinics shows that the most common causes 
of chronic cough are asthma, GORD, rhinitis, chronic bronchitis, COPD or cough 
which is idiopathic in origin (Table 1.1) (Irwin and Madison, 2000; Morice et al., 
2004). Cough is also a side-effect of certain medications, in particular ACE inhibitors 
(McEwan et al., 1989; McEwan and Fuller, 1989; Fuller, 1989). 
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 Diagnosis ( % of total) 
Reference Number 
of 
Patients 
 
Asthma 
Syndrome 
Gastro-
oesophageal 
disease 
Rhinitis Most 
common 
other % 
Irwin et al., 
1981 
49 25 10 29 Chronic 
bronchitis 
12 
Poe et al., 
1982 
109 36 0 8 Post 
infectious 
27 
Poe et al., 
1989 
 
139 35 5 26 Idiopathic 
12 
Irwin et al., 
1990 
102 24 21 41 Chronic 
bronchitis 
5 
O'Connell et 
al., 1994 
87 6 10 13 Idiopathic 
22 
 
Smyrnios et 
al., 1995 
71 24 15 40 Chronic 
bronchitis 
11 
Mello et al., 
1996 
88 14 40 38 Bronchiectasis 
4 
 
Marchesani et 
al., 1998 
87 14 5 56 Chronic 
bronchitis 
16 
McGarvey et 
al., 1998 
43 23 19 21 Idiopathic 
18 
 
Palombini et 
al., 1999 
78 59 41 58 Bronchiectasis
18 
 
Brightling et 
al., 1999 
91 31 8 24 Post viral 
13 
 
Simpson, 1999 86 6 22 28 Post viral 
13 
 
 
Table 1.1: The most common causes of chronic cough in patients investigated in 
specialist clinics. Table amended from Morice et al., 2004.  
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1.3. Experimental approaches in the study of cough    
 
Exposure to irritant substances to induce cough can provide a measure of the 
sensitivity of the cough reflex, both in the laboratory and in the clinic. As there are 
limitations to the current therapies available to treat cough, there is the need to 
develop new effective treatments. Therefore, clinical cough studies and animal 
models of cough are vital in order to elucidate disease pathophysiology, understand 
mechanisms occurring in the healthy and disease state and help in the identification of 
effective new drug therapies.    
 
1.3.1. Clinical assessment of cough 
In the past, the assessment of cough severity in the clinic was difficult as there were 
limited tools to objectively and practically investigate cough. There are now a number 
of techniques, which can be utilised in the clinic to determine the presence of cough 
and assess the response to antitussive treatment. These include measurement of cough 
reflex sensitivity after cough challenge, quality-of-life questionnaires and automated 
cough monitors.   
 
1.3.1.1. Cough challenge in the clinic 
The tussive stimuli CAPS and CA are the most widely utilised tussive agents used in 
clinical trials to determine cough reflex sensitivity of subjects. Participants involved 
in the clinical trial inhale an aerosol of the cough provoking agent and the numbers of 
coughs are determined during a set period of time, allowing comparisons of cough 
sensitivity between the healthy subjects and patients suffering from the disease in 
question. Clinical cough challenge testing also allows determination of the 
effectiveness of antitussive treatment therapy on the induced cough response. Often 
the analysis of cough sensitivity is based on reaching a given threshold resulting in a 
determination of the C2 and C5 value, which are defined as the concentration of 
tussive stimuli required to elicit 2 and 5 coughs per inhalation (Doherty et al., 2000; 
Dicpinigaitis et al., 2006; Morice et al., 2007). 
 
1.3.1.2. Cough questionnaires   
Assessments of cough severity can also be determined using specialist cough 
questionnaires, which measure the impact of chronic cough on daily life. The 
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questionnaires include a scoring system to determine the impact of chronic cough on 
the patient’s physical, social and psychological state.  Recently developed cough 
questionnaires have proved useful in establishing severity of cough and assessment in 
a validated and comparable manner. These include the Leicester Cough Questionnaire 
(Birring et al., 2003) and the Cough Specific Quality of Life Questionnaire (Baiardini 
et al., 2005). The cough questionnaires are particularly useful tools as cough severity 
by both the patient and the doctor may be unrecognised and poorly judged without the 
aid of objective assessment. 
 
1.3.1.3. Cough monitors 
Cough monitors have been developed to establish the frequency of cough, investigate 
occurrence of cough and assess the response to antitussive therapies. Recent 
technologies have led to the development of automated recording devices, which can 
provide practical, robust and unbiased monitoring of the cough response. These 
include the Hull Automatic Cough Counter (Barry et al., 2006), the Leicester Cough 
Monitor (Matos et al., 2007), the Vivometrics Lifeshirt (Coyle et al., 2005) and the 
Manchester Cough Diary (Smith, 2007).  
 
1.3.2. Animal models of cough   
Investigators have used a number of different approaches to mimic the cough reflex 
using animal models. The choice of animal, experimental design and end-points are 
determined by the objectives of the cough study. However, there are some limitations 
that should be taken into account, mainly whether animal models of cough accurately 
and relevantly compare to the human state. Furthermore, most of the information on 
the cough reflex has been determined from animal models of cough which display 
little or no airway disease pathology. There is still a great deal to discover about the 
mechanisms of enhanced cough, the modulation of sensory nerve function and 
sensitisation of the cough reflex under inflammatory conditions. This highlights the 
importance of the development of novel models of exacerbated cough which mimic 
characteristics of human airway inflammatory disease.  
 
Scientists investigating the neural pathways, physiology and pharmacological 
modulation of the cough reflex have conducted cough studies using a number of 
different species including guinea-pigs, cats, dogs, rabbits and rodents (Patel et al., 
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2003; Gardiner and Browne, 1984; Tatar et al., 1994; Hanacek et al., 1984; Kamei et 
al., 1993). Although a small proportion of conscious cough studies have been 
performed using rats and mice (Kamei et al., 1993; Kamei et al., 2006), there is 
scepticism as to whether these species evoke a cough response that resembles cough 
seen in man. Reservations against the use of rats and mice in studying the cough 
reflex is based on evidence that mice do not possess rapidy adapting receptors 
(RARs), which are believed to be one of the primary airway afferent nerve pathways 
involved in the cough reflex. Furthermore, the response evoked in rats following 
tussive stimulation may originate from the larynx rather than the tracheobronchial 
tree, thus eliciting a different nature of response to that seen in man (Belvisi and 
Bolser, 2002).  It is widely agreed that the most suitable species to investigate cough 
is the guinea-pig and a wealth of literature has been gathered using this species 
(Belvisi and Hele, 2003). 
 
1.3.2.1. Conscious guinea-pig models of cough 
The most common guinea-pig model of cough is performed by placing a conscious 
guinea-pig inside a transparent chamber, which contains a microphone allowing the 
cough sounds to be magnified. The guinea-pig is exposed to an aerosol of a tussive 
agent to induce a cough response. The concentration of tussive agent and length of 
exposure time to the aerosol are determined to produce optimal numbers of coughs. 
The cough response by the guinea-pig is recognised by the characteristic sound 
produced by the animal, observation of the change in posture of the animal and also 
monitoring of the characteristic changes in airflow. Since the establishment of the 
initial cough apparatus, the conditions for evaluating cough have advanced. As well as 
determining the number of coughs, specialised chambers have been developed to 
simultaneously evaluate other respiratory parameters. This highlights an advantage of 
measuring cough in the conscious state, as a non-invasive measure of airway 
reactivity, termed Penh, can be simultaneously determined using whole body 
plethysmography. Penh or ‘enhanced pause’ is a parameter which is used as an 
indicator of airflow obstruction, and is calculated from pressure signals and changes 
in the expiratory wave shape of the plethysmography signal (Lomask, 2006). Several 
studies which have utilised Penh to assess airway responsiveness in laboratory 
animals such as mice and guinea-pigs, have described a relationship between Penh 
values and airway resistance or bronchoconstriction (Hamelmann et al., 1997; Chong 
 28
et al., 1998; Dohi et al., 1999; Bergren, 2001a). However, there has been debate in the 
literature as to the functional relevance of measuring Penh and some authors have 
stated that Penh does not have a theoretical relationship to airway resistance 
(Lundblad et al., 2002; Mitzner and Tankersley, 2003; Lundblad et al., 2007). 
Although Penh measurements may present limitations in accurately representing 
changes in airway physiology, this parameter can be used as a useful indicator of 
airflow obstruction when measured simultaneously to conscious cough in the guinea-
pig.  
 
In the past, there were no automated techniques to recognise a guinea-pig cough and 
the number of coughs had to be counted manually. This allowed only one guinea-pig 
to be evaluated at one time. Recent advances in the evaluation of the cough response 
were possible following the development of an automated system of cough counting. 
This system utilises a custom-designed algorithm to recognise coughs in the 
conscious guinea-pig, thus allowing a number of animals to be evaluated at one time 
and also avoiding operator bias or error (Battram et al., 2005). The disadvantage to 
conscious cough measurements are that initiation of the cough reflex does not indicate 
specifically which fibre type is involved, unless the response can be 
pharmacologically modulated to deduce the nature of the response. However, the 
advantages are that the model mimics the conditions observed in the human setting as 
the cough is evoked in the conscious state and the nature of the guinea-pig cough 
response closely resembles that of man (Laude et al., 1993). 
 
1.3.2.2. Cough in anaesthetised animals  
Tussive responses can also be experimentally induced in anaesthetised animals and 
this method of cough evaluation has been described in cats, dogs and more recently 
guinea-pigs. The animal is subject to a suitable depth of anaesthesia to allow 
respiratory reflexes to remain intact and the larynx, trachea or bronchial mucosa can 
be stimulated to evoke cough. The experimental cough-provoking stimuli include 
mechanical probing, electrical stimulation with an electrode or administration of 
chemical stimuli such as CAPS, CA or bradykinin. This technique can detect action 
potentials travelling in the vagus nerve allowing direct assessment of the sensory 
nerve activity using an in vivo model. The cough in this anaesthetised setting is 
recognised both visually and by analysis of pressure changes on the characteristic 
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trace (Sant'Ambrogio et al., 1978; Karlsson et al., 1988; Tatar et al., 1988; Tatar et 
al., 1994; Canning et al., 2004). This technique is advantageous as the evaluation of 
the neuronal response can be assessed whilst maintaining the physiological 
environment by utilising the in vivo model. 
 
1.3.2.3. Examining sensory nerve activity using isolated tissues 
The development of in vitro and ex-vivo airway and sensory nerve preparations has 
allowed properties of airway afferents to be examined, which have been especially 
informative in identification of specific afferent nerve sub-types and their selectivity 
to tussive stimulation. The isolated vagus nerve is an effective preparation to 
investigate sensory nerve activation and the functional measurements of the effects of 
pharmacological agents in vitro. The vagus nerve is dissected free from guinea-pigs 
and placed in a ‘grease-gap’ recording chamber. The nerve can then be exposed to 
tussive stimuli and the pharmacology of these agents assessed by monitoring the level 
of depolarisation (Fox et al., 1995b; Birrell et al., 2002). This in vitro preparation can 
be utilised for pharmacological proof of concept studies prior to testing the effects of 
a compound in vivo. The disadvantages to this technique are that the extracellular 
recordings are a summation from the whole tissue, rather than analysis of single nerve 
fibre types. Also, as the depolarisation records a summation of the change in 
membrane potential of all of the axons within the vagus nerve, this may not 
correspond to the effects occurring in the peripheral airway afferent nerve endings 
(Patel et al., 2003). However, the isolated vagus nerve is stable enough to allow 
washing between compound applications and allows straightforward measurement 
and quantification of the sensory nerve activation. Furthermore, promising antitussive 
therapies have inhibited sensory nerve activation of the guinea-pig vagus nerve and 
comparably attenuated the number of coughs in the conscious guinea-pig (Patel et al., 
2003; Usmani et al., 2005). Importantly, the guinea-pig vagus nerve preparation 
responds in a comparable manner to the isolated human vagus nerve (Belvisi et al., 
1998; Usmani et al., 2005). 
 
In order to directly examine distinct afferent subtypes in the airways, isolated tissue 
preparations have been developed. Fox et al utilised a technique to isolate guinea-pig 
trachea and main bronchi, with vagus nerve attached. This preparation allowed 
 30
evaluation of defined afferent subtypes in the vagus nerve by determining conduction 
velocities, location and sensitivity to chemical or mechanical stimuli of single fibres 
(Fox et al., 1993; Fox et al., 1995b). Such guinea-pig vagally innervated airway 
preparations have been used to study the physiology and pharmacology of sensory 
nerve afferents in vitro (Undem et al., 2002). Furthermore, extracellular recordings 
taken from a trachea-larynx-bronchus preparation, with vagus nerve and sensory 
nerve ganglion attached, allows action potentials from single airway afferent nerve 
endings to be monitored (Riccio et al., 1996; Carr et al., 2003; Undem et al., 2004).  
The advantages to these techniques are that defined receptive fields and distinct 
afferent nerve sub-types can be monitored in response to either chemical or 
mechanical stimulation. 
 
1.4. Classification of airway sensory nerves  
 
Airway sensory nerves mediate central and local reflexes such as cough, 
bronchoconstriction, mucus secretion and microvascular leak. Cough is a symptom of 
a number of different diseases and it is accepted that irrespective of the cause, reflex 
cough is always produced via activation of airways sensory nerves. The sensory 
nerves can be broadly classified as either primarily mechanically sensitive or 
primarily chemically sensitive. The mechanically sensitive fibres are responsive to 
stimulation such as lung inflation, bronchospasm or light touch. The chemosensitive 
fibres are activated following exposure to chemicals including CAPS, bradykinin, 
CA, prostaglandin E2 (PGE2) or CS. The terminals of the airway afferent sensory 
nerves are located in or under the airway epithelium and the cell bodies originate in 
the vagal nerve cell bodies, which are the nodose or jugular ganglia. The airway 
sensory nerve ganglia have distinct embryological origins; the nodose ganglion is 
epibranchial placode derived and the jugular ganglion is neural crest derived. 
Therefore, neurons within the nodose and jugular ganglia express different growth 
factors and neurotrophins, which are essential for differentiation and survival (Ernfors 
et al., 1992; Begbie et al., 2002). As well as sensitivity to mechanical or chemical 
stimulation, identification and differentiation of the airway sensory fibres is based on 
the conduction velocity, origin, sites of termination within the airways and 
neurochemistry (Fox et al., 1993; Undem and Weinreich, 1993; Riccio et al., 1996). 
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Interestingly, the characteristics of the airway sensory nerve sub-types may be altered 
under certain experimental conditions, which will be discussed in detail later in the 
chapter. The following section provides an overview of the classification and 
physiology of airway afferent nerve sub-types. 
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Figure 1.1: The cough reflex. Airway sensory nerves (e.g. C-fibres, nociceptive Aδ-
fibres, rapidly adapting receptors (RARs), ‘cough receptors’ and slowly adapting 
receptors (SARs)) activated in response to a pro-tussive stimulus travel through the 
vagus nerve to the medulla, where they terminate in the nucleas tractus solitarius 
(NTS). Second order neurones relay the message to the respiratory pattern generator, 
which modifies the activity of the inspiratory and expiratory motorneurons and leads 
to cough. Figure modified from Reynolds et al., 2004. 
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1.4.1. Rapidly adapting receptors 
RARs are defined as irritant sensory receptors that respond rapidly to a mechanical 
stimulus including airway smooth muscle contraction and changes in lung volume 
(Bergren and Sampson, 1982; Canning et al., 2001; Widdicombe, 2003). These 
myelinated, fast velocity fibres conduct action potentials in the Aδ-range (~15 m/s) 
(Fox et al., 1993; Ricco et al., 1996).  Furthermore, RARs are distributed throughout 
the airways but are more abundant in the larger airways, highlighting a defensive role 
based on their extreme sensitivity to light touch (Mortola et al., 1975; Sant'Ambrogio 
et al., 1978; Canning et al., 2004).  RARs are sensitive to both inflation and deflation 
of the lungs and adapt rapidly in response to changes in airway mechanics (Pack and 
DeLaney, 1983; Ho et al., 2001). The RARs have their cell bodies in the nodose 
ganglion and are insensitive to direct stimulation with a chemical stimulus. However, 
bronchoconstriction, mucus production or oedema, induced by chemical stimulation 
with substances such as CAPS and bradykinin, can secondarily initiate RAR 
activation (Mohammed et al., 1993; Bonham et al., 1996; Bergren, 1997). 
Furthermore, the direct application of the chemical CA, activated RAR-like fibres 
measured by extracellular recordings in isolated guinea-pig airway nerve preparations 
(Kollarik and Undem, 2002).  
 
1.4.2. Slowly adapting receptors 
Upon first inspection, slowly adapting stretch receptors (SARs) may appear 
indistinguishable from RARs as they also conduct action potentials in the Aδ-range 
(~18 m/s), originate in the nodose ganglion and are sensitive to mechanical 
stimulation. Similarly to RARs, the SARs display activity upon lung inflation, airway 
smooth muscle constriction and airway wall oedema  (Widdicombe, 1961; Miserocchi 
and Sant'Ambrogio, 1974; Sant'Ambrogio et al., 1978). However, SARs can be 
differentiated from RARs based on their action potential conduction velocity and by 
their moderate response to sustained lung inflation (Schelegle and Green, 2001). 
SARs are active in tidal breathing related to the rhythmical inflation and deflation of 
the lungs and are believed to be involved in regulation of the Hering-Breuer reflex, 
which is important to prevent over-inflation of the lungs by controlling the 
termination of inspiration and the initiating of expiration when the lungs are 
adequately inflated (Schelegle, 2003).  
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1.4.3. C-fibre nociceptors  
The C-fibres are a population of chemosensitive sensory nerves that constitute a large 
proportion of the nerve terminals seen within the airway epithelium. Airway 
chemosensors are derived from the nodose and jugular ganglion, which are the vagal 
sensory ganglia. Additionally, airway chemosensors are derived from the dorsal root 
ganglion (DRG), adjacent to the upper thoracic spinal cord. C-fibres, which have non-
myelinated axons, characteristically conduct action potentials at a conduction velocity 
of  ~1 m/s (Fox et al., 1993; Ricco et al., 1996; Mazzone, 2004; Canning et al., 2006). 
The chemosensors are distinguished from mechanosensors by their relative 
insensitivity to mechanical stimulation and lung inflation and their sensitivity to 
stimulation with chemical stimuli such as CAPS, CA and bradykinin (Coleridge and 
Coleridge, 1984; Ricco et al., 1996; Bergren, 1997; Lee and Pisarri, 2001; Undem et 
al., 2004). The activation of C-fibres with a stimulus is caused by a direct effect on 
the peripheral sensory nerve terminal, rather than secondary to changes such as 
bronchoconstriction or mucus production (Kwong and Lee, 2002; Undem et al., 2004; 
Chuaychoo et al., 2005b). C-fibres express the membrane bound ligand-gated ion 
channel, the transient receptor potential vanilloid 1 (TRPV1) receptor, which renders 
this sub-type of airway afferent highly sensitive to stimulation with the TRPV1 
agonist CAPS (Caterina et al., 1997). The expression of TRPV1 on C-fibres has been 
utilised to determine distribution and localisation in the airways of animals and man 
(Groneberg et al., 2004a; Mitchell et al., 2005; Watanabe et al., 2006). 
 
C-fibre chemosensors (particularly in guinea-pigs and rats) have been found to 
synthesise the neuropeptides calcitonin gene related peptide (CGRP), substance P 
(SP) and neurokinin A (NKA) (Lundberg et al., 1985; Baluk et al., 1992; Hunter and 
Undem, 1999; Myers et al., 2002). Stimulation of the afferent fibre may cause an 
axon reflex, resulting in release of sensory neuropeptides both centrally and 
peripherally. The release of SP and NKA causes airway smooth muscle contraction, 
mucus secretion, vasodilatation and bronchial oedema, which has been proposed to 
account for some of the pathophysiology of airway inflammatory disease and has 
been collectively termed neurogenic inflammation (Barnes, 1986; Barnes, 1995). SP 
principally acts on the G-protein coupled Neurokinin 1 (NK1) receptor, whereas NKA 
mainly acts via NK2 receptors (Frossard and Advenier, 1991). Since C-fibres contain 
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neuropeptides and this unique neurochemical property has also been utilised to 
determine the airway distribution of these afferent fibres (Lundberg et al., 1984; Dey 
et al., 1990; Hunter and Undem, 1999). Although neurogenic inflammation had been 
investigated in laboratory animals, the importance of neurogenic inflammation in man 
is still not clear (Groneberg et al., 2004b). 
 
The airway C-fibres are sub-classified into bronchial and pulmonary, which has been 
distinguished according to ganglionic origin, sites of termination and differing 
responses to mechanical or chemical simulation (Coleridge and Coleridge, 1984; Carr 
and Undem, 2003b; Undem et al., 2004). Undem et al utilised a vagally innervated 
lung preparation to determine that there are two distinct C-fibre sub-types in the 
guinea-pig airways. They found that the C-fibres projecting from the jugular ganglion 
project to both the extrapulmonary and interpulmonary airways, whereas C-fibres 
originating in the nodose ganglion terminate in the intrapulmonary airways only. Both 
phenotypes of C-fibre responded with action potential discharge to stimulation with 
CAPS and bradykinin. However, the jugular-derived C-fibres express SP and CGRP, 
whereas the C-fibres with cell bodies in the nodose ganglion do not express SP under 
normal conditions (Undem et al., 2004).  
 
1.4.4. Aδ-nociceptors 
Airway chemosensors are not only comprised of C-fibres as there are a group of 
nociceptors that conduct action potentials in the Aδ range. The thinly myelinated Aδ-
nociceptor fibres differ from RARs or SARs as they originate in the jugular ganglia 
and express TRPV1. Furthermore, Aδ-nociceptors are less responsive to mechanical 
stimulation and are sensitive to chemical stimuli (Ricco et al., 1996; Kajekar et al., 
1999; Yu et al., 2005) 
 
1.4.5. The recently identified ‘cough receptor’  
The presence of another airway afferent fibre type involved in the cough reflex has 
recently been recognised and termed the ‘cough receptor’ (Canning et al., 2004). This 
newly identified fibre has similar characteristics to RARs as it originates in the 
nodose ganglia, is sensitive to mechanical stimulation, is responsive to exposure to 
acid or rapid changes in pH and is unresponsive to stimulation by CAPS or 
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bradykinin. These low threshold mechanosensors are located in the extrapulmonary 
airways, specifically within the wall of the larynx, trachea and bronchi and are distinct 
from the other mechanosensors as they are exquisitely sensitive to light punctuate 
mechanical stimulation or light touch, but not to bronchoconstriction and changes in 
lung volume and pressure. The conduction of action potentials following ‘cough 
receptor’ stimulation is slower (~5m/s) than that elicited by RARs. Furthermore, the 
‘cough receptor’ does not express TRPV1 receptors or SP (Ricco et al., 1996; 
Mazzone, 2004). Classification and characterisation of the ‘cough receptor’ has been 
carried out in the guinea-pig and it is still unclear as to whether these fibres exist in 
the airways of other species including man (Canning et al., 2004; Mazzone, 2004).  
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 C-fibres Aδ-
nociceptors
Cough 
Receptors
RARs SARs 
 
Conduction 
Velocity (m/s) 
 
 
~1 
 
~6 
 
~5 
 
~15 
 
~18 
Ganglionic Origin  
 
Jugular/ 
nodose/DRG
Jugular Nodose Nodose Nodose 
Extrapulmonary 
 
Yes Yes Yes No No 
Intrapulmonary 
 
Yes Yes Few Yes Yes 
Substance P 
 
Yes / No a No No No No 
TRPV1 
 
Yes Yes No No No 
Responsive to: 
 
     
Punctate 
mechanical 
 
Yes b Yes b Yes b Yes b Yes b 
Capsaicin 
 
Yes Yes No No c No c 
Hypertonic saline 
 
Yes Yes No Unknown Unknown
Bradykinin 
 
Yes Yes No No c No c 
Acid 
 
Yes Yes Yes Unknown No 
Bronchoconstriction 
 
No No No Yes Yes 
Distension 
<50cmH2O 
 
No No No Yes Yes 
Stretch No No No Yes Yes 
 
 
Table 1.2: Properties of the afferent nerve subtypes innervating the guinea-pig 
airways. 
 a To date three subtypes of C-fibres have been identified originating from the nodose, 
jugular and the upper thoracic dorsal root ganglion. 
b All airway afferent nerve subtypes can be activated by punctuate mechanical stimuli. 
However, the threshold for activation of nociceptors is approximately 100-fold higher 
than for mechanoreceptors. 
c Mechanoreceptors are insensitive to the direct action of these chemicals on the nerve 
terminal. However, chemical stimuli such as capsaicin and bradykinin can activate 
airway mechanoreceptors (particularly RARs) secondary to airway smooth muscle 
contraction, mucus secretion and oedema formation. Table amended from Mazzone, 
2004.  
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1.5. Pharmacological activation of airway sensory nerves         
 
Numerous chemical or mechanical tussive stimuli have been employed 
experimentally in animals and humans to increase our understanding of the cough 
reflex. However, there is still a great deal to learn about the mechanisms by which 
exogenous and endogenous tussive stimuli can activate sensory nerves to mediate 
cough. Irrespective of the sub-type of stimulus, a tussive agent can only activate 
sensory nerve terminals following interactions at the nerve membrane resulting in 
membrane depolarisation. The airway sensory nerves express different receptors and 
ion channels, which are activated by pharmacological agents to cause a cough. 
Therefore an understanding of the mechanisms by which cough is generated by these 
tussive stimuli could lead to the identification of novel and efficacious antitussive 
therapies. This section will provide an introduction to the tussive stimuli utilised for 
investigation in this thesis and the proposed mechanisms by which these tussive 
agents directly activate sensory nerves.  The subsequent sections of this chapter will 
provide a more detailed overview of evidence surrounding which airway afferent sub-
types are important in the sensory regulation of the cough reflex, followed by the 
current understanding surrounding mechanisms of cough reflex sensitisation.    
 
1.5.1. Capsaicin 
CAPS is a pungent extract from the Capsicum pepper and is a common tool used in 
cough experimentation as it is a potent stimulus acting on particular sub-sets of 
chemosensitive afferent neurones, the C-fibres and the nociceptive Aδ-fibres (Fox et 
al., 1993; Ricco et al., 1996; Caterina et al., 1997). Information regarding the 
specificity of CAPS for C-fibres has been obtained from in vivo and in vitro single 
fibre recordings.  Fox et al developed and utilised a novel technique to isolate guinea-
pig trachea and main bronchi, with vagus nerve attached. They distinguished distinct 
afferent subtypes in the vagus nerve by determining conduction velocities, location 
and sensitivity to chemical or mechanical stimuli. They found that CAPS and a low 
pH solution applied to the receptive fields of the single fibres did not evoke excitation 
of the Aδ-fibres, but did evoke a sustained firing of all C-fibres tested (Fox et al., 
1993; Fox et al., 1995b). Additional evidence is derived from extracellular recordings 
of isolated vagally innervated lung preparations, which demonstrate that CAPS 
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directly activates C-fibres derived from both the nodose and jugular ganglion (Undem 
et al., 2004).  
 
The action of CAPS on sensory nerves has proved an extremely useful tool in 
investigating the pain pathway and the activation of airway sensory nerves to cause 
cough (Caterina and Julius, 2001; Geppetti et al., 2006).  Furthermore, a 
comprehension of the mechanisms by which CAPS activates airway sensory nerves 
has provided the basis of the use of CAPS in cough experimentation both in the clinic 
and in animals for over two decades (Collier and Fuller, 1984; Forsberg and Karlsson, 
1986; Trevisani et al., 2004; Davenport et al., 2007). A recent publication reviewed 
the literature to determine the safety of CAPS cough challenge testing in man and 
found that there were no adverse events associated with any of the clinical studies 
using CAPS (Dicpinigaitis and Alva, 2005).   
 
1.5.2. Capsaicin and TRPV1 
CAPS activates airway sensory nerves via the stimulation of the type 1 vanilloid 
receptor (VR1), which is now more commonly referred to as the TRPV1 receptor.  
TRPV1 is a membrane bound ligand gated ion channel found on the neuronal plasma 
membrane (Bevan and Szolcsanyi, 1990; Caterina et al., 1997; Caterina et al., 2000). 
TRPV1 is a member of the TRP family of proteins, which can be broadly sub-divided 
into three main sub-classes; TRPM, TRPC and TRPV. TRPs are sensors of chemical 
and physical stimuli, as deduced from their localisation and their response to a range 
of stimuli. A role for TRPV1 in the cough reflex has been established as this receptor 
is uniquely sensitive to vanilloids such as CAPS and other tussive stimuli, as 
described below. TRPV1 mRNA and protein are highly expressed in small diameter 
nociceptive sensory afferents found within the DRG, trigeminal ganglion (TG) and 
vagal sensory ganglia. The distribution of TRPV1 and the corresponding sensitivity to 
CAPS of distinct sub-types of airway afferent neurones has been established using 
techniques to investigate TRPV1 expression. Thereby establishing that TRPV1 
mRNA and protein are present in both the jugular and the nodose ganglion (Helliwell 
et al., 1998; Michael and Priestley, 1999; Ichikawa and Sugimoto, 2003; Dinh et al., 
2004a; Ni et al., 2006). Furthermore, extensive immunohistochemical studies have 
mapped the anatomical location of TRPV1 within the guinea-pig airways and found 
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this receptor to be localised to axons throughout the respiratory tract. TRPV1 was 
often co-localised with the sensory neuropeptides SP and CGRP, although there are a 
population of TRPV1-positive neurons that do not express neuropeptides (Watanabe 
et al., 2005; Watanabe et al., 2006).   
 
Pharmacological evidence in favour of the TRPV1 mediated actions of CAPS are 
deduced from studies using the potent CAPS analogue resiniferatoxin and also the 
TRPV1 antagonists capsazepine and iodo-resiniferatoxin (IRTX). Resiniferatoxin has 
similar properties to CAPS, but acts at 1000-fold lower doses. Therefore, the highly 
specific activity of resiniferatoxin has been utilised to determine specific vanilloid 
receptor binding sites on DRG membranes (Szallasi and Blumberg, 1990). In 
addition, the TRPV1 antagonists capsazepine and IRTX inhibit a number of CAPS-
evoked neuronal responses (Bevan et al., 1992) including CAPS-induced contraction 
of guinea-pig trachea (Belvisi et al., 1992; Ellis and Undem, 1994; Undem and 
Kollarik, 2002), CAPS-induced excitation of sensory nerve activation (Fox et al., 
1995b) and CAPS-evoked cough in the conscious guinea-pig (Trevisani et al., 2004).  
 
1.5.2.1. TRPV1 gating 
TRPV1 is a six-transmembrane-spanning protein with a pore region located between 
transmembrane regions 5 and 6 (Caterina et al., 1997). The vanilloid receptor is a 
non-selective cation channel and gating of TRPV1 excites terminals of primary 
sensory neurons. Ligand binding to the TRPV1 ion channel results in a 
conformational change in the receptor protein and subsequent opening of the ion pore. 
If the influx of cations and the movement of charge across the membrane is of 
sufficient magnitude, action potentials are triggered, which leads to the initiation of 
depolarisation. (Kollarik and Undem, 2002). As well as action potential discharge, 
stimulation of TRPV1 receptors on jugular C-fibres evokes the release of pro-
inflammatory neuropeptides in the airways resulting in neurogenic inflammation 
(Groneberg et al., 2004b).  
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1.5.2.2. TRPV1 and nociception 
Activation of TRPV1 is involved in the sensory nerve mediated cough reflex 
pathway. Furthermore, TRPV1 mediates nociception and contributes to the detection 
of numerous thermal and chemical stimuli. TRPV1 has been shown to mediate the 
response to noxious temperatures above 37°C and has an activation threshold between 
42 and 53 ºC, which means it is effectively inactive at regular body temperature 
(Caterina et al., 1997). TRPV1 knock-out mice demonstrate impaired detection of 
painful heat and show modest thermal hypersensitivity under inflammatory conditions 
(Caterina et al., 2000). Therefore, TRPV1 is thought to mediate sensitisation in the 
peripheral nerve terminals of nociceptors, leading to a reduction in the threshold of 
activation. A central role of TRPV1 in the transduction of pain and in the neurogenic 
inflammatory response is now well established (Szallasi and Blumberg, 1999; 
Szolcsanyi, 2004; Groneberg et al., 2004b).  
 
1.5.2.3. Ligands for TRPV1 
As well as the exogenous TRPV1 agonists CAPS and resiniferatoxin, there is a 
growing list of endogenous agents that can activate and/or sensitise TRPV1, which 
has made TRPV1 a valuable therapeutic target. Activators of TRPV1 include low pH 
(pH 5-6) (Bevan and Geppetti, 1994; Jordt et al., 2000), anandamide (Zygmunt et al., 
1999; Kagaya et al., 2002; Jia et al., 2002), heat (Caterina et al., 1997), bradykinin 
(Carr et al., 2003; Kollarik and Undem, 2004), neurotrophins (Ji et al., 2002), 
prostaglandins (Moriyama et al., 2005), ATP (Tominaga et al., 2001) and leukotrienes 
(Hwang et al., 2000). The hypothesis that TRPV1 can be activated by numerous 
stimuli has been validated by electrophysiological patch-clamp recordings of the cell 
bodies of TRPV1-expressing cells (Tominaga et al., 1998; Zygmunt et al., 1999; 
Hwang et al., 2000) as well as pharmacological antagonism of TRPV1 (Belvisi et al., 
1992; Fox et al., 1995b). 
 
1.5.2.4. TRPV1 antagonists 
Capsazepine is a competitive antagonist of both TRPV1 binding and TRPV1-evoked 
responses (Bevan et al., 1992) and was the original TRPV1 antagonist used in 
characterising these effects. However, at higher concentrations required to completely 
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inhibit the effects of TRPV1, capsazepine has non-specific actions such as inhibition 
of voltage-gated calcium channels (Docherty et al., 1997) and nicotinic receptors (Liu 
and Simon, 1997). The interest in TRPV1 in inflammatory pain and in the cough 
reflex has led to the recent identification and development of novel TRPV1 
antagonists, which have improved potency and/or selectivity than capsazepine. IRTX, 
which is a structurally related analogue of the agonist resiniferatoxin, is at least 40-
fold more potent than capsazepine as a TRPV1 antagonist and is effective at 
inhibiting TRPV1 mediated responses in the airways both in vitro and in vivo (Wahl 
et al., 2001; Rigoni et al., 2003; Trevisani et al., 2004). Another commercially 
available TRPV1 antagonist is the GlaxoSmithKline compound SB366791 ((N-(3-
methoxyphenyl)-4-chlorocinnamide)), which has a higher potency and improved 
selectivity profile compared to capsazepine (Gunthorpe et al., 2004). Interestingly, 
coughing induced by CAPS, CA or anandamide in the conscious guinea-pig can be 
inhibited to some extent by the TRPV1 antagonists capsazepine and/or IRTX, 
suggesting that these three tussive stimuli all induce cough via the activation of 
TRPV1 (Lalloo et al., 1995; Jia et al., 2002; Trevisani et al., 2004).    
 
1.5.2.5. Capsaicin-induced desensitisation 
Exposure to TRPV1 agonists such as CAPS and resiniferatoxin not only activates 
sensory neurons but also provides resistance to subsequent CAPS exposure and 
certain painful stimuli, which is attributed to desensitisation (Jancso et al., 1967; 
Caterina and Julius, 2001). The duration of CAPS-induced desensitisation may last 
anywhere from hours to the lifetime of a subject depending on the dose of CAPS 
used, duration of treatment, route of administration and subject age and species 
(Caterina and Julius, 2001). Therefore, this phenomenon of desensitisation has 
highlighted the therapeutic potential of TRPV1 agonists in conditions mediated by 
heat-sensitive nociceptors such as TRPV1. In fact, topical application of CAPS in 
man results in a decreased sensitivity to subsequent painful thermal stimulation 
(Simone and Ochoa, 1991). Studies of the cough reflex have also described an 
inhibition of effects following treatment with TRPV1 agonists. Cough experiments in 
anaesthetised animals have shown that following systemic application of CAPS, 
cough induced by mechanical stimulation is inhibited, indicating that chemosensor 
activation by CAPS may be inhibitory to the cough reflex (Tatar et al., 1988; Tatar et 
al., 1994; Canning et al., 2004). Furthermore, in conscious guinea-pigs, treatment 
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with CAPS resulted in a depletion of SP and CGRP from sensory nerves and also 
decreased the cough response and level of bronchoconstriction evoked by subsequent 
stimulation with CAPS (Forsberg et al., 1988). Watanabe et al extensively studied the 
anatomical location of protein gene product 9.5 (PGP9.5), TRPV1 and the sensory 
neuropeptides SP and CGRP, in the guinea-pig respiratory system. They found that 
guinea-pigs chronically treated with sub-cutaneous CAPS demonstrated a complete 
loss of TRPV1-positive axons within the trachea and intrapulmonary airways as well 
as the loss of bronchoconstriction induced by subsequent CAPS exposure. Similarly 
there was an extensive depletion of SP and CGRP immunoreactive axons in CAPS 
treated animals (Watanabe et al., 2006).  
 
1.5.3. Citric acid 
The induction of cough by CA was first employed in the 1950s (Bickerman and 
Barach, 1954) and is still widely used today in clinical cough trials (Choudry et al., 
1989; Laude et al., 1993; Smith et al., 2006; Morice et al., 2007) and to induce cough 
in laboratory animals (Lalloo et al., 1995; Usmani et al., 2005). Protons have been 
shown to stimulate CAPS-sensitive fibres by opening TRPV1 receptors (Tominaga et 
al., 1998). Therefore, low pH solutions such as CA are believed to stimulate sensory 
nerves via similar mechanisms to CAPS and secondary to TRPV1 activation (Bolser 
et al., 1991; Lou and Lundberg, 1992; Bevan and Geppetti, 1994). Furthermore, 
TRPV1 antagonists attenuate the low pH-induced stimulation of C-fibres in vitro (Fox 
et al., 1995b) and CA-induced cough response in the conscious guinea-pig in vivo 
(Lalloo et al., 1995; Trevisani et al., 2004). As well as causing cough, inhalation of 
CA also induces bronchoconstriction in the guinea-pig, which is believed to occur 
secondary to the release of neuropeptides from C-fibres (Ricciardolo, 2001). 
Utilisation of in vitro guinea-pig trachea-bronchus-vagus preparations has 
demonstrated that acid can activate two of the primary vagal afferents believed to be 
involved in the cough reflex; C-fibres and Aδ-nociceptors (Kollarik and Undem, 
2002). Additionally, CA applied topically to the trachea or larynx of anaesthetised 
guinea-pigs causes cough, unlike other chemical stimulants CAPS and bradykinin, 
which do not cause cough in the anaesthetised state (Canning et al., 2004; Mazzone et 
al., 2005). Furthermore, Kollarik and Undem used pharmacological studies and 
TRPV1 knock-out mice to show that the actions of CA are mediated in part by 
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TRPV1 as well as the presence of TRPV1-independent mechanisms. They 
hypothesise  the TRPV1-independent actions of CA are mediated via stimulation of 
acid sensing ion channels (ASICs) located on the touch sensitive Aδ-fibres (Kollarik 
and Undem, 2004). Therefore, the mechanisms underlying CA-induced activation of 
airway sensory nerves are still not fully recognised and this field of research requires 
further investigation. 
 
1.5.4. Bradykinin 
There is considerable evidence describing a role for endogenous bradykinin in airway 
inflammation and involvement in sensory nerve activation (Barnes, 1986; Barnes, 
1995; Fox et al., 1996). Inhalation of exogenous bradykinin has been shown to cause 
bronchoconstriction and to be an effective tussive stimulus in man (Fuller et al., 1987; 
Choudry et al., 1989; Ichinose et al., 1992; Hope-Gill et al., 2003) and in guinea-pig 
(Bergren, 2001b; Canning et al., 2004). However, the tussive activity of bradykinin 
appears to be less powerful than the effects of other tussive agents such as CAPS or 
CA (Bergren, 2001b; Hope-Gill et al., 2003). The identification of an endogenous 
cough-provoking inflammatory mediator such as bradykinin requires further 
investigation to deduce the mechanisms of cough provocation. Bradykinin has been 
found to act on peripheral sensory nerve terminals via activation of the G-protein 
coupled bradykinin B2 receptor (McGuirk and Dolphin, 1992; Fox et al., 1993; 
Kajekar et al., 1999). However, the mechanisms linking bradykinin B2 receptor 
stimulation and the production of a cough response is unknown. Bradykinin 
application directly to the receptive fields of guinea-pig airways leads to an action 
potential discharge (Fox et al., 1993; Kajekar et al., 1999) and evidence suggests that 
the direct effects of bradykinin on sensory nerve afferents in the guinea-pig is via 
activation of C-fibres and does not involve the mechanosensitive Aδ-fibres (Fox et 
al., 1993; Bergren, 1997; Canning et al., 2004). Furthermore, bradykinin B2 receptors 
have been detected in the nodose ganglia of humans and rats using autoradiography 
(Krstew et al., 1998). Further evidence in favour of C-fibre mediated effects of 
bradykinin comes from work showing that airway delivery of bradykinin to 
anaesthetised guinea-pigs induces bronchoconstriction via neural mechanisms 
involving sensory neuropeptides  (Ichinose et al., 1990) and that bradykinin induces 
the release of the tachykinins SP and NKA from perfused guinea-pig lung (Saria et 
al., 1988). The involvement of sensory nerves and tachykinin release in response to 
 45
bradykinin was confirmed in a clinical trial showing that a tachykinin receptor 
antagonist inhibited both bradykinin-induced bronchoconstriction and coughing in 
asthmatic patients (Ichinose et al., 1992). Bradykinin-induced stimulation of airway 
sensory nerves has also been linked to the activation of TRPV1. Single unit 
extracellular recordings of C-fibre receptive fields in guinea-pig isolated airways 
showed that bradykinin-induced action potentials were significantly inhibited 
following antagonism of the TRPV1 receptor (Carr et al., 2003). A role for TRPV1 in 
bradykinin-induced C-fibre activation was further confirmed using TRPV1 knock-out 
mice, which showed that a proportion of the bradykinin-induced action potential 
discharge was inhibited in mice lacking TRPV1 receptors (Kollarik and Undem, 
2004).  
 
1.5.5. Prostaglandin E2 
There has been interest in the role of PGE2–mediated sensory nerve activation since it 
was discovered that as well as acting as a bronchodilator, inhaling aerosols of PGE2 
also caused irritation of the airways and cough in humans (Kawakami et al., 1973). 
Costello and colleagues characterised the PGE2-induced cough response in man and 
found that exposure to PGE2 produced two distinct phases of coughing. They also 
documented that PGE2 was 10,000 times more potent than CA in evoking coughing 
and that the response was accompanied by retrosternal soreness and tightness of the 
chest (Costello et al., 1985). There are few references in the literature describing the 
induction of cough in laboratory animals following PGE2. However, Gardiner did 
evaluate the tussive activity of prostanoid agonists in the cat and found that PGE2  
provoked coughing (Gardiner and Browne, 1984). PGE2 also activates sensory nerves 
in the guinea-pig, as application of PGE2 to the isolated vagus nerve preparation 
induces depolarisation (Patel et al., 2003). Prostaglandins have also demonstrated 
excitatory effects on guinea-pig vagal afferent ganglion cell bodies as deduced from 
electrophysiological studies (Undem and Weinreich, 1993). The mechanism by which 
PGE2 activates vagal afferent sensory nerves to initiate coughing is unknown.  It is 
hypothesised that the cough-provoking actions of PGE2 are secondary to stimulation 
of one or more of the prostaglandin receptors (EP1-4, DP1-2, TP, FP or IP), which 
may be localised to peripheral afferent nerve terminals.  
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1.5.6. Hypertonic saline     
Inhalation of hypertonic saline solutions are effective at evoking cough in guinea-pig 
(Lalloo et al., 1995; Gatti et al., 2006) and in man (Lowry et al., 1988; Fahy et al., 
1995; Koskela et al., 2005). Hypertonic saline is also a robust activator of airway 
sensory nerves using the isolated guinea-pig vagus nerve preparation (Birrell et al., 
2002; Patel et al., 2003) and excites fibres conducting in the Aδ-range as deduced 
from single fibre recordings of guinea-pig airway afferents (Fox et al., 1995a). The 
hypertonic saline-induced activation of Aδ-fibres is not inhibited by capsazepine (Fox 
et al., 1995b) and the cough response in the conscious guinea-pig is unaffected by 
pre-treatment with capsazepine (Lalloo et al., 1995), indicating a TRPV1-independent 
mechanism of cough provocation. The TRPV1-independent actions of hypertonic 
saline were confirmed using another TRPV1 antagonist, which showed that treatment 
of conscious guinea-pigs with IRTX had no effect on the cough response to 
hypertonic saline. Furthermore, a recent study determined that aerosolised protease-
activated-2 agonists potentiate the conscious cough response via TRPV1-dependent 
mechanisms. In this study CA and resiniferatoxin-induced cough were enhanced and 
hypertonic saline-induced cough was unaffected (Gatti et al., 2006). Therefore, 
evidence suggests that hypertonic saline acts independently of TRPV1.    
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Figure 1.2: Vagal afferent innervations involved in cough; probable mechanisms 
of sensory nerve stimulation by various cough-inducing stimuli. Amended from 
Undem et al., 2002. 
 
 
1.6. Which airway sensory nerves mediate the cough reflex? 
 
Research to determine precisely which airway afferent nerve sub-types mediate cough 
has not been conclusive and there has been debate in the literature regarding the 
primary sensory nerve(s) responsible for this reflex.  The use of different species, 
distinctive experimental set-ups and the state of consciousness or anaesthesia during 
investigation contributes to the differences in opinion as not all tussive stimuli evoke 
cough under all conditions (Mazzone et al., 2005). It is likely that all known types of 
sensory fibres participate in the cough reflex, but it is thought that in conscious 
animals, non-myelinated capsaicin-sensitive C-fibres and myelinated mechanically-
sensitive Aδ-fibres are the primary sensory pathways. More recently, the newly 
identified ‘cough receptor’ has also been proposed to be a primary afferent involved 
in the cough reflex (Canning et al., 2004; Mazzone, 2004). The differences in opinion 
might suggest divergence of multiple airway afferent pathways or the existence of 
primary and secondary pathways, which may be predominant in the ‘normal’ 
defensive cough reflex or in the ‘disease’ enhanced cough state. This section is 
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designed to give an overview of research aimed at understanding which airway 
sensory nerves are responsible for initiating cough and is not an exhaustive 
description of all findings. 
 
1.6.1. Rapidly adapting receptors and the cough reflex 
The RARs were originally believed to be the primary sensory nerve type responsible 
for the defensive cough reflex, since the rapid activation of RARs follows smooth 
muscle constriction, mechanical irritation and airways obstruction (Sant'Ambrogio et 
al., 1984; Widdicombe, 1998; Widdicombe, 2003). In vitro studies have shown that 
Aδ-fibres innervating guinea-pig airways are sensitive to stimulation with distilled 
water or hypertonic saline and this fibre type is unaffected by chemical stimulation 
with CAPS, bradykinin, low pH solutions or histamine (Fox et al., 1993; Pedersen et 
al., 1998).  However a number of in vivo studies have demonstrated that RARs are in 
fact activated by numerous chemical stimuli including CS, ammonia, CAPS, PGE2 
and histamine (Bergren and Sampson, 1982; Matsumoto, 1988; Mohammed et al., 
1993), which has been attributed to the resulting airways constriction or mechanical 
stimulation associated with exposure to these chemical stimuli. Early evidence 
supporting a role for RARs in cough came mainly from work in anaesthetised 
animals, particularly cats and dogs (Tatar et al., 1988; Tatar et al., 1994; 
Widdicombe, 1998). Widdicombe deduced from studies using cats that RARs mediate 
coughing (Widdicombe, 1954). Cough elicited by RAR activation was inhibited by 
cooling the vagus of anaesthetised dogs, which blocked the conduction in myelinated 
Aδ-fibres but not unmyelinated C-fibres (Tatar et al., 1994). Therefore, consideration 
of the chemosensitivity, mechanosensitivity and the distribution at all airway levels 
indicates that RARs play a key role in the cough reflex.  However, RAR stimulants 
such as histamine, leukotriene C4 and D4, SP and NKA have been ineffective at 
causing cough in the conscious state (Barnes et al., 1984; Joos et al., 1987; Canning et 
al., 2004; El Hashim and Amine, 2005). Further argument against a primary role for 
RARs in the cough reflex is derived from evidence that RARs are spontaneously 
active during the respiratory cycle, yet only evoke cough following specific 
mechanical stimulation (Bergren and Sampson, 1982; Canning et al., 2001; Mazzone 
and Canning, 2002). Therefore, perhaps only a specific sub-set of RARs mediate 
cough, or alternatively there is more than one afferent pathway acting synergistically 
in cough induction (Mazzone, 2004). It is possible that the secondary effects of C-
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fibre activation in vivo, which include bronchoconstriction, mucus secretion and 
plasma exudation, can evoke discharge in the mechanosensitive RARs. This theory is 
corroborated by studies in guinea-pigs, which show that bronchodilators may inhibit 
CAPS and bradykinin-induced activation of RARs (Bergren, 1997).  
 
1.6.2. Slowly adapting receptors and the cough reflex 
The role of SARs in the cough reflex is unclear as there is little evidence in the 
literature supporting the role of this fibre-type in cough. Unlike RARs, the SARs are 
not thought to be directly involved in the cough reflex. Single unit recordings of 
vagus nerves in rabbits show that their activity is not altered following stimulation 
with ammonia to evoke cough (Matsumoto, 1988). Furthermore, systemic injection of 
CAPS, which is a stimulant known to evoke cough in conscious animals and humans, 
activated C-fibres and RARs but did not activate SARs in anaesthetised rats (Ho et 
al., 2001) However, even though SARs may not play a direct role in the initiation of 
cough, SARs may act to modulate the cough reflex. Experiments on anaesthetised 
rabbits have demonstrated that inhibition of SAR activity with sulphur dioxide results 
in attenuation of the ammonia-induced cough response (Hanacek et al., 1984). 
Furthermore, inhalation of the loop diuretic furosemide appeared to sensitise SARs as 
well as inhibit RAR activity in anaesthetised rats (Sudo et al., 2000). In addition, 
SARs have been proposed to play a regulatory role on cough and breathing, by 
facilitating input into the central nervous control of cough pattern generation (Bolser 
and Davenport, 2002). Similarly to the other airway afferents, there may be species 
differences in the modulation of cough by SAR afferents. Therefore, thorough 
research is required to establish the role of SARs in possible regulation, control or 
modulation of the cough reflex.    
 
1.6.3. Chemosensors and the cough reflex 
There is an abundance of evidence in favour of a role of chemosensors in the cough 
reflex. Importantly, there are a number of chemical stimuli such as CAPS, 
resiniferatoxin, CA and bradykinin which are potent tussive agents in animals and in 
man in the conscious state (Forsberg and Karlsson, 1986; Choudry et al., 1989; Laude 
et al., 1993; Bergren, 2001b). The mechanisms of CAPS, CA and bradykinin-induced 
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cough are thought to be mediated via activation of the TRPV1 receptor, which is 
expressed on C-fibres and Aδ-nociceptors (Fox et al., 1995b; Ricco et al., 1996; 
Undem and Kollarik, 2002; Kollarik and Undem, 2004). Furthermore, the TRPV1 
antagonists capsazepine and IRTX significantly inhibit CAPS and CA-induced cough 
in the conscious guinea-pig (Lalloo et al., 1995; Trevisani et al., 2004) and the 
TRPV1 ion channel openers anandamide and resiniferatoxin also evoke cough in 
animals and humans in the conscious state (Laude et al., 1993; Jia et al., 2002). C-
fibres can be distinguished from other airway afferent sub-types as they are known to 
synthesise and release neuropeptides. Treatment with NK receptor antagonists has 
been shown to inhibit CA, CAPS or bradykinin-induced cough in guinea-pig, cats and 
dogs, which has ben attributed to a central mechanism of action (Girard et al., 1995; 
Bolser et al., 1997; Chapman et al., 2004). Studies in anaesthetised guinea-pigs have 
documented that the central administration of NK receptor antagonists prevented the 
C-fibre mediated sensitisation of the cough reflex (Mazzone et al., 2005). However, 
the antitussive effect of neurokinin antagonists in man has not been proven. This is 
likely because the majority of studies investigating the expression of tachykinins are 
conducted using the guinea-pig, which may express a higher density of tachykinin 
containing fibres compared to most mammals (Baluk et al., 1992; Lamb and Sparrow, 
2002; Undem et al., 2004). A clinical study by Fahy et al showed that an NK1 
antagonist did not inhibit hypertonic saline induced bronchoconstriction or cough in 
patients with mild asthma (Fahy et al., 1995). Whereas, Ichinose and colleagues found 
that a dual NK1 and NK2 tachykinin receptor antagonist did inhibit bradykinin-
induced bronchoconstriction and cough in asthmatic subjects (Ichinose et al., 1992).   
 
Considering the potency of chemical stimulants in evoking cough in the conscious 
state, it is surprising that activation of airway chemosensors with stimuli such as 
CAPS and bradykinin does not cause cough in anaesthetised animals even though 
cough can be evoked in anesthetised animal models following mechanical probing, 
electrical stimulation or exposure to acid (Tatar et al., 1994; Karlsson et al., 1993; Lee 
and Pisarri, 2001; Canning et al., 2004). Furthermore, the systemic application of 
CAPS does not initiate a cough response and has been shown to inhibit cough evoked 
by mechanical stimulations in anaesthetised animal models, indicating that C-fibre or 
chemosensor activation may be inhibitory to the cough reflex (Tatar et al., 1988; 
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Tatar et al., 1994). Conversely, Mazzone et al found that CAPS applied to the trachea 
or microinjected into the NTS of anaesthetised guinea-pigs, can act to increase 
mechanical and acid-induced cough reflex sensitivity, which was mimicked by 
microinjection of SP into the NTS (Mazzone et al., 2005). Therefore, the majority of 
arguments against a primary and direct role of chemosensors in cough are derived 
from work in anaesthetised animals. It is unclear as to why there are discrepancies 
between the cough-provoking and sensitising actions of C-fibre stimulants between 
the conscious and anaesthetised setting. Perhaps the nociceptive pathways are 
sensitive to the effects of general anaesthesia, thereby suppressing the C-fibre 
mediated responses. However, evidence has shown that other C-fibre mediated 
effects, such as bronchospasm and mucus secretion, do remain intact despite 
anaesthesia (Roberts et al., 1981; Davis et al., 1982; Bergren, 1997; Canning et al., 
2001). These findings have led some to believe that in conscious animals, C-fibre 
stimulants may elicit a conscious perception of airway irritation and it is the cortical 
processing derived from an ‘urge-to-cough’ that provokes the resulting tussive 
response. Indeed, a clinical study has shown that cough induced by inhalation of 
CAPS can be voluntarily suppressed (Hutchings et al., 1993). 
 
Chemosensors and TRPV1 may play a fundamental role in cough associated with 
chronic airway inflammatory diseases in man, as patients with asthma, cough variant 
asthma and COPD demonstrate a greater cough sensitivity to inhalation of CAPS 
(Fujimura et al., 1994; Wong and Morice, 1999; Doherty et al., 2000; Millqvist, 
2000). However, other groups have reported that cough reflex sensitivity to CAPS 
does not significantly differ between asthmatics and normal subjects (Fujimura et al., 
1998; Dicpinigaitis, 2001). Interestingly, a significant increase in expression of 
TRPV1-positive nerves has been detected in the airway epithelium of patients 
suffering from chronic cough, which correlated with the tussive response to CAPS 
(Groneberg et al., 2004a). Furthermore, the expression of TRPV1 is more abundant in 
the airway smooth muscle of chronic coughers compared to normal human airways 
(Mitchell et al., 2005). 
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1.6.4. The recently identified ‘cough receptor’ and the cough reflex 
In 2004, Canning and colleagues published findings regarding a previously 
unidentified fibre type in the guinea-pig, which they have characterised and named 
the ‘cough receptor’ (Canning et al., 2004). As described previously, these 
extrapulmonary, low threshold mechanosensors, which are distinct from RARs, SARs 
and C-fibres are sensitive to light punctuate mechanical stimulation and also to 
exposure to acid. There is a wealth of literature describing the induction of cough in 
animals and humans by mechanical irritation and by changes in pH (Ricco et al., 
1996; Nishino et al., 1996; Wong et al., 1999; Kollarik and Undem, 2002; Morice et 
al., 2007), which could potentially be attributed to ‘cough receptor’ activation. The 
location of these receptors in the larger airways suggests that they may be an 
important airway afferent in cough reflex defence mechanisms. Interestingly, unlike 
C-fibres and RARs, activation of the ‘cough receptors’ can initiate cough in both 
anaesthetised and conscious guinea-pigs (Canning et al., 2004). The ‘cough receptors’ 
are unresponsive to stimulants such as histamine, methacholine, leukotriene C4, SP 
and NKA, which induce bronchoconstriction but are ineffective at evoking cough 
(Chausow and Banner, 1983; Barnes et al., 1984; Joos et al., 1987; El Hashim and 
Amine, 2005). Furthermore, the ‘cough receptor’ has not been identified in rats or 
mice, which are both species that do not cough (Canning et al., 2004; Mazzone, 
2005). Specific mechanical stimulation or irritation of the upper airways certainly 
evokes cough in species other than the guinea-pig, including dogs, cats and in man 
(Tatar et al., 1994; Nishino et al., 1996; Bolser et al., 1997).  Therefore, further 
research is needed to confirm whether equivalent guinea-pig ‘cough receptor’ fibre-
types exist in the larger airways of man.  
 
1.7. Central nervous regulation of the cough reflex 
 
There is still a great deal to learn about the central nervous mechanisms underlying 
the cough reflex. Interestingly, cough is a respiratory event that can be initiated via a 
reflex pathway or accurately initiated voluntarily. It is believed that the conscious 
cough reflex involves complex integrations mediated in the brainstem, which is under 
the control of regulatory mechanisms and also voluntarily cortical control (Shannon et 
al., 2004). The activation of airway sensory nerves results in signal transmission to 
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neurones in the nucleus tractus solitarius (NTS), which are located in the dorsal 
medulla. The synaptic inputs from second order neurons are then reorganised into a 
logical output and relayed to a group of respiratory-related neurones that comprise the 
central cough pattern generator. The central cough generator then coordinates the 
activity of medullary respiratory motorneurons to generate a cough  (Bonham et al., 
2004). There is a relationship between the brainstem neuronal pathways involved in 
cough and the neuronal pathways involved in breathing, which are linked to the 
‘respiratory pattern generator’. Shannon and colleagues related the brainstem neuronal 
pathways involved in cough and breathing by analysing nervous activity in 
‘respiratory modulated’ and ‘non-respiratory modulated’ neurones in the brainstem 
following application of tussive stimuli to the airways (Shannon et al., 2000; Baekey 
et al., 2001). The complex network of neurons in the medulla, which include the NTS, 
botzinger, pre-botzinger and ventral respiratory group, act to process the motor 
patterns of the cough reflex as well as other airway defensive reflexes such as the 
expiration reflex and sneezing, however very little is known about the interaction 
within and among these networks (Shannon et al., 2004).  
 
1.8. Experimental models and mechanisms of cough reflex sensitisation  
 
It is hypothesised that the activity of sensory nerves may be enhanced during airway 
disease, resulting in exacerbation of the protective cough reflex and manifestation of 
chronic cough. The majority of cough research in the laboratory has focussed on the 
direct tussive stimuli-induced activation of airway afferent nerves to initiate cough. In 
comparison, there is less research on the mechanisms of sensitisation resulting in an 
enhanced cough response upon stimulation with tussive agents. Focus of further 
research should therefore be aimed at understanding the neural mechanisms that occur 
in the disease state in the hope of pharmacologically modulating the cough response 
back to a normal level, rather than inhibit the basic protective cough pathway 
altogether.  
 
1.8.1. Cigarette smoke     
Smoking is a powerful irritant of the respiratory tract and is the main cause for 
developing COPD, which is defined by The Global Initiative on Obstructive Lung 
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Disease as “a disease state characterised by airflow limitation that is not fully 
reversible”. Principle symptoms of COPD include cough, breathlessness and 
increased sputum, and this complex inflammatory disease is characterised by 
increased neutrophilia, macrophages and mucus hypersecretion in the lung (Barnes, 
2004). The act of coughing is an essential reflex in COPD aimed at clearing excess 
mucus; however chronic and unrelenting cough due to pathological alterations to 
cough reflex sensitivity can contribute to the deterioration in quality of life. Chronic 
coughing in COPD may be caused by a number of factors including airway 
inflammation, mucus hypersecretion and enhanced cough reflex sensitivity but their 
relative contributions remain to be elucidated (Smith and Calverley, 2004). It is 
probable that the mechanically sensitive sensory nerves could be activated following 
mucus accumulation at the receptive field and that inflammatory mediators associated 
with airway inflammatory disease could directly activate and sensitise airway sensory 
nerves (Carr and Undem, 2003a). It is believed that smoking alters the activity of the 
cough reflex by enhancing the responsiveness of the afferent fibres that mediate 
cough; however the mechanisms mediating this change in airway afferent activity are 
still unclear.  
 
Both chronic and acute CS exposures in laboratory animals can enhance the cough 
response induced by tussive stimuli, thus providing research models to mimic the 
conditions seen in man.  
 
1.8.1.1. Modulation of the human cough reflex with cigarette smoke 
Sufferers of COPD may present with chronic cough as described above. Furthermore, 
clinical studies have demonstrated that cough reflex sensitivity induced 
experimentally by tussive agents is augmented in patients with airway inflammatory 
diseases. COPD patients exhibited a lower cough threshold to aerosolised CA 
compared to healthy volunteers (Wong and Morice, 1999). Furthermore, challenge 
with inhaled CAPS resulted in an enhanced cough response in patients with COPD 
compared to healthy individuals (Doherty et al., 2000). The effects of smoking on 
cough reflex sensitivity have also been investigated in the clinic. Interestingly, the 
cough response to CAPS in healthy smokers was diminished compared to the tussive 
effects in non-smokers, perhaps caused by long-term smoke-induced desensitisation 
of the receptors responsible for mediating cough (Millqvist and Bende, 2001; 
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Dicpinigaitis, 2003a). As early as 2 weeks after smoking cessation, the cough reflex 
sensitivity to CAPS is enhanced. The subsequent resumption of smoking after 2-12 
weeks of abstinence results in a diminished cough response once more (Dicpinigaitis 
et al., 2006; Sitkauskiene et al., 2007). 
 
1.8.1.2. Modulation of the conscious guinea-pig cough reflex with cigarette smoke 
Karlsson et al published work describing an exacerbation of the CA and CAPS 
induced conscious cough response in guinea-pigs following daily exposures to CS for 
two weeks. They monitored the resolution of the enhanced cough and found that the 
hyper-responsiveness to tussive agents gradually returned to normal over a period of 3 
weeks. Furthermore, CS exposure did not augment the level of bronchoconstriction 
induced by CA, CAPS or histamine. There was a significant increase in CGRP-like 
material in tracheal tissue taken from CS-exposed guinea-pigs compared to controls, 
suggesting that CS causes a tussive hyper-responsiveness targeting specifically 
CAPS-sensitive CGRP containing sensory nerves  (Karlsson et al., 1991). Joad et al 
found that guinea-pigs exposed to smoke from one to six weeks of age demonstrate a 
tussive hyper-reactivity and an augmented airway obstruction (measured as Penh) in 
response to aerosolised CA, which was inhibited by injection of an NK1 antagonist 
into the NTS (Joad et al., 2004). Therefore, the authors suggest that SP may play an 
important role in modulating cough via the brainstem network (Bonham et al., 2004). 
Bergren has published data investigating the effects of a chronic smoke exposure 
regime on cough reflex sensitivity, which involved exposing guinea-pigs to smoke 
once a day for up to 120 days. Similarly to previous observations, exposure to smoke 
did not modulate the response to histamine or methacholine but did exacerbate the 
response to the chemical stimulants CAPS and also bradykinin. Furthermore, 
inhalation of a dual NK receptor antagonist significantly inhibited the CAPS-induced 
cough, therefore the mechanism of enhanced cough following smoke was believed to 
involve CAPS-sensitive sensory nerve C-fibres and the release of neuropeptides 
(Bergren, 2001b; Bergren, 2001c). Similarly, guinea-pigs chronically exposed to CS 
demonstrated a significant increase in CAPS-induced airway hyperresponsivness 
compared to controls, which was attenuated by treatment with NK1 and NK2 receptor 
antagonists and the effects attributed to an increase in SP synthesis and release in the 
jugular ganglion (Kwong et al., 2001). Recently, Lewis and colleagues published 
work describing the development and pharmacological modulation of acute CS 
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models of exacerbated cough using CA and CAPS. The enhanced cough responses 
were inhibited by treatment with codeine, terbutaline, atropine and a dual NK 
antagonist, however there was no significant effect on cough numbers following 
treatment with the TRPV1 antagonists capsazepine or IRTX (Lewis et al., 2007).  
 
1.8.1.3. Modulation of sensory neuronal function with cigarette smoke  
As well as obtaining evidence using conscious guinea-pig models of cough, work 
should focus on understanding the modulation of neural function in the hyper-
responsive state. There are a handful of studies which have documented the direct 
effects of CS upon activation of specific airway afferent sub-types. Recordings of 
afferent receptor activity, has suggested that RARs and C-fibres mediate the direct 
effects of CS on sensory nerves. RARs in the anaesthetised guinea-pig were directly 
activated by inhalation of CS (Bergren and Sampson, 1982) and experiments on 
anaesthetised dogs showed that a single breath of CS evoked an intense burst of 
discharge in C-fibres (Lee et al., 1989; Kou and Lee, 1990; Kou and Lee, 1991). 
Single unit recordings of vagal afferents in anaesthetised rats showed that CS 
activated C-fibres, had a mild stimulatory effect in a proportion of RARs and had no 
effect on SARs (Ho et al., 2001).  Mutoh et al found that chronic exposure to smoke 
increased CAPS-induced C-fibre impulse reactivity in anaesthetised guinea-pigs 
(Mutoh et al., 1999). Additional studies by this group investigated whether 
augmentation of the cough reflex response also occurred via central nervous 
mechanisms and found that prolonged exposure to smoke significantly augmented the 
peak and duration of NTS neuronal responses via central nervous reflex mechanisms 
(Mutoh et al., 2000).  
 
1.8.2. Allergic animal models 
Investigators have also derived evidence about the mechanisms of enhanced coughing 
and cough reflex sensitisation using animal models of allergic airway inflammation. 
There are a number of studies that have demonstrated enhanced coughing in response 
to inhaled CAPS one or more days after antigen challenge in sensitised guinea-pigs 
(Kudlacz et al., 1996; Xiang et al., 1998; Liu et al., 2001; Katayama et al., 2001; 
Myou et al., 2001). The enhanced cough responses following allergen challenge are 
associated with airway eosinophilia. Similarly to studies describing pharmacological 
modulation of the enhanced cough following CS exposure, the augmented CAPS-
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induced cough response following allergen challenge is attenuated by treatment with 
NK1, NK2 and dual NK antagonists (Kudlacz et al., 1996; Xiang et al., 1998). 
Interestingly, allergic inflammation in guinea-pig airways leads to the production of 
the neuropeptides SP, CGRP and NKA in the large diameter low-threshold Aδ-
mechanosensors in the nodose ganglia, which do not constitutively express 
neuropeptides under normal conditions (Fischer et al., 1996; Undem et al., 1999; 
Myers et al., 2002; Dinh et al., 2005).  
 
1.8.3. Inflammatory mediators    
Many inflammatory mediators not only initiate cough but act to sensitise the cough 
reflex to other tussive agents. This phenomenon could contribute to the enhanced 
cough reflex sensitivity associated with airway inflammatory diseases. Augmented 
sensitivity to tussive stimuli such as CAPS has been demonstrated in patients with 
airway inflammatory disease including upper respiratory tract infections, asthma and 
COPD (O'Connell et al., 1996; Wong and Morice, 1999; Doherty et al., 2000). 
 
1.8.3.1. Modulation of the cough reflex by bradykinin 
As well as directly causing cough, bradykinin sensitises the cough reflex to 
subsequent tussive stimulation. In vitro electrophysiological studies by Fox et al, 
showed that exposure to bradykinin resulted in a significant increase in subsequent 
single vagal C-fibre responses to CAPS (Fox et al., 1996). Furthermore, 
corresponding in vivo studies were carried out which showed that CA-induced cough 
was augmented in guinea-pigs previously exposed to bradykinin and/or the ACE 
inhibitor, captopril, and in both cases the augmentation was prevented by treatment 
with a bradykinin B2 receptor antagonist. These findings suggest that sensitisation of 
airway sensory nerves by bradykinin may underlie the mechanisms of cough caused 
by taking ACE-inhibitors (McEwan et al., 1989; Fox et al., 1996). The enzyme ACE 
acts to break down bradykinin, therefore the accumulation of bradykinin in the 
airways of patients taking ACE-inhibitors could be the cause of increased cough 
sensitivity often associated with this therapy (Fox et al., 1996). More recently, 
Mazzone and colleagues demonstrated that bradykinin applied to the trachea of 
anaesthetised guinea-pigs or administered as an aerosol into the airways, significantly 
reduced the threshold for cough activation by CA or electrical stimulation (Mazzone 
et al., 2005).  
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1.8.3.2. Modulation of the cough reflex by prostaglandins 
In addition to directly causing cough, prostaglandins also sensitise the cough reflex to 
CAPS. A clinical study by Choudry et al documented that the cough response induced 
by CAPS is significantly heightened following inhalation of PGE2, suggesting that an 
enhanced cough reflex sensitivity in man could be caused by endogenously produced 
PGE2 in the airways (Choudry et al., 1989). Stone et al examined the effect of 
prostaglandin-induced sensitisation of the human cough response to CAPS and found 
that inhaled prostaglandin F2α (PGF2α) had a significantly more marked effect than 
PGE2 (Stone et al., 1992). Furthermore, the augmented CAPS cough response 
following exposure to PGF2α is inhibited by inhaled salbutamol but not by ipratropium 
bromide (Nichol et al., 1990). The mechanisms underlying the augmented sensitivity 
of airway sensory nerves and the cough reflex following exposure to prostaglandins is 
unknown. It is possible that modulation of membrane properties occurs secondarily to 
activation of specific prostanoid receptors located on the peripheral nerve terminals, 
which could be further investigated using specific prostanoid agonists and antagonists 
to modulate the response. A study in anaesthetised rats found that intravenous 
infusion of PGE2 potentiated the stimulatory effects of CAPS on C-fibres but had no 
effect on the sensitivity of RARs or SARs to lung inflation (Ho et al., 2000). Evidence 
in favour of a direct action of PGE2 on sensory nerve endings has been described 
using whole cell voltage clamp recordings in cultured rat nodose and jugular sensory 
neurons, which have been retrogradely labelled with fluorescent tracer. The results 
show that pre-treatment with PGE2 amplified the whole cell current elicited by CAPS 
(Kwong and Lee, 2002).  Further research in this field is required, in order to 
understand the mechanisms by which prostanoids such as PGE2 sensitise airway 
sensory nerves and the cough reflex. 
 
1.8.4. Neurotrophins  
The neurotrophins may be implicated in the modulation of airways afferent nerves 
leading to chronic cough as there is an increasing body of evidence that neurotrophins 
mediate effects on sensory nerve function in inflammatory diseases. The 
neurotrophins, which include nerve growth factor (NGF), brain derived neurotrophic 
factor (BDNF), glial derived neurotrophic factor (GDNF), neurotrophin-3 (NT3) and 
neurotrophin-4 (NT4), are essential for the differentiation and survival of developing 
neurons (Levi-Montalcini et al., 1996; Lewin and Barde, 1996). Peripherally, the 
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neurotrophins have a discrete neuronal specificity; NGF acts primarily on neural 
crest-derived sensory neurones (dorsal root, jugular and TG) and BDNF promotes the 
survival of placode-derived nodose ganglia (Lindsay, 1996).  The biological effects of 
neurotrophins are mediated by binding to two different receptor types, the 
tropomyosin-related kinase (TrkA, TrkB, TrkC) family of receptor tyrosine kinases 
and the p75NTR receptor. NGF preferentially activates TrkA receptors whereas BDNF 
is selective for TrkB receptors (Maliartchouk and Saragovi, 1997; Klesse and Parada, 
1999). The ligand-induced activation of the neurotrophin Trk receptors involves 
homodimerisation and autophosphorylation and the activation of multiple signal 
transduction pathways. The p75NTR receptor belongs to the family of death receptors, 
shows strong homology with the tumour necrosis factor-α p75 receptor and binds all 
of the neurotrophins (Frossard et al., 2004).  
 
1.8.4.1. Neurotrophins and the cough reflex 
To date there have been few reports regarding the role of neurotrophins in the 
enhanced cough response. Hele et al found that repeated subcutaneous treatment with 
NGF sensitised the cough reflex, demonstrated by an enhanced conscious cough 
response to CA in the guinea-pig as well as increased sensory nerve activation in the 
guinea-pig isolated vagus nerve (Hele et al., 2002). The airway epithelium lies in 
close proximity to airway sensory nerve endings and is a proposed source of 
neurotrophins (Fox et al., 2001), providing a localised resource to the direct actions 
on airway afferents. Clinically, Hope-Gill and colleagues compared the pathogenesis 
of cough in patients with idiopathic pulmonary fibrosis (IPF) and in healthy subjects. 
They found that those with IPF had a heightened cough sensitivity to inhaled CAPS, 
bradykinin and SP, which was associated with significantly higher levels of NGF and 
BDNF in patients sputum (Hope-Gill et al., 2003). A more recent clinical study in 
chronic coughers found that concentrations of neurotrophins in serum and sputum 
were not increased in patients with chronic persistent cough compared to healthy 
subjects. However, detection of NGF in the sputum did correlate with the duration of 
cough (Chaudhuri et al., 2005).  In addition, patients with respiratory symptoms who 
showed sensitivity to scents and chemicals, had a significant increase in NGF in nasal 
lavage fluid, which was associated with CAPS-induced cough sensitivity (Millqvist et 
al., 2005). 
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1.8.4.2. Neurotrophins in airway inflammatory disease 
A role for neurotrophins in modulating sensory innervation leading to allergic 
inflammation and airway hyper-reactivity has been demonstrated (Braun et al., 
1999a). Increased levels of neurotrophins are present in the bronchoalveolar lavage 
(BAL) fluid and serum of patients with airway inflammatory disease (Bonini et al., 
1996; Sanico et al., 2000). BDNF levels are also elevated in the BAL fluid of mice 
displaying characteristics of allergic airway inflammation (Braun et al., 1999b). The 
release of neurotrophins is further stimulated following allergen challenge as elevated 
levels of NGF, BDNF and NT-3 are present in the BAL fluid of patients with asthma 
and in a mouse model of airway inflammation, after allergen provocation (Virchow et 
al., 1998; Braun et al., 1999a). Furthermore, treatment of mice with NGF enhanced 
airway hyper-responsiveness to a similar extent as that seen in allergen-sensitised 
mice (Braun et al., 2001). Comparably, treatment of mice, guinea-pigs and rats with 
anti-NGF antibodies inhibited the development of airway hyper-reactivity in models 
of allergic airway inflammation (Braun et al., 1998; de Vries et al., 2002; Glaab et al., 
2003).  
 
1.8.4.3. Modulation of sensory neuronal function with neurotrophins 
Further support in favour of neurotrophin-induced modulation of airway sensory 
nerve function is derived from evidence that neurotrophins regulate the production of 
neuropeptides leading to sensory hyperrinnervation. Since neuropeptides are released 
following activation of airway sensory nerve C-fibres, this could implicate a direct 
link with mechanisms surrounding cough sensitisation. Furthermore, both mRNA and 
protein expression of the neurotrophin-specific Trk receptors have been detected in 
airway sensory nerve ganglion (Michael and Priestley, 1999; Dinh et al., 2004b). 
Hoyle et al directly examined the role of NGF in hyperinnervation of the airways by 
generating transgenic mice which over-express NGF in the lung. They found that 
mice over-expressing NGF had an augmented expression of SP as measured by 
immunohistochemistry and an enzyme immunoassay (Hoyle et al., 1998). The effects 
of NGF on airway inflammation were mediated via the production of neuropeptides, 
as a dual neurokinin antagonist inhibited the inflammatory response in NGF over-
expressing mice (Quarcoo et al., 2004). Recently, analysis of a guinea-pig model of 
allergic airway inflammation documented that an increase in NGF in the BAL fluid 
was accompanied by an enhanced expression of SP in the lung tissue and the nodose 
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ganglion, which was attributed to the activation of TrkA receptors on sensory nerves 
(de Vries et al., 2006). A role for neurotrophin-induced neuropeptide synthesis in 
airway afferent nerves is further supported by evidence that instillation of NGF into 
the trachea of guinea-pigs is associated with an increase in the expression of SP in 
airway afferents. In addition, NGF induced a change in the phenotype of innervation 
as SP was expressed in a proportion of large-diameter mechanosensitive Aδ fibres in 
the nodose ganglion, which does not constitutively express this neuropeptide (Hunter 
et al., 2000).  This phenotypic switch has been confirmed in another species, as NGF 
injected into the lower airways of mice induced SP and TrkA expression in large-
diameter CAPS-insensitive vagal sensory neurons (Dinh et al., 2004b).  
 
As well as regulation of the production of neuropeptides, another mechanism by 
which neurotrophins may sensitise airway sensory nerve activity is through an 
increased expression of the TRPV1 receptor, thus resulting in enhanced 
chemosensitivity. In fact, transgenic NGF mice are more sensitivite to the constrictive 
effects of inhaled CAPS, compared to wild types (Hoyle et al., 1998; Path et al., 
2002) and treatment of rat nodose-jugular cultures with BDNF regulates CAPS 
sensitivity, as measured by calcium uptake (Winter, 1998). Perforated patch clamp 
recordings of CAPS-responsive DRG cells in culture shows that NGF acutely 
sensitises the response to CAPS (Shu and Mendell, 1999). Dinh et al investigated the 
effect of NGF on the expression of TrkA, SP and TRPV1 in labelled sensory neurons 
from the nodose-jugular complex of mice. They found that in the control group, 
TRPV1 and SP were co-localised. However, NGF injected into the lower airways 
induced an increase in the expression of TrkA and SP in CAPS-insensitive large 
diameter sensory neurons but did not alter the expression of TRPV1 (Dinh et al., 
2004b). Conversely, evidence in favour of neurotrophin-mediated expression of 
TRPV1 is provided by Ji et al, who showed that intrathecal administration of NGF to 
rats induced an increased expression of TRPV1 protein but not mRNA level 
expression in the DRG. This effect was further corroborated with in vitro treatment of 
DRG cultures with NGF, which also resulted in an increase in TRPV1 protein 
expression (Ji et al., 2002). Similarly, treatment of rat TG neuronal cultures with NGF 
did not alter TRPV1 mRNA levels but did significantly increase the abundance of 
TRPV1 protein compared to controls (Price et al., 2005). As neurotrophins have been 
shown to affect the neurophysiology of the airways by modulating the synthesis of 
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neuropeptides and ion channels located on sensory nerve afferents, it is speculated 
that neurotrophins may play an important role in sensitisation of the cough reflex.    
 
1.9. Antitussive therapies 
 
The site of action of antitussive therapies can be broadly classified into two groups; 
those that act centrally and those that act peripherally to suppress cough. Centrally 
acting cough suppressants are often associated with neurological side-effects such as 
sedation and physical dependence, which can limit their effective use. Peripherally 
acting antitussives exert their effects by acting outside of the central nervous system 
by targeting peripheral vagal sensory nerve afferents, which could potentially prove a 
better approach, avoiding unwanted side-effects. Considering the numerous causes of 
cough and the complexity of cough provocation, there are diverse targets in the search 
for effective new antitussive therapies. Certain therapeutic strategies in the treatment 
of cough do not utilise antitussives per se, rather they target the underlying condition 
that causes the cough, for example the treatment of asthma, COPD or GORD. Other 
treatment strategies focus on inhibiting the sensory nerve activation, irrespective of 
the cause. As described previously, much research has focussed on understanding the 
neural mechanisms of enhanced cough in order to target specific ion channels, 
receptors or molecules that are expressed by peripheral sensory nerves. 
 
The development of novel efficacious antitussive therapies would be extremely 
beneficial in cough that presents as a troublesome symptom associated with a number 
of inflammatory airway diseases. However, cough is an important defence mechanism 
that helps to clear excessive secretions and foreign material from the airway. 
Therefore, the ideal antitussive would cause a suppression of the exacerbated cough 
reflex, leaving the normal protective cough reflex intact. As currently available 
antitussives have been shown to possess little clinical efficacy, the identification of 
novel therapeutic targets will be of immense therapeutic benefit and will greatly 
enhance the quality of life of patients who suffer from chronic cough, which can be a 
debilitating and depressing symptom. 
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1.9.1. Current over-the-counter antitussive therapies 
There are numerous OTC, non-prescription cough medications available today for the 
treatment of acute cough and the total world market for cough remedies is estimated 
at over $4 billion per year. Since acute cough is often associated with the common 
cold, OTC cough remedies can be composed of a combination of medications 
designed to relieve the various symptoms, including antihistamine, decongestants, 
mucolytics and expectorants (Irwin and Madison, 2000). OTC lozenges act to soothe 
the throat and often contain local anaesthetics or menthol, which are believed to act 
locally in the upper airways to relieve irritation by reducing neural transmission. 
Dextromethorphan is an isomer of the opioid analgesic levomethorphan and is a 
commonly used antitussive devoid of analgesic or sedative properties. It constitutes 
the pharmacological component of many OTC cough therapies. However, a recent 
study involving over 2100 participants determined the effectiveness of OTC cough 
remedies to be of little clinical relevance (Schroeder and Fahey, 2002). Many of the 
current cough remedies are believed to simply act as lubricants and coat the throat to 
prevent the urge to cough, rather than effectively pharmacologically modulating the 
cough reflex. In fact, a recent review proposes that the beneficial effect of cough 
syrups is largely associated with a placebo effect rather than a pharmacological effect 
(Eccles, 2006).  
 
1.9.2. Opiates 
The opiates, codeine, morphine and diamorphine, are currently the most effective and 
widely used treatments for cough. Codeine is generally accepted as the standard or 
reference antitussive agent against which new medications can be compared. 
Recently, a clinical trial using morphine sulphate, demonstrated effective antitussive 
therapy in chronic coughers who did not respond to specific antitussive treatments 
(Morice et al., 2007). Like opioid induced analgesia, the antitussive effects of the 
opioids are generally mediated centrally by brainstem opioid receptors, although they 
may also act peripherally on receptors located on sensory nerve endings. Although 
clinical evidence has shown codeine treatment to cause a significant inhibition of 
cough induced in normal volunteers (Eddy, 1969), recent studies have shown that 
codeine is no more effective than placebo in patients with COPD and problematic 
cough (Smith et al., 2006). Furthermore, the use of the centrally acting opiates in 
chronic cough is seriously limited as at the effective doses they can cause unwanted 
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side-effects such as respiratory depression, physical dependence, gastrointestinal 
problems and vomiting (Belvisi and Geppetti, 2004). Therefore sufferers of chronic 
cough may often choose to not take antitussives at all and the use of morphine is 
generally restricted to treating patients with severe distressing cough, which often 
occurs in terminal illnesses such as lung cancer.  
 
1.9.3. Local anaesthetics 
Local anaesthetics such as lignocaine are peripherally acting antitussives when 
delivered locally to the airways and may be useful in treating chronic cough that is 
resistant to other treatments. Nebulised lignocaine has been shown to be effective in 
reducing CAPS-induced cough in man (Choudry et al., 1990; Millqvist, 2000). 
However, the effects of local anaesthetics are transient and long-term use may result 
in increased risk of inspiration of liquids. The mechanism of action of local 
anaesthetics in reducing action potential generation is believed to be through 
inhibition of voltage gated sodium channels (Scheuer, 2007), therefore reducing the 
generation of action potentials and transmission in sensory nerves.  
 
1.9.4. Current specific antitussive therapies to treat the causes of cough 
Since there are currently no efficacious non-specific antitussive therapies, the current 
treatment strategy for chronic cough depends on making an accurate diagnosis of the 
underlying cause. However, not all cough is effectively treated using this approach, in 
particular in those who suffer from idiopathic cough. Furthermore, those treated for 
the underlying disease would often benefit from additional specific antitussive therapy 
to alleviate persistent symptoms.  
 
Investigators have suggested that the suppression of chronic cough may be 
successfully achieved with specific therapy. For example, patients presenting with 
asthma, cough variant asthma or eosinophilic bronchitis are often treated with inhaled 
corticosteroids. Cough secondary to post-nasal drip syndrome can be effectively 
treated with topical corticosteroids, nasal decongestants or anti-histamines. There is a 
common association between GORD and chronic cough and the current first line 
treatments are proton pump inhibitors or H2-receptor antagonists. Cessation of 
smoking or the use of bronchodilators may be effective in cough associated with 
chronic bronchitis. Chronic cough induced by specific drug therapy such as ACE 
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inhibitors is most successfully treated by discontinuing use of the drug and seeking an 
alternative (Irwin and Madison, 2000; Morice et al., 2004).  
 
Chronic cough is also a symptom of airway inflammatory diseases such as COPD 
(Smith and Calverley, 2004) and patients demonstrate an enhanced cough reflex 
sensitivity following exposure to CAPS (Doherty et al., 2000). However, there is a 
debate as to whether a non-specific antitussive should be used to treat diseases such as 
COPD, which present with an underlying mucus hypersecretory response, since 
suppression of the cough response could lead to an accumulation of mucus and an 
increase in the risk of infection and exacerbations. Nevertheless, efficacious 
antitussives would be extremely beneficial providing the pharmacological modulation 
was carefully monitored to treat the enhanced cough response and leave the protective 
mechanisms intact.   
 
1.9.5. Potential new antitussive targets 
There is a need to develop novel, effective and safe antitussive therapies. As 
described in this chapter, there are a number of clinical and laboratory based studies 
investigating the neural mechanisms of cough and the modulation of sensory nerve 
function associated with an enhanced cough reflex response. Therefore, there are 
currently a number of antitussive targets aimed at specific ion channels, receptors or 
molecules that are expressed by peripheral sensory nerves or act to modulate airway 
afferent nerve function. These include peripherally acting opiates and antagonists 
acting peripherally on TRPV1, NK or bradykinin receptors. Other novel therapeutic 
approaches include the inhibition of prostanoid synthesis or function as well as 
inhibition of neurotrophins. Other potential targets for investigation include potassium 
channel openers and cannabinoid agonists, which have both been shown to inhibit the 
in vitro activation of sensory nerves as well as the in vivo CA-induced cough in the 
guinea-pig (Fox et al., 1997; Patel et al., 2003). The methylxanthine derivative 
theobromine is also effective in inhibiting CAPS-induced coughing in the conscious 
guinea-pig, depolarisation of isolated guinea-pig and human vagus nerve as well as 
effectively suppressing CAPS-induced cough in man (Usmani et al., 2005). 
Therefore, research aimed at understanding the neural mechanisms of peripheral 
sensitisation of airway sensory nerves, may lead to the successful development of new 
pharmacological approaches and therapeutic possibilities in the treatment of cough.  
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1.10. Thesis plan 
 
As described in this chapter, cough is a vital defence reflex to protect the airways. 
Although there is a wealth of information known about cough, the specific 
mechanisms underlying the production of a cough are not fully understood. 
Furthermore, modulation of the cough reflex can lead to sensitisation and an 
exacerbated response. This irritating and often debilitating symptom may be attributed 
to an underlying disease; however in many cases the cause of cough is unknown. As 
there are currently no efficacious non-specific antitussive therapies, modelling and 
investigating the cough response could lead to the identification of novel therapeutic 
strategies. Therefore, the aims of this thesis are to use a multi-disciplinary approach to 
investigate the cough reflex and the modulation of airway sensory nerves associated 
with an enhanced cough reflex. This will be achieved by; 
 
1. Developing in vivo and in vitro guinea-pig models of cough and sensory nerve 
activation, using distinct tussive stimuli, which have been shown to elicit 
cough in man.  
 
2. Investigating whether exposure to CS alters the activity of the cough reflex in 
guinea-pigs by modulating the responsiveness of the afferent fibres that 
mediate cough.  
 
3. Investigating the role of the neurotrophins, NGF and BDNF, in enhanced 
sensory nerve function and sensitisation of the cough reflex.  
 
4. Examining whether the CS-induced model of enhanced cough and airway 
inflammation is associated with an increased expression of TRPV1. 
Furthermore, the work will aim to investigate the potential antitussive activity 
of TRPV1 antagonists on the cough reflex.  
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CHAPTER 2 
 
 
 
 
 
 
GENERAL METHODOLOGY 
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2.1. Introduction 
 
This chapter outlines the general methodology for the in vivo and in vitro studies 
carried out for this thesis. Further details of individual experimental protocols are 
written in the methodology sections at the start of each results chapter. The reagents 
used in these studies, as well as their appropriate vehicle or diluent and their source 
are listed in appendix І.    
 
The experiments described in this thesis were carried out at two different sites, either 
at Novartis Horsham Research Centre (Novartis; Horsham, UK) or at the National 
Heart and Lung Institute (NHLI; London, UK). Therefore, in order to describe the 
experiments and results accurately, I will indicate in the specific methodologies at 
which establishment the studies were performed. In addition, appendix ІІ contains a 
list of figures in the thesis and whether the results were derived from studies 
performed at Novartis and/or the NHLI.  
 
2.2. In vivo experiments 
 
2.2.1. Animals (Novartis & NHLI) 
Male Dunkin-Hartley guinea-pigs (300-500g), purchased from Harlan-Olac (Bicester, 
UK) or Charles River (France), were used for the in vivo cough experiments. In vivo 
studies were carried out at either Novartis or at the NHLI. For the in vitro functional 
studies and primary cell culture experiments carried out at the NHLI, male Dunkin 
Hartley guinea-pigs (200-500g) and male Sprague Dawley rats (200-300g) were 
purchased from Harlan-Olac (Bicester, UK). Wherever possible, it was ensured that 
the same animal supplier was used for any project or sequence of work carried out for 
the thesis. The suppliers for specific studies will be described at the start of each 
methodology section in the results chapters. 
 
Animals were housed for at least 7 days before being used for experimental 
procedures. Food and water were supplied ad libitum. United Kingdom Home Office 
guidelines for animal welfare based on the Animals (Scientific Procedures) Act 1986 
were strictly followed. In vivo studies performed at the NHLI were carried out under a 
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Home Office license, which received approval from the Imperial College Ethical 
Review Process. In vivo studies performed at Novartis were performed under a Home 
Office license and were reviewed and approved by the Novartis Ethical Review 
Process. 
 
2.2.2. Tussive agent-induced cough (Novartis) 
Conscious and unrestrained guinea-pigs were placed in individual plastic transparent 
whole body plethysmograph chambers (Buxco, USA). The apparatus consisted of 4 
plethysmograph chambers receiving aerosol from a single nebuliser. Guinea-pigs 
were exposed to an aerosol of the appropriate vehicle or a single concentration of the 
aerosolised tussive agents. The tussive agents used to evoke cough were either a 
nebulised aqueous solution of CAPS (10 or 15µM for 7 minutes), CA (0.075, 0.15, 
0.3, 0.6 or 1.2M for 10 minutes), bradykinin (0.1, 1 or 10mg/ml for 10 minutes), 
PGE2 (0.01, 0.1 or 1mg/ml for 10 minutes) or hypertonic saline (7, 9 or 11% NaCl v/v 
for 10 minutes). The aerosol was generated with an Aerogen nebuliser (Buxco, USA) 
for use with CAPS and CA (Lewis et al., 2007). The aerosol was generated with a 
DeVilbiss nebuliser (DeVilbiss, Somerset, USA) for use with bradykinin, PGE2 and 
hypertonic saline (Lalloo et al., 1995). The number of coughs and level of airflow 
obstruction were recorded for a total of 15 minutes for CAPS, bradykinin, PGE2 and 
hypertonic saline. Cough and airflow obstruction induced by CA were recorded for 20 
minutes in total. Details of the methodology for measurements are described below in 
sections 2.2.3.1 & 2.2.3.2. 
 
2.2.3. Tussive agent-induced cough (NHLI) 
Conscious and unrestrained guinea-pigs were placed in individual plastic transparent 
whole body plethysmograph chambers (Buxco, USA). The apparatus consisted of two 
plethysmograph chambers receiving aerosol from a single nebuliser, which allowed 
two guinea pigs to be exposed at one time. Guinea-pigs were exposed to an aerosol of 
the appropriate vehicle or a single concentration of the aerosolised tussive agents. The 
tussive agents used to evoke cough were either a nebulised aqueous solution of CAPS 
(15, 30, 60 or 90µM for 5 minutes) or CA (0.1, 0.2, 0.3 or 0.4M for 10 minutes). The 
aerosol was generated with an Aerogen nebuliser (Buxco, USA). The number of 
coughs and level of airflow obstruction induced by CAPS or CA were measured for a 
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total of 10 minutes.  Details of the methodology for measurements are described 
below in sections 2.2.3.1 & 2.2.3.2. 
 
2.2.3.1. Measurement of the number of coughs (Novartis & NHLI)  
Cough in the guinea-pig was detected by characteristic pressure changes in the 
plethysmography chamber and recorded by the Buxco Cough Analyser (Buxco, 
USA). The cough produces a transient increase in airflow over and above the normal 
flow, which is detected by the analyser and appears as a characteristic change in flow, 
which is visualised on the computer screen. The Buxco Cough Analyser utilises a 
specific algorithm to count coughs in a given time period, by recognition of a flow 
waveform that crosses a positive threshold to a negative one within a given maximum 
time period. Each plethysmography chamber was fitted with a microphone, which 
was connected to an external speaker, allowing the cough sounds to be magnified. 
The observer could confirm the number of coughs by recognition of the change in 
waveform, recognition of a characteristic high sound, coupled with a quick, large 
abdominal movement of the guinea-pig. 
 
2.2.3.2. Measurement of the level of airflow obstruction (Novartis & NHLI)  
The use of the whole body plethysmography chamber allowed the level of airflow 
obstruction and the number of coughs to be simultaneously measured, by analysis of 
the pressure differences between a main chamber and a reference compartment. A 
bias flow generator supplied air to each plethysmography chamber at a rate of 2L/min 
and withdrew air at a rate of 2.5L/min. The respiration of the animal and changes in 
volume or pressure in the main chamber were detected, resulting in a box flow signal. 
The level of airfow obstruction is computed from the box flow signal and is 
represented by an arbitrary value called Penh or ‘enhanced pause’, which monitors 
airflow changes in the chamber with a differential pressure transducer connected to an 
airway mechanics analyser (Biosystem XA software, Buxco, USA). 
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Figure 2.1: Diagrammatic representation of the Buxco whole body 
plethysmography system 
The system consists of A) Max ΙΙ preamplifier connected to a computer using 
Biosystem XA software, B) whole body plethysmography chambers, C) nebuliser and 
aerosol distribution chamber, D) aerosol system controller, E) drying tube, F) Bias 
flow regulator. Diagram amended from Buxco Whole Body Plethysmography User 
Manual Version 1.0r7-2/2007.    
 
2.2.4. Cigarette smoke exposure (Novartis) 
Guinea-pigs were exposed to CS from 4 standard filtered cigarettes (2R4F, University 
of Kentucky, USA) once daily for 2, 5 or 8 days. The methods and experimental 
parameters were based on methods described by Lewis et al (Lewis et al., 2007). The 
smoke exposure systems consist of a puffer (Datum Products, Horsham, UK), pump 
(Cole-Parmer Instrument Company Ltd, London, UK) and exposure chamber and 
allow animals to be placed in pairs in 7-litre Perspex chambers unrestrained. The puff 
volume was set at 25ml and CS collected over a 3 second period. The CS was 
immediately pumped undiluted into the chamber, and in the 30-second interval 
between the puffs of smoke, animals received normal air (500ml/min). Each cigarette 
took approximately 7 minutes to burn; therefore guinea-pigs were exposed to CS from 
4 cigarettes for a period of approximately 30 minutes each day. Control guinea-pigs 
were exposed to air only (500ml/min) in identical chambers, for the same length of 
time. The animal behaviour and welfare was monitored throughout the exposure 
periods and monitored regularly thereafter. 
 
2.2.5. NGF or BDNF exposure (NHLI) 
Guinea-pigs were placed in a perspex exposure chamber (600 X 240 X 350mm) and 
exposed to either aerosolised vehicle or NGF (0.1, 1 or 10µg/ml) or BDNF (0.1, 1 or 
(A) 
(B)
(C) 
(F)
(E) 
(D)
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10µg/ml) for 30 minutes, once daily for 8 days. The aerosol was generated with a 
System 22 side-stream nebuliser connected to a System 22 CR60 high flow 
compressor pump. The animal behaviour and welfare was monitored throughout the 
exposure periods and monitored regularly thereafter. 
 
2.2.6. Pharmacokinetic analysis of the concentration of SB366791 in guinea-pig 
blood plasma (Novartis)  
The jugular vein of each guinea-pig was cannulated 36 hours prior to SB366791 
administration, to allow serial blood sampling. Guinea-pigs were dosed with vehicle 
or SB366791 (1, 10 or 30mg/kg, i.p.). The vehicle in the first pharmacokinetic (PK) 
study was 20 % ethanol plus 20% Cremaphor EL in saline, and the dose volume was 
1ml/kg. The formulation concentrations were 1 and 10mg/ml for the 1 and 10mg/kg 
doses respectively. The 1mg/ml formulation was a clear solution and the 10mg/ml 
formulation was a suspension. The vehicle in the second PK study was DMSO plus 
Cremaphor EL in 20% aqueous ß-cyclodextrin (1:4:15 v/v), and the dose volume was 
10ml/kg. The formulation concentrations were 1 and 3mg/ml for the 10 and 30mg/kg 
doses respectively. The 1mg/ml and 3mg/ml formulations were clear solutions; the 
3mg/ml solution precipitated at this concentration and so was dosed within 30 minutes 
of preparation.  
 
Serial blood samples (150µl) were removed at 5, 15, 45, 90, 150, 240, 360 and 1440 
minutes after administration of SB366791. An equal volume of heparinised saline was 
administered to the animal after removal of each blood sample. Plasma was separated 
from blood samples and analysed for SB366791 by Liquid Chromatography - Mass 
Spectrometry/Mass Spectrometry (LC-MS/MS) analysis.  
 
2.2.7. Monitoring animal health (Novartis & NHLI) 
Guinea-pigs were constantly monitored throughout procedures and during recovery. 
Animals were checked for signs of adverse events such as withdrawal with lack of 
mobility and respiratory distress. If such events occurred, the individual experiment 
would be terminated and the animal euthanised.  
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2.3. Analysis of in vivo experimental samples 
 
2.3.1. Bronchoalveolar lavage fluid sampling and processing (Novartis & NHLI) 
Guinea-pigs were euthanised with an overdose of sodium pentobarbitone (200mg/kg, 
i.p.). The trachea was exposed, using blunt dissection, and cannulated in order to 
obtain BAL fluid. The lungs were lavaged with Hanks Balanced Salt Solution (HBSS) 
or Roswell Park Memorial Institute (RPMI) 1640 at a volume of 1ml/100g. This was 
delivered into the airways by injecting the solution through the tracheal cannula and 
retrieving the lavage fluid. The process was repeated and the BAL samples were 
pooled for each animal. The BAL samples were kept at 4°C until an aliquot was taken 
in order to carry out total cell counts and to produce slides for differential counting, as 
described below in section 2.3.2.1. The remaining BAL was centrifuged (300 x g, 10 
minutes, 4°C) and the supernatant was collected and stored at -80ºC for future 
analysis.  
 
2.3.2. Lung tissue and vagal sensory nerve ganglia sampling and processing 
(Novartis & NHLI)     
Immediately after collection of BAL fluid, the thoracic cavity was exposed and the 
lower left lung lobe was tied off, removed and flash frozen by immersion in liquid 
nitrogen. The frozen lung samples were then stored at -80ºC for potential future 
analysis of protein concentrations measured by Enzyme Linked ImmunoSorbent 
Assay (ELISA). In experiments where histological assessment of the lung was 
performed, the remaining lung was insufflated with 10% neutral buffered formalin 
(NBF). The lung was tied off at the trachea and fully immersed in NBF for 24 hours 
until histological processing and analysis.  
 
During certain studies, immediately after the removal of the lungs and/or the vagus 
nerve (see section 2.4.1), the left and right nodose and jugular ganglia (see Figure 2.2) 
were dissected and immediately immersion fixed in NBF for histological assessment. 
24 hours later, the nodose and jugular ganglia were processed as separate wax tissue 
blocks for histological processing. 
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Figure 2.2: Diagram of the trachea, vagus nerves, nodose ganglion, jugular 
ganglion, recurrent laryngeal nerves (RLN) and superior laryngeal nerves (SLN) 
Figure taken from Canning et al., 2004.  
 
 
2.3.2.1. Total cell counts and cytospin preparations (Novartis & NHLI) 
Total cell counts were determined in the BAL fluid and in lung tissue digests, using a 
Sysmex F-820 automated cell counter (Sysmex UK Ltd, Milton Keynes, UK). 
Differential cell counts were determined by light microscopy (x40 magnification) 
from cytospin preparations. These were prepared by centrifuging 100µl aliquots in a 
cytopsin (Shandon, Runcorn, UK) at 700rpm for 5 minutes at room temperature. The 
slides were fixed and stained using modified Wright-Giemsa stain (Sigma-Aldrich, 
Poole, UK). Leukocyte numbers were determined by differential counts on 300 cells 
per slide, according to standard morphological criteria. The numbers of neutrophils, 
eosinophils and lymphomononuclear (LMN) cells were expressed as cells/ml. 
Eosinophils are recognised by their bi-lobed nucleus, which stains dark blue. The 
cytoplasm of eosinophils contains granules, which attract the acid component of the 
stain (eosin) and therefore stain red-pink. Neutrophils are recognised by their multi-
lobed nucleus, which attracts the basic component of the stain and is dark blue. The 
cytoplasm of the neutrophils appears transparent as the granules are small and only 
stain faintly pink. LMN cells contain no granules and have large darkly stained nuclei. 
 
2.3.3. Protein expression measured by Enzyme Linked ImmunoSorbant Assays 
(NHLI)     
ELISAs were used to quantify the levels of a protein of interest within the BAL and 
lung tissue supernatant samples. Approximately 200mg of lung tissue was 
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homogenised in phosphate buffered saline (PBS) using an Ultramax T25 
homogeniser. The samples were then spun in a microcentrifuge (13000 x g, 20 
minutes, 4ºC), the supernatant collected and assayed for measurement of protein 
levels.  
 
ELISAs were performed using human Duoset kits purchased from R&D Systems 
(R&D Systems Europe, Oxfordshire, UK). Immunosorbant 96 well plates (Fisher 
Scientific, Loughborough, UK) were coated (100µl per well) with the specific 
primary capture antibody of interest (diluted 1:180 in PBS) and incubated overnight at 
room temperature. The solution containing the primary antibody was removed and the 
plates were washed three times with wash buffer (PBS and 0.05% Tween 20, pH 7.4) 
to clear any unbound antibody. The plates were incubated for a minimum of 1 hour 
with 200µl of blocking buffer (1% bovine serum albumin (BSA), 5% sucrose in PBS 
with 0.05% NaN3). The plates were washed 3 times with wash buffer and then 
incubated with 100µl of standard curve samples and supernatant samples (diluted in 
1% BSA in PBS) at room temperature for 2 hours. Following a wash step, the specific 
secondary detection antibody (made up in 1% BSA in PBS) was added to the plate for 
2 hours at room temperature. The plates were washed and streptavidin conjugated to 
horseradish-peroxidase (HRP; diluted 1:200 in 1% BSA in PBS) was added to the 
plate for 20 minutes. The plates were washed again and then developed with a 
substrate solution (H2O2 and tetramethylbenzidine (1:1 v/v)). The plates were covered 
and left for up to 20 minutes until the solution developed into a blue colour. The 
reaction was stopped with the addition of 50µl of stop solution (2N H2SO4) and the 
protein levels were read colourmetrically at 450nm on a spectrophotometer 
(Labsystems Multiskan MCC/340). Quantification of protein levels were interpolated 
from a standard curve constructed to known concentrations. The specific assays and 
detection limits will be described in the relevant results chapter.    
 
2.3.4. Immunohistochemical detection of mucus in the guinea-pig lung (Novartis) 
Immunohistochemistry for the detection of mucus was performed on histological lung 
sections, based on methods described by Stevenson et al (Stevenson et al., 2005). 24 
hours after the lungs were excised from guinea-pigs, insufflated and immersion fixed 
in NBF, histological processing and assessment was carried out to determine the area 
of mucus staining in the airways. The lung lobes from one animal were processed as 
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one wax tissue block. Using a closed VIP tissue processor (Bayer plc, Newbury, UK), 
the samples were processed to paraffin wax and then embedded in fresh paraffin wax. 
Sections of lung (3µm) were cut, fixed onto Polysine slides and dried overnight at 
37ºC. Sections were dewaxed in xylene and rehydrated using descending 
concentrations of industrial methylated spirits (IMS). In order to block endogenous 
peroxidase in the sections, slides were incubated with 0.5% hydrogen peroxidase in 
methanol for 30 minutes at room temperature. The epitopic sites were unmasked by 
treating with 0.1% trypsin in 0.1% CaCl. In order to prevent non-specific binding of 
the secondary antibody, sections were incubated for 30 minutes at room temperature 
with 0.1% bovine serum albumin (BSA) made up in Tris buffered saline (TBS, pH 
7.6). Sections were drained and then incubated overnight at 4ºC with fluoroscein 
isothiocyanate (FITC)-conjugated Ulex Europeaus agglutinin-1 (UEA-1), which was 
diluted 1:8000. Sections were washed in TBS and incubated with peroxidase 
conjugated anti-FITC for 30 minutes at room temperature (diluted 1:100). Sections 
were incubated with the chromagen diaminobenzidene (DAB) and the cell nuclei 
were lightly counterstained with haematoxylin. The sections were then dehydrated 
through graded IMS, cleared in xylene and coverslipped.  
 
2.3.4.1. Quantification of mucus staining in the guinea-pig lung (Novartis) 
The area of UEA-1 staining was assessed under a Zeiss Axioplan 2 microscope (x20 
magnification) with an Imaging Associates KS400 image analyser (Imaging 
Associates, Bicester, UK).  All large and small airways in sections taken from both 
lung lobes were scored for each animal. Random scoring of each slide was carried out 
without knowledge of which group was associated with which sample. Data are 
presented as area of mucus staining, which is calculated as a ratio of stained area 
(µm2) to length (µm) of epithelium scored.  
 
2.3.5. Immunohistochemical staining of the guinea-pig vagal sensory nerve 
ganglion (Novartis & NHLI) 
Immunohistochemistry for the detection of SP, TRPV1 and PGP9.5 was performed on 
histological vagal sensory nerve ganglion sections. Conditions were optimised for 
assessment of immuno-positive staining and the specificity of the staining was 
confirmed by assessment of the SP-immunoreactivity in the nodose and jugular 
ganglion, as described in sections 6.2.2 and 6.3.1. 24 hours after the nodose and 
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jugular ganglion were excised from guinea-pigs and immersion fixed in NBF, 
histological processing and assessment was carried out to determine the protein 
expression of targets of interest. The nodose and jugular ganglia were processed as 
separate wax tissue blocks. Using a closed tissue processor, the samples were 
processed to paraffin wax and then embedded in fresh paraffin wax. Sections of 
ganglia (9µm) were cut, fixed onto Polysine slides and dried overnight at 37ºC. 
Sections were dewaxed in xylene and rehydrated using descending concentrations of 
IMS. In order to block endogenous peroxidase in the sections, slides were incubated 
with 3% hydrogen peroxidase made up in distilled water, for 30 minutes at room 
temperature. The epitopic sites were unmasked using citrate buffer (10mM, pH 6.0, 2 
x 10 minutes) in a microwave oven. The slides were left to cool for 15 minutes and 
then washed in PBS buffer (1% BSA and 0.1% Tween 20 in PBS).  In order to 
prevent non-specific binding of the secondary antibody, sections were incubated for 
30 minutes at room temperature with goat serum. This was diluted 1:6 in PBS buffer 
containing 4 drops/ml of Avidin block. Sections were drained and then incubated 
overnight at 4ºC with rabbit polyclonal antibodies directed against SP, TRPV1, 
PGP9.5 or rabbit isotype control. The SP antibody was diluted 1:10,000, TRPV1 was 
diluted 1:11,000 and PGP9.5 was diluted 1:3000 in PBS buffer and 4 drops/ml biotin 
block. Sections were washed in PBS buffer and incubated for 1 hour at room 
temperature with a goat anti-rabbit biotinylated secondary antibody (diluted 1:200 in 
PBS buffer). Sections were washed with PBS and incubated for 30 minutes with 
streptavidin-HRP, which had been diluted 1:200 in PBS. Following a wash step, 
sections were incubated with the chromagen DAB for 5 minutes and then the cell 
nuclei were lightly counterstained with haematoxylin. The sections were then 
dehydrated through graded IMS, cleared in xylene and coverslipped. Image 
acquisition and quantification of TRPV1 staining was performed as described below 
in section 2.3.5.1.  
 
2.3.5.1. Quantification of TRPV1 staining in the guinea-pig vagal sensory nerve 
ganglion (NHLI) 
Images of the ganglion were acquired using an Olympus BX51 system microscope 
equipped with a Quicam Q-imaging Fast1394 camera, linked to a computer with 
Image Pro-plus Version 5.1 image analysis software (Media Cybernetics, UK). In 
order to compare and quantify the consecutive sections stained for detection of 
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PGP9.5 and TRPV1, images were taken of each slide (x10 magnification), ensuring 
that images of the same field were obtained from consecutive sections. The images 
were analysed by counting 200 PGP9.5 immuno-positive cell bodies in total (100 
PGP9.5-positives were counted in two distinct fields) and specifying the areas 
containing the 200 PGP-positively identified cell bodies within the field. The numbers 
of TRPV1-positive cell bodies were expressed as a percentage of PGP-positive cell 
bodies, by counting the immuno-positive cell bodies for TRPV1 within the specified 
areas. 
 
2.4. In vitro experiments 
 
2.4.1. Sensory nerve activation in the isolated guinea-pig vagus nerve 
preparation (NHLI) 
Guinea pigs were killed by cervical dislocation. The trachea was exposed and the 
vagus nerves (see Figure 2.2), which run caudal to the nodose ganglion and parallel to 
the trachea, were dissected and placed in oxygenated (95% O2 and 5% CO2) Krebs-
Henseleit Solution (KHS) (mM: NaCl – 118; KCl- 5.9; MgSO4 – 1.2; NaH2PO4 – 1.2; 
CaCl2 – 2.5; glucose – 6.6; NaHCO3 – 25.5). Particular care was taken not to damage 
or stretch the nerves. The nerves were then carefully cleared of any connective tissue 
and de-sheathed. The de-sheathed vagus nerve was cut in half, into approximately 
12mm sections. Each section was individually mounted in a ‘grease-gap’ recording 
chamber as previously described (Patel et al., 2003). The section of nerve was drawn 
longitudinally through a narrow channel (2mm in diameter, 10mm in length) in a 
perspex chamber. The nerve was constantly perfused with oxygenated KHS at a flow 
rate of 2ml/min and the temperature of the perfusate was maintained at 37ºC by 
means of a water bath. A small volume of vaseline was injected slowly into the 
channel, in order to coat the centre of the vagus. This created an area of high 
resistance, and electrically isolated the extracellular space between the two ends of the 
nerve. Ag/AgCl electrodes (Mere 2 Flexible reference electrodes, World Precision 
instruments (WPI)) were filled with KHS and placed at either end of the narrow 
channel so that contact was made with either end of the mounted nerve. DC potential 
was measured via a DAM 50 differential amplifier (WPI) and the DC voltages were 
amplified × 10, filtered at 1000Hz, and sampled at 5Hz. Two systems run in parallel 
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allowing measurements to be taken from two different pieces of tissue 
simultaneously. Depolarising responses were recorded onto a pen chart recorder, 
which was calibrated such that 1cm was equivalent to 0.1mV. The superfusing KHS 
solution could be quickly and easily changed to that containing a known concentration 
of another solution by means of a tap. Depolarising responses were recorded in 
response to stimulation with sensory nerve stimuli and are expressed as an increase in 
mV from baseline. The details of the specific agonist and antagonist studies will be 
described in the results chapters. 
 
When available, human trachea with branches of the vagus nerve attached, were 
obtained from donor patients undergoing heart-lung transplantation, which were 
surplus to requirement. Nerve depolarisations were induced by superfusion of the 
human vagus nerve sections with CAPS (100µM) and the effect of antagonists was 
determined, as described above by following the same protocol as had been used for 
the guinea-pig isolated vagus studies. 
 
2.4.2. Capsaicin-induced contraction of the isolated guinea-pig trachea (NHLI) 
Guinea-pigs were killed by cervical dislocation and tracheal strips were prepared as 
described previously (Patel et al., 1995). The trachea and lungs were exposed, rapidly 
removed and placed in KHS solution of the following composition (mM): NaCl – 
118; KCl – 5.9; MgSO4 – 1.2; NaH2PO4 – 1.2; CaCl2 – 2.5; glucose – 6.6; NaHCO3 – 
25.5. The trachea was dissected from the main lungs and bronchi and carefully 
cleared of connective tissue. The trachea was opened longitudinally by cutting 
through the cartilage and the epithelium was removed by gently rubbing with a cotton 
bud. Tracheal strips, each containing three to four cartilaginous strips, were then 
prepared for mounting in organ baths. During preparation, the tissues were 
continuously bathed in oxygenated (95% O2 and 5% CO2) KHS solution. 
Indomethacin (10µM) was present in the KHS solution throughout the experiments to 
prevent the formation of endogenous prostaglandins. Tracheal strips were carefully 
attached to silk surgical thread and were mounted under a resting tension of 1g, in 
10ml organ baths (Linton Instrumentation, Norfolk, UK), which contained 
oxygenated KHS solution (pH 7.4, 37oC). The tissues were allowed to equilibrate for 
1 hour, followed by maximal contraction induced by the addition of Acetylcholine 
(10-2M). The isometric tension was measured using force displacement transducers 
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(Model FT-03; Grass Instruments Co., Quincy, MA, USA) connected to a data 
acquisition system (Biopac MP100 Workstation; Biopac Systems Inc., Goleta, CA, 
USA) operating on a computer using ‘AcqKnowledge’ software (Biopac Systems 
Inc., Goleta, CA, USA). After repeated washing and once the tone had reached 
baseline, the vehicle or antagonists were added to the baths for 1 hour. Details of the 
studies are described in the relevant results chapter. One concentration of antagonist 
was tested per tissue. Cumulative concentration response curves were then generated 
to the TRPV1 agonist, capsaicin (10-9 – 10-4M).   
 
Contractile responses are expressed as absolute values in mg tension. Concentration-
response curves were analysed by least-squares, non-linear iterative regression with a 
curve fitting program (GraphPad Prism software, USA) and pEC50 values were 
interpolated from curves of best-fit. Estimates of antagonist affinity were calculated 
using the equation pKB = log (CR-1) – log [B] (Schild, 1949), where CR is the 
concentration ratio calculated from the EC50 of agonist in the presence of the 
antagonist divided by the EC50 of the agonist alone, KB is the equilibrium dissociation 
constant and [B] is the concentration of antagonist. In the experiments described, the 
term pA2 is substituted for pKB as data were obtained using one concentration of the 
antagonist. 
 
2.4.3. Trigeminal ganglion dissection and cell culture (NHLI) 
Male Sprague-Dawley rats (250-300g) or male Dunkin-Hartley guinea pigs (250-
300g) were used. Animals were killed by cervical dislocation and the trigeminal 
ganglions (TGs) were rapidly dissected. TGs from two animals (4 TGs in total) were 
placed in calcium and magnesium free HBSS. TGs were cultured based on previously 
described methods (Price et al., 2005). The samples were centrifuged (1000 x g, 2 
minutes, 4ºC) and the cold HBSS was removed and replaced with 12mls of room 
temperature HBSS, in order to wash the cells. TGs were centrifuged again (1000 x g, 
2 minutes, 4ºC), the HBSS removed and replaced with 4mls of HBSS. TGs were 
enzymatically digested with 5mg/ml collagenase (30 minutes, 37ºC), with gentle 
mixing every 10 minutes. The samples were centrifuged (1000 x g, 2 minutes, 4ºC) 
and the supernatant removed, taking particular care not to remove the TGs. 15mls of 
HBSS was added to wash the cells. The samples were centrifuged (1000 x g, 2 
minutes, 4ºC) and the HBSS was removed down to a volume of 4.5mls to re-suspend 
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the pellet. This was followed by the addition of 0.1% Trypsin for 15 minutes at 37ºC, 
with intermittent mixing every 5 minutes, and further supplemented with 10 units of 
DNAse for 10 minutes at 37ºC. TG cell suspensions were then centrifuged (1000 x g, 
2 minutes, 4ºC) and the supernatant removed. They were then re-suspended in 3mls of 
37ºC basal culture medium containing high glucose Dulbecco’s Modified Eagle’s 
Medium (DMEM), 1X penicillin-streptomycin-glutamine, 3µg/ml of 5-Fluoro-2'-
deoxyuridine and 7µg/ml uridine as mitotic inhibitors. TG cell suspensions were 
gently triturated with a P1000 pipette tip in order to break up the tissue. Once the 
tissue flowed evenly, suspensions were successively triturated with a Pasteur pipette 
followed by 19- and 23-gauge needles. Care was taken not to over-triturate with the 
needles. TG cell suspensions were then transferred to a new tube and adjusted to the 
total volume needed for plating. The DMEM culture media was treated with vehicle 
or NGF (0.1, 1 or 10µg/ml) or BDNF (0.1, 1 or 10µg/ml). Neuron density for plating 
was determined by counting neurons with a hemocytometer. Neuronal cultures of TGs 
were plated at equal densities, at a volume of 200µl, on 8 well poly-D-lysine pre-
coated Lab-Tek ІІ chamber slides (Fisher Scientific, UK). The DMEM culture media 
containing the desired concentrations of vehicle or NGF or BDNF were changed on 
day 2. On day 5, immunocytochemistry (ICC) and image acquisition was performed 
as described below in section 2.4.3.1.  
 
2.4.3.1. Immunocytochemistry and image acquisition on trigeminal ganglion cultures 
(NHLI) 
TG cultures were washed 3 times in PBS and then fixed for 1 hour in 3.7% 
formaldehyde in PBS. After fixation, TG cultures were washed 3 times in PBS and 
permeabilised in PBS containing 10% normal goat serum (NGS) and 0.2% Triton X-
100 for 1 hour. TG cultures were blocked in PBS containing 10% NGS (3 x 
10minutes). TG cultures were exposed to anti-neurofilament 200 (NF-H) mouse 
monoclonal antibody (diluted 1:300), overnight at 4ºC. Control experiments omitted 
the primary antibody and labelled with secondary antibody only. The following day, 
the primary antibody was washed off with PBS (3 x 5 minutes) and goat anti-mouse 
Alex-Fluor 488 (diluted 1:300) was added for 1 hour at room temperature. Cultures 
were washed with PBS (3 x 5 minutes). The chambers were removed from the 
chamber slides, to leave just the slide, which was coverslipped.  
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Images were acquired using an Olympus BX51 system microscope equipped with a 
Quicam Q-imaging Fast1394 camera, linked to a computer with Image Pro-plus 
Version 5.1 image analysis software (Media Cybernetics, UK). In order to capture the 
complete cellular area for neuron counts, twenty images (x20 magnification) were 
taken of each well. The photos were analysed and the number of surviving neurons 
counted using the image analysis software. A threshold setting was determined so that 
all neurons displaying fluorescence above background were counted as positive. 
 
2.5. Statistical analysis 
 
Values are expressed as mean ± standard error of the mean (sem) of n observations. 
To analyse experiments containing two groups, statistical significance was determined 
using an unpaired t-test with the independent group compared to the corresponding 
control group. If the data were non-parametric then the Mann Whitney rank sum test 
was used. To analyse experiments containing more than two groups, statistical 
significance was determined using one-way analysis of variance (ANOVA) followed 
by Dunnett’s post-test for parametric data. If the data were non-parametric then a 
Kruskal-Wallis test followed by a Dunn’s multiple comparisons test was used. All 
treatment groups were compared to the appropriate control group. A p-value of less 
than 0.05 was considered statistically significant and denoted with *. 
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CHAPTER 3 
 
 
 
 
 
 
CHARACTERISATION OF IN VIVO MODELS OF 
COUGH AND IN VITRO MODELS OF SENSORY NERVE 
ACTIVATION 
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3.1. Aims and rationale 
 
The aim of these studies was to develop and characterise conscious guinea-pig cough 
models using different tussive stimuli, known to elicit cough in man. Furthermore, the 
aim was to characterise the corresponding effects of these tussive stimuli on sensory 
nerve activation using an in vitro vagus nerve preparation.   
 
The production of a cough is a primary defence mechanism for clearing excessive 
secretions and foreign material from the airways. However, sensory nerve activity 
may be enhanced during disease such that these reflexes become exacerbated and 
harmful. The changes which occur in the disease state leading to an enhanced, 
problematic cough reflex warrants further investigation. By utilising a range of tussive 
stimuli, this allows comparisons to be made between the numbers of coughs 
produced, the type of cough response and whether there is any associated airflow 
obstruction. It should be noted that during the model development, distinct patterns of 
response to different tussive stimuli were observed. Therefore for the purpose of this 
thesis, coughs induced by CA and CAPS have been classified as ‘Type 1’ and the 
coughs induced by bradykinin and PGE2 have been classified as ‘Type 2’, which will 
be described in detail in the results section.  
 
Further work in this chapter aimed to investigate whether exposing guinea-pigs to 
CA, in order to determine cough sensitivity and rank the guinea-pigs, impacts on the 
numbers of coughs produced in subsequent experiments. The rationale behind ranking 
the guinea-pigs according to cough response was derived from evidence that the 
coughs evoked by guinea-pigs can vary in number, even between animals which are 
in the same group and exposed to the same concentration of tussive agent. 
Furthermore, variation can occur between different batches of animals, even when 
obtained from the same supplier. In addition, guinea-pigs may be non-responsive to 
exposure to tussive agents, which creates an increased spread of the data and requires 
the use of larger numbers per group to achive statistically significant results. 
Therefore during previous cough studies at the NHLI, guinea-pigs were exposed to 
CA one week prior to the main study, in order to determine the cough number 
produced by each individual animal. Consequently, the non-responders, which were 
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classified as those which coughed 3 times or less, were excluded from the future main 
study. For the main study, the remaining guinea-pigs were ranked and grouped 
according to numbers of coughs produced and then animals from each grouping were 
randomly distributed between groups, in order to achieve similar average numbers of 
coughs per treatment group. 
 
To complement the in vivo models of cough, corresponding in vitro models of sensory 
nerve activation using the isolated vagus nerve preparation were characterised. 
Therefore, by establishing this range of techniques and models, they could be utilised 
in future studies for the development of disease relevant models of enhanced cough, 
thus allowing the study of associated mechanisms. 
 
3.2. Methods 
 
3.2.1. Animals (Novartis & NHLI) 
Male Dunkin-Hartley guinea-pigs (300-500g) were purchased from Harlan-Olac 
(Bicester, UK) or Charles River (France). Guinea-pigs were purchased from Harlan-
Olac for the in vitro isolated vagus nerve experiments. Guinea-pigs were purchased 
from Harlan-Olac for the concentration-response studies using CA or CAPS and to 
investigate whether screening of the cough response impacts on the numbers of 
coughs produced in subsequent cough experiments. Due to difficulties in sourcing 
guinea-pigs, the supplier for the in vivo concentration-response studies using 
bradykinin, PGE2 or hypertonic saline was changed to Charles River. All guinea-pigs 
for subsequent in vivo cough studies were supplied by Charles River. 
 
3.2.2. Citric acid or capsaicin-induced cough (Novartis)  
Conscious and unrestrained guinea-pigs were placed in individual plastic transparent 
whole body plethysmograph chambers (Buxco, USA). Guinea-pigs were exposed to 
an aerosol of the appropriate vehicle or a single concentration of the aerosolised 
tussive agents. The tussive agents used to evoke cough were either a nebulised 
aqueous solution of CA (0.075, 0.15, 0.3, 0.6 or 1.2M for 10 minutes) or a nebulised 
aqueous solution of CAPS (10 or 15µM for 7 minutes). The number of coughs and 
level of airflow obstruction were recorded as described previously (Chapter 2.2.2). 
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3.2.3. Citric acid or capsaicin-induced cough (NHLI) 
Conscious and unrestrained guinea-pigs were placed in individual plastic transparent 
whole body plethysmograph chambers (Buxco, USA). Guinea-pigs were exposed to 
an aerosol of the appropriate vehicle or a single concentration of the aerosolised 
tussive agents. The tussive agents used to evoke cough were either a nebulised 
aqueous solution of CA (0.1, 0.2, 0.3 or 0.4M for 10 minutes) or a nebulised aqueous 
solution of CAPS (15, 30, 60 or 90µM for 5 minutes). The number of coughs and 
level of airflow obstruction were recorded as described previously (Chapter 2.2.3). 
 
3.2.4. Repeated exposure to citric acid or capsaicin (NHLI) 
To investigate whether ranking the guinea-pigs according to CA-induced cough 
response impacts on the numbers of coughs produced in subsequent cough 
experiments, guinea-pigs were randomly assigned to one of three groups and exposed 
to either saline or CA (0.3M) or CAPS (30µM) once a week for four consecutive 
weeks.  The order of repeat exposures was designed with the primary intention of 
determining whether exposure to CA impacts on subsequent CA or CAPS-induced 
cough responses. The experiments within this study were performed one week apart 
as during previous cough studies at the NHLI, guinea-pigs were exposed to CA 
exactly one week prior to the main study, in order to determine the cough number and 
allow ranking of each individual animal. During these studies, the number of coughs 
and level of airflow obstruction were measured each week as described in chapter 
2.2.3. Table 3.1 displays the three different treatment groups with each group 
receiving a different combination of tussive agent exposure over the course of four 
weeks.   
 
 Week 1 Week 2 Week 3 Week 4 
Group 1 CA CA CA CA 
Group 2 CA CAPS CAPS CA 
Group 3 Saline CAPS CAPS CA 
 
Table 3.1: Summary of experimental design for examining the effect of repeated 
exposure to tussive stimuli on the subsequent cough response  
Once a week for 4 weeks, guinea-pigs were exposed to either aeroslised CA (0.3M), 
CAPS (30µM) or saline.  
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3.2.5. Bradykinin, PGE2 or hypertonic saline-induced cough (Novartis) 
Conscious and unrestrained guinea-pigs were placed in individual plastic transparent 
whole body plethysmograph chambers (Buxco, USA). Guinea-pigs were exposed to 
an aerosol of the appropriate vehicle or a single concentration of the aerosolised 
tussive agents. The tussive agents used to evoke cough were either a nebulised 
aqueous solution of hypertonic saline (7, 9 or 11% NaCl for 10 minutes), PGE2 (0.01, 
0.1 or 1mg/ml for 10 minutes) or bradykinin (0.1, 1 or 10mg/ml for 10 minutes). The 
number of coughs and level of airflow obstruction were recorded for a total of 15 
minutes, as described previously (Chapter 2.2.3) 
 
3.2.6. Sensory nerve activation in isolated guinea-pig vagus nerve preparations 
(NHLI) 
To characterise an in vitro assay of sensory nerve activity, guinea-pigs were killed by 
cervical dislocation and the vagus nerve dissected as previously described in the 
methods chapter (Chapter 2.4.1). Nerve depolarisations were induced by perfusion of 
the vagus with vehicles or known concentrations of either low pH solution (pH 5.0, 
composition in mM: NaCl – 118.5; KCl – 1.7; KH2PO4 – 6.6; MgSO4.7H2O – 1.2; 
NaH2PO4 – 0.1; glucose – 10; CaCl – 2.5), CAPS (0.1, 1, 10 or 100µM), bradykinin 
(1, 3, 10 or 30µM), PGE2 (3, 10, 30 or 100µM) or hypertonic saline (1, 2, 4 or 8% 
NaCl v/v). A single concentration of solution containing one of the vehicles or one of 
the five stimulants was applied to a section of vagus nerve for a period of two minutes 
at which point the tissue was washed until the baseline returned to the resting state. 
This was repeated in turn using a single concentration of one of the other five stimuli 
until the nerve had been exposed to one concentration of each of the stimuli in turn. It 
was ensured that the choice of stimulant and concentration of stimulant were applied 
in a random order for each individual experiment.  
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3.3. Results 
 
3.3.1. Development of in vivo guinea-pig models of conscious cough using the 
tussive agents citric acid and capsaicin  
Prior to the start of this PhD, concentration-response studies using the cough 
provoking stimuli CA and CAPS had been performed at Novartis in order to develop 
conscious guinea-pig models of cough (Figure 3.1). As well as measuring numbers of 
coughs evoked, the level of airflow obstruction, measured as Penh, was 
simultaneously determined. These results have been included as they form a basis for 
development of other cough models in this chapter and also the basis of additional 
studies using the tussive agents CA and CAPS.  
 
Exposure of guinea-pigs to aerosolised CA results in a concentration-related increase 
in the number of coughs evoked. The sub-maximal concentrations of 0.3M (pH 1.45) 
and 0.6M CA (pH 1.40) resulted in 11.8 ± 3.0 coughs and 16.0 ± 3.8 coughs 
respectively. Furthermore, the level of CA-induced airflow obstruction, measured as 
Penh, was also concentration-related; increasing significantly from 0.5 ± 0.02 Penh 
units in the control group to 4.9 ± 1.4 Penh units and 5.2 ± 0.8 Penh units in the 0.3M 
and 0.6M CA groups respectively. Guinea-pigs exposed to the vehicle (saline) did not 
cough (Figure 3.1). Figure 3.1 shows that exposure of guinea-pigs to 10µM and 15µM 
CAPS results in 2.0 ± 0.7 coughs and 5.7 ± 1.2 coughs respectively. Furthermore, the 
15µM CAPS group was associated with a statistically significant increase in airflow 
obstruction (from 0.45 ± 0.03 Penh units to 5.1 ± 1.1 Penh units) compared to control.  
 
The concentration-response studies using CA and CAPS at Novartis, were designed to 
achieve maximal numbers of coughs whilst avoiding excessive bronchoconstriction. 
Therefore, a balance needed to be achieved between the length of exposure time to 
tussive agent, the concentration of tussive agent used and the length of monitoring 
time in order to achieve maximal cough numbers. As exposure to CAPS induces 
significant changes in Penh, the original dose-response studies at Novartis did not 
employ concentrations above 15µM CAPS as the associated airflow obstruction was 
deemed too high and a significant number of coughs, comparable to previously 
published values (Lalloo et al., 1995; Trevisani et al., 2004), had been produced by 
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using 15µM CAPS. It was found that optimal numbers of coughs were achieved if 
guinea-pigs were exposed to CAPS for 7 minutes and the numbers of coughs and 
level of airflow obstruction measured during the 7 minute exposure period and for a 
further 8 minutes. Furthermore, it was determined that in order to measure maximal 
numbers of coughs using CA, guinea-pigs would be exposed to 10 minutes of CA and 
the numbers of coughs and level of airflow obstruction measured during the 10 
minute exposure period and for a further 10 minutes (Lewis et al., 2007). 
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Figure 3.1: Concentration-responses to citric acid or capsaicin in the conscious 
guinea-pig  
Guinea-pigs were exposed to aerosolised vehicle (saline) or a single concentration of 
citric acid (0.075 – 1.2M) for 10 minutes. The A) number of coughs and B) airflow 
obstruction (Penh) were recorded for the 10 minute exposure period and for 10 
minutes after. n = 8 in each group. In a separate study, guinea-pigs were exposed to 
vehicle (10% ethanol in saline) or a single concentration of capsaicin (5 - 15µM) for 7 
minutes. The C) number of coughs and D) airflow obstruction (Penh) were recorded 
for the 7 minute exposure period and for 8 minutes after. n = 5 in the vehicle and 5µM 
groups and n = 9 in the 10µM and 15µM groups. Data are presented as A & C) 
individual data points and mean ± sem; B & D) mean ± sem. *p<0.05 compared to 
control. This figure is historical data provided by Novartis. A & B were performed by 
Cliff Battram. 
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The results in Figure 3.2 display the concentration-response studies using aerosolised 
CA or CAPS, performed at the NHLI. Guinea-pigs exposed to the vehicle controls did 
not cough. There is a concentration-related increase in the number of coughs induced 
by CA, resulting in 8.0 ± 2.0 coughs and 12.0 ± 2.3 coughs in the 0.3M and 0.4M 
groups respectively, which were associated with significant increases in airflow 
obstruction compared to control. Exposure of guinea-pigs to CAPS also causes a 
concentration-related production of cough, resulting in 3.3 ± 1.0 coughs and 7.5 ± 2.3 
coughs in the 30µM and 60µM groups respectively. The 30µM and 60µM CAPS-
induced cough responses were associated with a significant increase in Penh 
compared to control; 6.2 ± 1.4 Penh units and 8.5 ± 1.2 Penh units respectively. 
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Figure 3.2: Concentration-responses to citric acid or capsaicin in the conscious 
guinea-pig  
Guinea-pigs were exposed to aerosolised vehicle (saline) or a single concentration of 
citric acid (0.1 – 0.4M) for 10 minutes. The A) number of coughs and B) airflow 
obstruction (Penh) were recorded for the 10 minute exposure period. In a separate 
study, guinea-pigs were exposed to vehicle (1% ethanol and 1% Tween 80 in saline) 
or a single concentration of capsaicin (15 - 90µM) for 5 minutes. The number of C) 
coughs and D) level of airflow obstruction (Penh) were recorded for the 5 minute 
exposure period and for 5 minutes after. Data are presented as A & C) individual data 
points and mean ± sem; B & D) mean ± sem. *p<0.05 compared to control. n = 10 in 
each group. 
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3.3.2. Investigating whether ranking guinea-pigs according to cough response 
impacts on the numbers of coughs produced in subsequent experiments  
Before proceeding with cough studies for the thesis, it was important to determine 
whether exposing guinea-pigs to CA in order to rank them according to cough 
sensitivity, impacted on the cough response in subsequent experiments. Therefore, a 
study was designed in order to investigate whether exposure to the tussive agent CA 
had an effect on numbers of coughs produced in the following weeks. Table 3.2 
displays the mean ± sem number of coughs produced following exposure to a tussive 
agent in each experiment. The inclusion of Group 1 aimed to determine whether 
repeated exposure to CA impacted on the cough response in successive weeks. The 
results from Group 1 show that exposure of guinea-pigs to CA, once a week for 4 
weeks, did not result in a statistically significant alteration in cough response over 
time, although there was some variability in the response given the number of cough 
were 4.2 ± 0.9 in week 1 and 2.5 ± 1.0 coughs in week 3 (Figure 3.3A). 
 
 Week 1: 
Number of 
coughs 
Week 2: 
Number of 
coughs 
Week 3: 
Number of 
coughs 
Week 4: 
Number of 
coughs 
Group 1 CA 
4.2 ± 0.9 
CA 
4.9 ± 1.4 
CA 
2.5 ± 1.0 
CA 
5.8 ± 1.2 
Group 2 CA 
5.1 ± 1.5 
CAPS 
0.9 ± 0.5 
CAPS 
0.3 ± 0.3 
CA 
6.1 ± 1.6 
Group 3 Saline 
0.0 ± 0.0 
CAPS 
2.9 ± 0.7 
CAPS 
0.0 ± 0.0 
CA 
4.0 ± 0.8 
Table 3.2: Data displaying mean ± sem number of coughs produced following 
exposure to tussive agents  
Once a week for 4 weeks, guinea-pigs were exposed to either aeroslised CA (0.3M), 
CAPS (30µM) or saline. The number of coughs was determined for 10 minutes in 
total. n = 10 in each group. Data are presented as mean ± sem. 
 
Group 2 was designed to determine if exposure to CA in week 1 impacted on coughs 
induced by CAPS and CA in successive weeks. Figure 3.3B shows that the CA cough 
response is not significantly altered between week 1 (5.1 ± 1.5 coughs) and week 4 
(6.1 ± 1.6 coughs) despite guinea-pigs being exposed to CAPS in weeks 2 and 3. The 
mean number of coughs induced by CAPS is lower than that evoked by CA; in week 
2 the number of CAPS-induced coughs is 0.9 ± 0.5 and in week 3 the number of 
CAPS-induced coughs is 0.3 ± 0.3 (Figure 3.3).  
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Figure 3.3: The effect of repeated exposure to tussive agents on the number of 
coughs in the conscious guinea-pig  
In Group 1 (A), guinea-pigs were exposed to citric acid (0.3M) once a week for 4 
weeks and the number of coughs were determined each week. In Group 2 (B), guinea-
pigs were exposed to citric acid (0.3M) in week 1, capsaicin (30µM) in week 2, 
capsaicin (30µM) in week 3 and citric acid (0.3M) in week 4 and the number of 
coughs were determined each week. In Group 3 (C), guinea-pigs were exposed to 
saline in week 1, capsaicin (30µM) in week 2, capsaicin (30µM) in week 3 and citric 
acid (0.3M) in week 4 and the number of coughs were determined each week. Data 
are presented as individual data points and mean ± sem. *p<0.05. n = 10 in each 
group. 
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In group 3, guinea-pigs exposed to saline in week 1, which was the vehicle control for 
CA, did not cough. In week 2 (group 3), guinea-pigs were exposed to CAPS resulting 
in 2.9 ± 0.7 coughs. By comparing the CAPS-induced coughs produced in group 2, 
week 2 (0.9 ± 0.5 coughs; 7 out of 10 guinea-pigs did not cough) with the CAPS-
induced coughs produced in group 3, week 2 (2.9 ± 0.7 coughs; 2 out of 10 guinea-
pigs did not cough), this suggests that CA exposure in week 1 may impact on the 
number of coughs evoked by CAPS in subsequent weeks (Figures 3.3B & 3.3C).  
 
In group 3, there is a significant decrease in the cough response following CAPS 
exposure from 2.9 ± 0.7 coughs in week 2 to 0.0 ± 0.0 coughs in week 3 (Figure 
3.3C). In group 3, the number of coughs (4.0 ± 0.8 coughs) caused by CA exposure in 
week 4 appears to be unaltered by previous exposure to CAPS and is consistent with 
the number of CA-induced coughs in group 1 (group 1, week 1; 4.2 ± 0.9 coughs). 
 
3.3.3. Development of in vivo guinea-pig models of conscious cough using the 
tussive agents bradykinin, prostaglandin E2 and hypertonic saline       
As well as creating models of cough using the more commonly used tussive stimuli, 
concentration-response studies were carried out to establish less well-characterised 
models of cough. The studies using bradykinin, PGE2 and hypertonic saline 
highlighted an interesting observation; distinct patterns of respiratory response occur 
following exposure to different tussive agents. The nature of the cough response 
evoked following exposure to CA and CAPS were very similar. Likewise, the type of 
coughs induced by bradykinin and PGE2 were identical, but very different to the 
previously established tussive responses induced by CA or CAPS. Therefore, the 
different cough-provoking agents produce distinct in vivo cough types in the guinea-
pig, which for the purpose of comparison and identification; I have classified as ‘Type 
1’ or ‘Type 2’ coughs. Type 1 coughs, which are single, powerful and louder, are 
characteristically produced following exposure to CA or CAPS. Whereas Type 2 
coughs, which are a bout of weaker, quieter coughs, are characteristically produced 
following exposure to bradykinin or PGE2. The responses evoked following exposure 
to hypertonic saline were not clearly identifiable as either Type 1 or Type 2 coughs. 
The responses evoked by hypertonic saline differed to the Type 1 coughs as they were 
not accompanied by the characteristic cough sound, were less powerful in intensity 
and evoked a different and distinct change in posture. Therefore, as the responses to 
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hypertonic saline were not confirmed as coughs, they have been counted and termed 
respiratory events. Figure 3.4 displays typical traces of characteristic coughs or 
respiratory events obtained during the concentration-response studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Trace showing typical cough or respiratory patterns in response to 
exposure to tussive stimuli  
Exposure of guinea-pigs to citric acid or capsaicin results in ‘Type 1’ coughs (A), 
which are characteristically single, powerful and louder. Exposure of guinea-pigs to 
hypertonic saline results in a respiratory event (B). Exposure of guinea-pigs to 
bradykinin or PGE2 results in a bout of weaker, quieter ‘Type 2’ coughs (C). Images 
were obtained through real-time screen-capture of the computer screen. 
 
Figures 3.5 and 3.6 demonstrate a concentration-response relationship for bradykinin-
induced cough and PGE2–induced cough respectively. The data are represented both 
as scatter graphs as well as bar graphs, so as to show the spread of the data and the 
number of cough responders. This is important in order to choose suitable sub-
maximal concentrations to use in subsequent experiments. There are few references in 
the literature regarding bradykinin-induced cough in the conscious guinea-pig. The 
doses of bradykinin for these studies were designed based on work by Canning and 
colleagues, who aerosolised a 10mg/ml bradykinin solution to evoke a reproducible 
cough response in the conscious setting (Canning et al., 2004).  
 
A)
C)
B
ox
 F
lo
w
 
(1
6 
m
l/s
)
Time (2 sec)
Time (2 sec)B
ox
 F
lo
w
 
(1
6 
m
l/s
)
B)
Time (2 sec)
B
ox
 F
lo
w
 
(2
0 
m
l/s
)
B
ox
 F
lo
w
 
(1
6 
m
l/s
)
B
ox
 F
lo
w
 
(1
6 
m
l/s
) B
ox
 F
lo
w
 
(2
0 
m
l/s
)
 95
Exposure of guinea-pigs to 1mg/ml or 10mg/ml bradykinin caused a significant 
increase in cough reflex activation compared to control, resulting in 17.5 ± 6.8 coughs 
and 14.1 ± 3.0 coughs respectively. These Type 2 coughs were characteristically 
composed of one or two bouts of coughing, with each bout producing on average 
between seven and fifteen coughs. Guinea-pigs exposed to the vehicle did not cough. 
The group exposed to 1mg/ml bradykinin did not have associated airflow obstruction, 
whereas the 10mg/ml bradykinin group experienced a significant increase in airflow 
obstruction compared to control (Figure 3.5).  
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Figure 3.5: Concentration-response to bradykinin in the conscious guinea-pig  
Guinea-pigs were exposed to vehicle (saline) or a single concentration of bradykinin 
(0.1 - 10mg/ml) for 10 minutes. The A) number of coughs and B) airflow obstruction 
(Penh) were recorded for the 10 minute exposure period and for 5 minutes after. Data 
are presented as A) individual data points and mean ± sem; B) mean ± sem. *p<0.05 
compared to control. n = 8 in each group. 
 
There are no references in the literature describing PGE2-induced cough in the 
conscious guinea-pig. Therefore the concentrations for the dose-responses studies 
were extrapolated from work by Tilley at al, who found that 0.1mg/ml aerosol of 
PGE2 to be a suitable dose to investigate bronchomotor tone in the mouse (Tilley et 
al., 2003).  The results from the dose-response studies depict a significant cough 
response induced by PGE2 compared to control, resulting in 16.5 ± 5.8 coughs and 
15.9 ± 4.6 coughs in the 0.1mg/ml and 1mg/ml groups respectively (Figure 3.6A). 
The PGE2-induced Type 2 cough responses were not accompanied by statistically 
significant changes in Penh in the 1µg/ml PGE2 group, which is perhaps caused by 
the variance in Penh values within this group (Figure 3.6C).   
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Figure 3.6: Concentration-response to PGE2 in the conscious guinea-pig  
Guinea-pigs were exposed to vehicle (0.1M phosphate buffer) or a single 
concentration of PGE2 (0.01 - 1mg/ml) for 10 minutes. The A) number of coughs and 
B) airflow obstruction (Penh) were recorded for the 10 minute exposure period and 
for 5 minutes after.  Data are presented as A) individual data points and mean ± sem; 
B) mean ± sem. *p<0.05 compared to control. n = 8 in each group. 
 
Published data in the literature employ a 10 minute exposure to an aerosol of 
hypertonic saline (7% NaCl) solution in order to evoke approximately 5 coughs 
(Lalloo et al., 1995; Trevisani et al., 2004). Therefore, the studies described here were 
designed in order to establish a hypertonic saline-induced conscious cough model. As 
the responses evoked were not clearly identifiable as either Type 1 or Type 2 coughs, 
the responses induced by hypertonic saline have been counted as respiratory events. A 
significant increase in respiratory events or coughs was not achieved following a 10 
minute exposure of 7, 9 or 11% hypertonic saline compared to control. Furthermore, 
hypertonic saline exposure did not result in an associated airflow obstruction 
compared to control (Figure 3.7). 
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Figure 3.7: The effect of hypertonic saline exposure in the conscious guinea-pig  
Guinea-pigs were exposed to vehicle (0.9% saline) or hypertonic saline (7, 9, 11% 
NaCl) for 10 minutes. The A) number of respiratory events and B) airflow obstruction 
(Penh) were recorded for the 10 minute exposure period and for 5 minutes after. Data 
are presented as A) individual data points and mean ± sem; B) mean ± sem. n = 8 in 
the 7% group and n = 4 in the vehicle, 9% and 11% groups. 
 
3.3.4. Characterisation of in vitro models of sensory nerve activation  
As well as developing in vivo models of cough, the aim was to characterise an in vitro 
model of sensory nerve activation, utilising the guinea-pig vagus nerve, which is a 
technique that has successfully been used to distinguish the effects of potential 
antitussives (Birrell et al., 2002; Patel et al., 2003). The effect of the sensory nerve 
stimuli and tussive agents low pH solution (low pH solution is used to mimic the 
effects of CA in vitro), CAPS, bradykinin, PGE2 and hypertonic saline were 
investigated in this in vitro assay of sensory nerve activation. The low pH solution 
provided a more suitable physiological solution than CA, for performing and 
maintaining the isolated nerve preparation experiments. A single low pH solution (pH 
5) was used, which was comparable to a low pH solution used in previously published 
single fibre studies (Fox et al., 1995b).   
 
Figure 3.8 shows the results obtained using the isolated guinea-pig vagus nerve 
preparation. The level of depolarisation, which is a measurement of sensory nerve 
activity, was measured in response to stimulation of the nerve with one of the tussive 
stimuli, as depicted in Figure 3.9. Concentration-response studies were carried out 
using the tussive agents in order to characterise the model and also to choose suitable 
sub-maximal doses to take forward for future studies. Stimulation of the isolated 
vagus nerve with the tussive agents previously shown to evoke cough in the guinea-
pig in vivo, resulted in depolarisation of the nerve. Concentration-response studies 
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highlight that distinct patterns of response occur in vitro, since the level of sensory 
nerve activation differs in response to stimulation with different agents. For example, 
the size of the response following stimulation of the nerve with the maximal effective 
concentration of CAPS (10µM, 0.48 ± 0.06 mV) is much larger than the response 
following the maximally effective concentration of PGE2 (10µM, 0.16 ± 0.03 mV) or 
the maximally effective concentration of bradykinin (10µM, 0.15 ± 0.03 mV). 
Incubation of the vagus nerve with hypertonic saline induced a concentration-related 
increase in the level of depolarisation (8%; 0.73 ± 0.05 mV). Incubation with the 
vehicles (0.1% DMSO, 0.1% ethanol or 0.1% water) did not induce depolarisation of 
the vagus nerve (Figure 3.8). 
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Figure 3.8: Characterisation of sensory nerve activation following stimulation of 
the guinea-pig isolated vagus nerve with sensory nerve stimuli  
Vagus nerves were dissected free from naïve guinea-pigs. Depolarisation of the 
isolated vagi were then monitored and recorded during separate 2 minute exposures to 
the vehicles, low pH solution, capsaicin, bradykinin, PGE2 or hypertonic saline 
(NaCl) solution. n = 6 in the low pH, capsaicin and NaCl groups. n = 4 in the 
bradykinin and PGE2 groups. Data are presented as mean ± sem. *p<0.05 compared 
with controls. 
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Figure 3.9: Representative trace showing the effect of capsaicin on the 
depolarisation of the guinea-pig in vitro isolated vagus nerve  
The isolated vagus nerve section is incubated with a tussive stimulus, which results in 
a depolarising response. After 2 minutes, the section of nerve is washed with KHS 
solution until the response returns to baseline. The response is expressed as an 
increase in mV from baseline.   
 
 
3.4. Discussion 
 
The work described in this chapter has shown that there are a number of stimuli that 
can induce cough and can be used to increase our understanding of the cough reflex.  
Furthermore, the nature of the cough response can differ depending on the stimuli 
used. In addition, studies in this chapter have shown that exposure to one cough 
provoking agent can directly impact on subsequent cough responses to the same agent 
or to another agent. These findings have been extended to include characterisation of 
an in vitro assay to measure sensory nerve activation.   
 
The tussive stimuli chosen for investigation in this thesis have all previously been 
shown to elicit cough in man; CA (Bickerman and Barach, 1954; Morice et al., 2007), 
CAPS (Collier and Fuller, 1984; Davenport et al., 2007), bradykinin (Fuller et al., 
1987; Ichinose et al., 1992), PGE2  (Kawakami et al., 1973; Costello et al., 1985) and 
hypertonic saline (Lowry et al., 1988; Fahy et al., 1995). The guinea-pig was the 
species of choice for investigating cough, as it is capable of evoking a reproducible 
and conscious cough reflex response following exposure to tussive agents. 
Furthermore, guinea-pigs have historically been used to study mechanisms associated 
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with the cough reflex (Winter and Flataker, 1955; Patel et al., 2003; Trevisani et al., 
2004). The in vivo guinea-pig models of cough described in this thesis measure the 
number of coughs evoked in the conscious state, which is particularly important as 
there is evidence describing differences in the effects of C-fibre stimulants, such as 
CAPS and bradykinin, on the ability to evoke cough in the conscious or anaesthetised 
setting. In fact, stimulation with CAPS does not cause cough when applied to the 
trachea or larynx of anaesthetised guinea-pigs (Canning et al., 2004; Mazzone et al., 
2005), whereas inhalation of CAPS is a potent tussive agent in conscious guinea-pigs 
(Forsberg and Karlsson, 1986; Bolser et al., 1991; Lalloo et al., 1995). Another 
advantage of measuring conscious cough is that Penh, which is a non-invasive 
indicator of airflow obstruction, can be simultaneously determined (Lomask, 2006; 
Lewis et al., 2007).  
 
The production of a cough in the guinea-pig is identifiable by the change in breathing 
pattern, the characteristic sound produced and also the characteristic posture of the 
animal. Previously, automated cough recognition software for guinea-pigs was not 
available and the coughs had to be counted manually. This allowed only one guinea-
pig to be evaluated at one time, making experiments repetitive, time and labour-
intensive. However, recently the Buxco automated system of cough counting was 
developed, which differentiated between a sneeze and a cough and allowed a number 
of animals to be evaluated at one time as well as avoiding operator error (Battram et 
al., 2005). This cough automation software was developed to recognise coughs 
induced by CA and CAPS (Type 1 coughs); therefore the distinct Type 2 coughs 
produced by bradykinin and PGE2 were manually counted. The description of two 
different types of cough in the guinea-pig is a novel finding, which may mimic the 
varied manner of cough encountered in man. Moreover, one would not expect every 
cough in man to be of the same nature, intensity and strength due to the multiple 
causes of cough production and also the different and distinct sensory nerve afferents 
which the cough-provoking stimuli can activate.     
 
The results in this chapter show that exposure of guinea-pigs to CAPS or CA results 
in a significant cough response as well as a significant increase in Penh compared to 
vehicle controls. The tussive agent CAPS, which is the pungent extract from peppers 
in the Capsicum family (Caterina et al., 1997; Caterina and Julius, 2001),  has been 
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used for over 20 years as a cough provoking agent in clinical trials as it causes cough 
in a reliable, dose-dependent and safe manner (Midgren et al., 1992; Dicpinigaitis, 
2003b; Dicpinigaitis and Alva, 2005). As well as causing cough, stimulation with 
CAPS can also result in bronchoconstriction, mucus hypersecretion and plasma 
extravasation (Fuller et al., 1985; Kou and Lee, 1990; Lei et al., 1992). Exposure to 
CA has also been widely used for over 50 years to induce cough in man (Bickerman 
and Barach, 1954; Morice et al., 2007). Laude et al carried out comparative cough 
studies and showed that guinea-pig and man evoke comparable cough responses to 
CAPS and CA in a concentration-related manner. However they also found that the 
bronchoconstriction induced by CAPS and CA was more prolonged in the guinea-pig 
compared to the transient effects seen in man  (Laude et al., 1993).  
 
The nature of the cough responses evoked following exposure to CA and CAPS 
during the in vivo studies are in agreement with current literature on the subject 
(Lalloo et al., 1995; Trevisani et al., 2004; Lewis et al., 2007). However, the 
measurement of cough and numbers of coughs evoked can vary dependent on a 
number of factors including the cough detection system, the concentration of tussive 
agent, the size of the chamber and the length of exposure time to tussive agent. 
Therefore, caution should be taken when comparing cough responses across different 
systems. Even though the experimental cough-detection equipment was almost 
identical, wherever possible for the work in this thesis, a series of experiments 
developed at one site, e.g. at Novartis, was followed with subsequent experiments 
carried out at the same site.  
 
In addition to the development of in vivo models of cough, an in vitro model of 
sensory nerve activation was also characterised. By utilising the isolated vagus nerve 
taken from guinea-pigs, the results show that stimulation of the nerve with CAPS or a 
low pH solution (which is used to mimic the effects of CA in vitro) results in a 
significant increase in depolarisation compared to control, which is consistent with 
previous reports (Fox et al., 1995b; Birrell et al., 2002; Usmani et al., 2005). The 
model of sensory nerve activation provides a reliable adjunct to the in vivo cough 
experiments as it provides functional in vitro data, before progressing to in vivo 
studies which are more costly and may be complicated by PK issues. Furthermore, it 
has previously been established that the isolated guinea-pig vagus nerve responds in a 
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comparable manner to that of isolated human vagus nerve (Belvisi et al., 1998). In 
addition, the in vitro assessments can be utilised for future pharmacological profiling 
and proof of concept studies prior to further in vivo experiments. However, the data 
obtained with the isolated vagus nerve should be interpreted with some caution as the 
tussive stimuli are applied to the main trunk of the nerve. Therefore, the resulting 
depolarisation response is caused by a summation of the changes in membrane 
potential of all of the axons within the vagus nerve and the activation of receptors 
located on the membrane of the axon may not correspond to the effects occurring in 
the peripheral endings (Patel et al., 2003).  
 
The specific receptors located on sensory nerve endings have been identified and 
classified into different types based on their functional properties (Fox et al., 1993; 
Undem and Weinreich, 1993; Riccio et al., 1996). There is evidence to suggest that 
stimulation of sensory nerves with CAPS is mediated via activation of C-fibres, which 
was discovered through single vagal afferent nerve fibre recordings (Fox et al., 1993). 
It is now well accepted that the actions of CAPS on sensory nerves are through 
stimulation of the TRPV1 receptor, which is a membrane bound ligand gated ion 
channel located on C-fibres (Bevan and Szolcsanyi, 1990; Caterina et al., 1997; 
Caterina et al., 2000). Upon agonist binding to an ion channel such as TRPV1, the ion 
pore opens, allowing influx of cations and the initiation of depolarisation (Kollarik 
and Undem, 2002). CA is believed to activate sensory nerves via the same mechanism 
as CAPS as protons and low pH solutions also selectively stimulate CAPS-sensitive 
sensory nerves (Lou and Lundberg, 1992; Bevan and Geppetti, 1994; Fox et al., 
1995b). In guinea-pigs, inhaled CA and CAPS trigger a cough response that is 
accompanied by bronchoconstriction. This is in agreement with previous reports 
(Forsberg et al., 1988) and is believed  to be caused by the release of neuropeptides 
from C-fibres (Ricciardolo et al., 1999), secondary to TRPV1 activation. C-fibres are 
believed to contain neuropeptides such as CGRP, and also tachykinins such as SP and 
NKA. Stimulation of the nerve endings results in an axon reflex and the release of 
sensory neuropeptides, local neurogenic inflammation, and also central nervous 
system reflexes such as mucosal vasodilatation, mucus secretion and 
bronchoconstriction (Groneberg et al., 2004b). Despite the current understanding, 
research to determine precisely which airway afferent nerves are activated in response 
to CA and CAPS has been the subject of debate.  Previously, in vivo studies in 
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anaesthetised cats has shown that aerosolised CAPS activated all C-fibres and also a 
proportion of RARs tested (Mohammed et al., 1993). Furthermore, extracellular 
recordings of single jugular and nodose vagal ganglion neurons showed that CA not 
only activated C-fibres but also Aδ-fibres and hypothesised that the TRPV1-
independent actions of CA were through activation of ASICs (Kollarik and Undem, 
2002). Interestingly, Canning and colleagues have shown that C-fibre stimulants such 
as CAPS and bradykinin do not evoke cough when applied topically to the trachea or 
larynx of anaesthetised guinea-pigs, however application with CA does cause cough 
in this in vivo model. Therefore, research to determine precisely which airway afferent 
nerves mediate cough when activated has not been conclusive as many species have 
been used to investigate cough, and the different tussive stimuli and state of 
consciousness or anaesthesia during investigation contributes to the differences in 
opinion (Mazzone, 2005). Furthermore, acid is believed to activate the recently 
identified ‘cough receptors’, whereas CAPS does not (Canning et al., 2004). These 
finding provide evidence that CA and CAPS may act via distinct mechanisms to 
induce cough and this field of research warrants further investigation.  
 
The next studies were designed in order to investigate whether carrying out studies to 
rank guinea-pigs following exposure to CA, had an effect on the numbers of coughs 
produced by further exposure to tussive stimuli in the following weeks. The results 
suggest that the CAPS-induced cough response may be decreased one week after 
exposure to CA. The mechanism of subsequent reduction in cough response may 
possibly be caused by desensitisation of the TRPV1 receptor located on C-fibres. 
Interestingly, inhibition of the cough reflex did not occur when investigating the 
effect of repeated weekly exposures of guinea-pigs to CA, thus suggesting distinct 
mechanisms of cough provocation by CA and CAPS. However, exposure of guinea-
pigs to CAPS results in a complete block of the CAPS-induced cough response in the 
following week. Perhaps CAPS is specifically stimulating cough via activation of 
TRPV1 receptors, whereas CA may have multiple mechanisms of action including the 
activation of TRPV1. Almost twenty years ago, Forsberg and colleagues investigated 
the effect of pre-treatment of guinea-pigs with CAPS on the cough response. They 
found that CAPS pre-treatment produced a long lasting (>10 weeks) depletion of SP 
and CGRP in sensory nerves. Furthermore, 2 and 10 weeks later guinea-pigs had a 
significantly decreased cough response and level of bronchoconstriction following 
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stimulation with CA or CAPS (Forsberg et al., 1988). Desensitisation of the CAPS 
response is thought to be caused by an extracellular Ca2+ dependent reduction of 
TRPV1 responsiveness, physical damage or degeneration of the nerve terminal, or 
depletion of neurokinins from sensory nerve endings (Tominaga and Tominaga, 
2005). Recent studies investigating the effect of chronically treating guinea-pigs with 
CAPS sub-cutaneously, showed a complete loss of TRPV1-immunopositive axons 
within the trachea and intrapulmonary airways. In addition, there was a loss of 
bronchoconstriction induced by subsequent CAPS exposure and an extensive 
depletion of SP and CGRP immunoreactive axons in CAPS treated animals 
(Watanabe et al., 2006). The possibility that pre-exposure of guinea-pigs to CA is 
depressing the cough response induced by CAPS in successive weeks resulted in the 
decision to not carry out ranking studies in future experiments.   
 
The work in this chapter has demonstrated that in addition to a cough response 
induced by CA and CAPS, guinea-pigs also cough to other tussive stimuli. 
Bradykinin, an endogenous metabolite of the kallikrein-kinin system, also directly 
activates airway afferent sensory nerves in vitro to cause depolarisation and in vivo to 
cause cough. The results show that bradykinin induces a novel type of cough reflex 
response, which have been termed ‘Type 2’ coughs and are described as a bout of 
quieter, less powerful coughs, compared to the single, louder, powerful coughs 
evoked by CA and CAPS. Furthermore, the higher concentration of bradykinin tested 
caused a statistically significant level of airflow obstruction compared to the control 
group. Stimulation of the isolated vagus nerve with bradykinin resulted in a 
concentration-related increase in depolarisation. The actions of bradykinin on 
peripheral nerve terminals is via G-protein coupled bradykinin B2 receptors (Ichinose 
and Barnes, 1990; McGuirk and Dolphin, 1992; Fox et al., 1993; Kajekar et al., 
1999). However, the mechanisms linking bradykinin B2 receptor activation and 
production of a cough is unknown. Bradykinin was recognised to cause cough in man 
following a clinical trial to investigate the effect of inhaled bradykinin on 
bronchoconstriction in normal and asthmatic subjects (Fuller et al., 1987). There have 
since been a handful of clinical studies which have noted the presence of bradykinin-
induced cough (Choudry et al., 1989; Ichinose et al., 1992; Hope-Gill et al., 2003), 
although further examination is required to determine whether bradykinin-induced 
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cough in man resembles the Type 1 or Type 2 variety described in this chapter. 
Stimulation of vagal single fibres with bradykinin indicates that bradykinin is an 
activator of C-fibres (Fox et al., 1993). In addition, electrophysiological recordings of 
guinea-pig nodose ganglion neurons show that bradykinin induces membrane 
depolarisation in a sub-set of C-type neurons  (Undem and Weinreich, 1993). As well 
as directly causing cough, bradykinin has been shown to sensitise airway sensory 
nerves and lower the threshold for cough activation, which underlies the mechanism 
of cough caused by ACE-inhibitors (Fox et al., 1996). There are very few references 
describing bradykinin-induced cough in the conscious guinea-pig (Bergren, 2001b; 
Canning et al., 2004). A paper published by Canning et al in 2004 shows that 
bradykinin induces cough in the conscious guinea-pig but is ineffective at eliciting a 
cough in the anaesthetised setting. By looking at the characteristic trace in the 
publication, which measures pressure changes in the chamber in order to detect 
cough, the bout of bradykinin-induced coughs appear similar to the findings in this 
thesis (Canning et al., 2004). 
 
Unlike CA and CAPS, the inflammatory mediator PGE2 is not routinely used in 
animal models to induce cough. The results in this chapter show that PGE2 induces a 
significant cough response compared to control, which has identical characteristics to 
the Type 2 cough response evoked by bradykinin. Furthermore, PGE2-induced cough 
is not accompanied by a significant change in Penh.  In addition, PGE2 activates 
sensory nerves located in the vagus, as stimulation with PGE2 caused a significant 
increase in depolarisation, which is consistent with previous reports using this 
stimulant (Patel et al., 2003). A study published in 1984, which evaluated a  range of 
prostanoids for their ability to cause cough in the cat, found that PGE2 produced an 
early phase of coughing (Gardiner and Browne, 1984). Literature reviews of the 
subject highlighted that there are in fact no previously published data describing 
guinea-pig models of cough induced by PGE2. This is likely because of the high cost 
of PGE2 and also as currently employed models of cough using CA and CAPS are 
deemed robust, cost-effective and efficient for screening of potential antitussive 
therapies (Karlsson et al., 1990; Patel et al., 2003; Trevisani et al., 2004; Usmani et 
al., 2005). The ability of inhaled PGE2 to cause cough is however in agreement with 
published clinical trial data. Inhaled PGE2 was originally investigated as a potential 
therapy for treatment of airway inflammatory diseases due to its bronchodilator 
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actions. However, the development of prostanoid agonists for this therapeutic purpose 
was hindered as PGE2 also caused irritancy of the upper airway and reflex cough as a 
side-effect (Kawakami et al., 1973; Costello et al., 1985). Additionally, inhaled PGE2 
markedly potentiates the responses to subsequent inhalation with CAPS, suggesting 
that the cough reflex is sensitised in the presence of PGE2 in the airways (Choudry et 
al., 1989).  The mechanism by which PGE2 initiates depolarisation in the peripheral 
terminals of vagal afferent sensory nerves is unknown. Perhaps the action of PGE2 on 
sensory nerves is secondary to activation of one of the nine prostanoid receptor sub-
types (EP1-4, DP1-2, TP, FP or IP) located on peripheral afferent terminals, although 
which specific prostanoid receptor is responsible for the initiation of PGE2-induced 
cough is unknown.  
 
Hypertonic saline is a known tussigenic agent in humans (Lowry et al., 1988; Fahy et 
al., 1995; Koskela et al., 2005) and in guinea-pigs (Lalloo et al., 1995; Gatti et al., 
2006). In vivo cough studies and in vitro single fibre recordings of sensory nerves 
have shown that hypertonic saline excites RARs (Fox et al., 1995a). Treatment of 
guinea-pigs with the TRPV1 antagonist capsazepine inhibited cough induced by CA 
and CAPS but had no effect on hypertonic saline-induced cough (Lalloo et al., 1995). 
More recently, this observation was confirmed, hence hypertonic saline-induced 
cough is considered to act independently of TRPV1 activation (Trevisani et al., 2004; 
Gatti et al., 2006). The in vivo dose-response studies in this thesis were designed to 
replicate previously established models, which exposed guinea-pigs to a 7% 
hypertonic saline solution for 10 minutes (Lalloo et al., 1995; Trevisani et al., 2004). 
Attempts to establish an in vivo guinea-pig model of hypertonic saline-induced cough 
were unsuccessful as a reproducible number of coughs were not achieved with a 10 
minute exposure to 7%, 9% or 11% hypertonic saline. As the responses evoked were 
not clearly identifiable as either a Type 1 cough or Type 2 cough, they were termed 
respiratory events. The reason for the lack of cough response to hypertonic saline in 
this setting is unknown and may be due to differences in the experimental set-up 
including the supplier of guinea-pigs, size of the chamber and flow of aerosol into and 
out of the chamber. However, stimulation of the isolated vagus nerve with hypertonic 
saline did excite sensory nerves in a concentration-dependent manner, which is in 
agreement with previous findings (Birrell et al., 2002; Patel et al., 2003). The 
resulting depolarisations following stimulation with hypertonic saline were larger than 
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the maximal responses to the other tussive stimuli. It was also observed that the onset 
of depolarisation was more rapid in response to hypertonic saline compared to 
stimulation with the other tussive agents, possibly further highlighting an alternative 
mechanism of action.  
 
This is the first time that a number of different guinea-pig in vivo models of cough 
and in vitro models of sensory nerve activation have been developed and directly 
compared using the tussive stimuli CA, CAPS, bradykinin, PGE2 and hypertonic 
saline. The results show that there are distinct patterns of response elicited following 
exposure to the tussive agents. The response can differ according to maximum 
numbers of coughs produced, the type of cough produced, the associated sound and 
posture of the animal and the level of airflow obstruction. In addition, the 
development of novel models of cough raises the question that perhaps some of these 
stimuli, such as BK and PGE2, are more clinically relevant, than CA and CAPS, as 
they are endogenously produced. Considering the causes of cough are diverse, as 
cough can be a symptom of a number of different respiratory diseases including 
asthma, COPD, post-viral infection and GORD, the differences in types of cough may 
ultimately correlate with different causes and mechanisms of cough production. These 
findings highlight the complexity of understanding the mechanisms surrounding 
cough. Although there are different causes and types of cough response, the link 
between them all is the activation of sub-sets or airway sensory nerves activating the 
cough reflex.  The development of guinea-pig cough models described in this chapter 
will be valuable in further studies aimed at investigating the mechanisms of cough 
production and the potential changes in disease models associated with an enhanced 
problematic cough reflex. 
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4.1. Aims and rationale 
 
The aim of these studies was to investige whether exposure to CS alters the activity of 
the cough reflex in guinea-pigs by modulating the responsiveness of the airway 
afferent fibres that mediate cough.  
 
Most research in the field of cough has focussed on stimuli that activate airway 
sensory nerves to initiate cough, whereas there are fewer studies investigating 
sensitisation of the cough reflex. In addition, most of the information on the cough 
reflex comes from animal models of cough in which there is no airway inflammatory 
disease modelling. Therefore, the effect of pathological changes in the airways in 
modulating the cough reflex response is still unknown and the pharmacological 
changes that are occurring in exacerbated cough are not well understood.  
 
CS is a powerful irritant of the respiratory tract and is the main cause for developing 
COPD (Barnes, 2004). Therefore, CS was chosen as a disease-relevant stimulus as 
cough is a frequent and troublesome symptom reported by patients with a range of 
respiratory diseases including COPD (Morice et al., 2004). Furthermore, patients with 
COPD have demonstrated an increased CA and CAPS-induced cough reflex 
sensitivity compared to healthy subjects (Wong and Morice, 1999; Doherty et al., 
2000). The CS model decribed in this chapter is an acute challenge model and is not 
representative of COPD; therefore the stimulus CS was used as a tool to investigate 
the potential modulation of the cough reflex in an airway inflammatory disease 
setting. The initial work in this chapter focussed on investigating the effect of CS 
exposure on the CA and CAPS-induced cough response. Subsequent studies at the 
chosen time-point investigated the effect of CS exposure on the cough response 
induced by the cough-provoking agents bradykinin, PGE2 and hypertonic saline. 
Furthermore, by utilising a range of tussive stimuli, the modulation of sensory nerve 
activation following CS exposure was examined using the in vitro isolated guinea-pig 
vagus nerve preparation.  
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4.2. Methods 
 
4.2.1. Animals (Novartis) 
Male Dunkin-Hartley guinea-pigs (300-500g) were purchased from Charles River, 
France. Animals were housed for at least 7 days before undergoing experimental 
procedures. Food and water were supplied ad libitum. United Kingdom Home Office 
guidelines for animal welfare based on the Animals (Scientific Procedures) Act 1986 
were strictly followed. In vivo studies performed at Novartis were reviewed and 
approved by the Novartis Ethical Review Process. 
 
4.2.2. Cigarette smoke exposure (Novartis) 
Guinea-pigs were exposed to CS from 4 standard filtered cigarettes (2R4F, University 
of Kentucky, KY) once daily for 2, 5 or 8 days as described in the methods chapter 
(Chapter 2.2.4). Control guinea-pigs were exposed to air only (500ml/min) in 
identical chambers, for the same length of time. The animal behaviour and welfare 
was monitored throughout the CS exposure periods and thereafter during the study. 
 
4.2.3. Tussive agent-induced cough (Novartis)  
Guinea-pigs were exposed to CS as described above in section 4.2.2. 24 hours after 
the final CS or air exposure, the conscious and unrestrained animals were placed in 
individual plastic transparent whole body plethysmograph chambers (Buxco, USA). 
The tussive agents used to evoke cough were either a nebulised aqueous solution of 
CA (0.3M for 10 minutes), CAPS (10µM for 7 minutes), hypertonic saline (7% NaCl 
for 10 minutes), PGE2 (0.1mg/ml for 10 minutes) or bradykinin (3mg/ml for 10 
minutes). The number of coughs and level of airflow obstruction were recorded as 
described in chapter 2.2.2. 
 
4.2.4. Bronchoalveolar lavage fluid sampling and processing (Novartis) 
60 minutes after the cough experiment, guinea-pigs were euthanised with an overdose 
of sodium pentobarbitone (200mg/kg i.p). The trachea was exposed by blunt 
dissection and then cannulated in order to obtain BAL fluid as described previously in 
chapter 2.3.1. 
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4.2.5. Total cell counts and cytospin preparations (Novartis) 
Total cell counts for BAL fluid recovered from the airway lumen were quantified 
using an automated Sysmex cell counter (Sysmex UK Ltd, Milton Keynes, UK). 
Differential cell counts of neutrophils, eosinophils and LMN cells recovered from the 
airway lumen were determined by light microscopy (x40 magnification) from 
cytospin preparations, which were prepared as described previously (Chapter 2.3.2.1). 
The numbers of leukocytes were expressed as number of cells/ml. 
 
4.2.6. Immunohistochemical detection of mucus in the guinea-pig lung (Novartis) 
60 minutes after the cough experiments and immediately following the collection of 
BAL fluid, the trachea and lungs were excised from guinea-pigs, insufflated with 
NBF and immersion fixed in NBF for histological assessment. 24 hours later, the lung 
lobes were processed as wax tissue blocks. Sections of lung (3µm) were cut, placed 
onto Polysine slides and were stained with UEA-1 using an indirect 
immunoperoxidase method to determine the area of mucus staining in the large and 
small guinea-pig airways, as described in chapter 2.3.4.  
 
4.2.7. Quantification of mucus staining in the guinea-pig lung (Novartis) 
The area of UEA-1 staining was assessed under a Zeiss Axioplan 2 microscope (x20 
magnification) with an Imaging Associates KS400 image analyser (Imaging 
Associates, Bicester, UK).  All large and small airways in sections taken from both 
lung lobes were scored for each animal. Random scoring of each slide was carried out 
without knowledge of which group was associated with which sample. Data are 
presented as area of mucus staining, which is calculated as a ratio of stained area 
(µm2) to length (µm) of epithelium scored.  
 
4.2.8. Sensory nerve activation in isolated guinea-pig vagus nerve preparations 
(Novartis & NHLI) 
Guinea-pigs were exposed to CS or air at Novartis as described above in section 4.2.2. 
24 hours after the final exposure, guinea-pigs were killed by cervical dislocation and 
the vagus nerves dissected, as previously described in the methods chapter 2.4.1. The 
nerves were placed in oxygenated KHS and transported to the NHLI immediately 
after dissection. Nerve depolarisations were induced by perfusion of the vagus with 
sub-maximal concentrations of either low pH solution (pH 5.0), CAPS (1µM), BK 
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(3µM), PGE2 (10µM) or hypertonic saline (2% NaCl). A solution containing one of 
the five stimulants was applied to a section of vagus nerve for a period of two minutes 
at which point the tissue was washed until the baseline returned to the resting state. 
This was then repeated in turn using one of the other five stimuli until the nerve had 
been exposed to each of the stimuli in turn. The five stimuli were applied in the same 
order for each experiment in order to keep the conditions identical for comparison of 
vagus nerve taken from the CS group or control group. Depolarising responses were 
recorded in response to stimulation with the sensory nerve stimuli and the data are 
expressed as an increase in mV from baseline.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Schematic representation of the experimental protocol and end-
points used for the cigarette smoke studies  
 
4.2.9. Monitoring animal health (Novartis) 
Guinea-pigs were constantly monitored throughout procedures and during recovery. 
Animals were checked for signs of adverse events such as withdrawal with lack of 
mobility and respiratory distress. If such events occurred, the individual experiment 
would be terminated and the animal euthanised.  
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4.3. Results 
 
4.3.1. The effect of cigarette smoke exposures on citric acid or capsaicin-induced 
cough and airflow obstruction in the conscious guinea-pig 
The initial studies for this chapter aimed to determine the effect of CS exposure on the 
CA or CAPS-induced conscious cough reflex. A time-course study was designed to 
expose guinea-pigs to CS once a day for 2, 5 or 8 days. In order to determine the 
effect of CS on the number of coughs, sub-maximal concentrations of the tussive 
agents CA and CAPS were selected. The results show that guinea-pigs challenged 
with CS display enhanced cough sensitivity to both the tussive agents CA and CAPS 
(Figures 4.2 & 4.3). Similar to the nature of the coughs described in the 
concentration-response studies, the type of CA and CAPS-induced cough response 
following exposure to CS comprised only Type 1 coughs. Following 2, 5 and 8 days 
of daily exposures the number of coughs induced by 0.3M CA was significantly 
increased in the CS-exposed guinea-pigs compared to the time-matched controls. The 
exposure to CS, once a day for 8 days, resulted in a 2.6-fold increase in the CA-
induced number of coughs from 12.7 ± 2.1 in the time-matched controls to 33.2 ± 4.4 
in the CS exposed group. The enhanced CA cough responses following CS exposure 
were accompanied by an increase in Penh compared to time-matched controls, 
reaching statistical significance at the 8 day time-point from 7.6 ± 1.1 Penh units in 
the control group to 10.3 ± 1.1 Penh units in the CS exposed group (Figure 4.2B).   
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Figure 4.2: The effect of 2, 5 or 8 days of repeated cigarette smoke exposures on 
citric acid-induced cough and airflow obstruction in the conscious guinea-pig  
Guinea-pigs were exposed to smoke generated from 4 cigarettes, once daily for 2, 5 or 
8 days. Control guinea-pigs were exposed to air for the same length of time. 24 hours 
after the final exposure, the A) number of coughs and B) airflow obstruction (Penh) 
induced by citric acid were measured. Data are presented as A) individual data points 
and mean ± sem; B) mean ± sem. *p<0.05 compared with time-matched controls. n = 
12 in each group. 
 
Significant exacerbation of the Type 1 cough response induced by CAPS did not 
occur following 2 or 5 days of repeated CS exposures. However, there was a 
statistically significant enhancement of the cough response after the eighth exposure 
from 2.4 ± 1.2 coughs in the time-matched controls to 13.1 ± 2.3 coughs in the CS 
group, which is a 5.5-fold increase (Figure 4.3A). Exposure to CAPS did not result in 
a statistically significant difference in the level of airflow obstruction between the CS-
exposed groups and the time-matched controls (Figure 4.3B).  
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Figure 4.3: The effect of 2, 5 or 8 days of repeated cigarette smoke exposures on 
capsaicin-induced cough and airflow obstruction in the conscious guinea-pig  
Guinea-pigs were exposed to smoke generated from 4 cigarettes, once daily for 2, 5 or 
8 days. Control guinea-pigs were exposed to air for the same length of time.  24 hours 
after the final exposure, the A) number of coughs and B) airflow obstruction (Penh) 
induced by capsaicin were measured. Data are presented as A) individual data points 
and mean ± sem; B) mean ± sem. *p<0.05 compared with time-matched controls. n = 
12 in each group. 
 
4.3.2. The effect of cigarette smoke exposures on mucus production in the 
guinea-pig lung 
Having demonstrated an enhanced cough reflex, the guinea-pig cough model was 
characterised, by investigating any changes in mucus production between the CS-
exposed and air-exposed groups. The primary assessment of mucus staining was 
carried out using the lectin UEA-1, which is the standard in-house technique, utilised 
at Novartis (Stevenson et al., 2005). The mucus within the guinea-pig lung sections 
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was detected with UEA-1 using an indirect immunoperoxidase method and DAB was 
the chromagen of choice as the dark brown chromagen produces a suitable contrast of 
colour allowing the image-analysis computer programme to detect the changes in 
expression and thus allow quantification between groups. 
 
The acute insult of repeated CS exposures clearly induced a change in the mucus 
production of the large and small airways in guinea-pigs. Figure 4.4 displays a 
statistically significant increase in the area of stained mucus after 5 and 8 days of 
daily CS exposures, as quantified by image analysis. The representative cross-sections 
in figure 4.5 illustrate the mucus staining using UEA-1, displaying an increase in the 
area of mucus lining the airways after 8 CS exposures.  
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Figure 4.4: The effect of cigarette smoke exposure on mucus production in the 
guinea-pig lung  
Guinea-pigs were exposed to smoke generated from 4 cigarettes, once daily for 2, 5 or 
8 days. Control guinea-pigs were exposed to air for the same length of time. 24 hours 
after the final exposure, lungs were dissected and processed for histological analysis. 
Mucus staining was assessed using image analysis. n = 6 in each group. Data are 
presented as mean ± sem. *p<0.05 compared with time-matched controls. 
Histological analysis and assessment of mucus staining was performed by the 
histology group at Novartis.   
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A)     B) 
 
 
Figure 4.5: Representative cross sections showing an increase in area of mucus 
staining in lungs taken from guinea-pigs exposed to cigarette smoke  
Guinea-pigs were exposed to smoke generated from 4 cigarettes, once daily for 8 
days. Control guinea-pigs were exposed to air for the same length of time. The 
representative cross sections show large airways from A) air-exposed or B) cigarette 
smoke-exposed guinea-pigs. Lung sections were stained using the lectin UEA-1 to 
identify mucus in the airways. Photographs were taken with x 20 objective. 
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4.3.3. The effect of cigarette smoke exposures on bronchoalveolar lavage fluid 
leukocyte infiltration 
Figure 4.6 displays the results from differential cell counts in the BAL fluid to 
determine the abundance of neutrophils, eosinophils and LMN cells. There is an 
inflammatory response associated with the acute CS exposure regime as demonstrated 
by statistically significant neutrophilia after 5 and 8 days of CS exposure. The 
numbers of eosinophils in the BAL fluid were not significantly altered at any time-
point. However, the LMN cell influx was statistically significantly increased after 8 
CS exposures compared to the time-matched group. 
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Figure 4.6: The effect of cigarette smoke exposure on bronchoalveolar lavage 
fluid leukocyte infiltration  
Guinea-pigs were exposed to smoke generated from 4 cigarettes, once daily for 2, 5 or 
8 days. Control guinea-pigs were exposed to air for the same length of time. 24 hours 
after the final exposure, lungs were lavaged and cytospin slides prepared for A) 
neutrophil, B) eosinophil and C) lymphomononuclear cell numbers to be determined 
by differential counting. n = 8 in each group. Data are presented as mean ± sem. 
*p<0.05 compared with time-matched controls. 
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4.3.4. Confirming the effects of cigarette smoke exposure on cough induced by 
citric acid or capsaicin  
The exposure regime comprising 8 challenges was chosen for future investigation as 
there was a significant enhancement of the Type 1 cough response induced by both of 
the tussive agents, CA and CAPS, at this time-point. The augmented cough sensitivity 
induced by CS was confirmed with a second study using CA and CAPS. As well as 
confirming the effects of CS on CA and CAPS-induced cough, the primary aim of the 
repeat study was to obtain tissues, including the sensory nerve ganglion, for future 
analysis of protein expression as described later in chapter 6. In addition, it was also 
essential to determine that the guinea-pigs were coughing in response to stimulation 
with tussive agents and not spontaneously due to previous challenges with CS. The 
results in Figure 4.7 show that exposure to CS, once a day for 8 days, causes a 
statistically significant increase in CA-induced cough numbers from 17.4 ± 2.3 
coughs in the time-matched controls to 44.5 ± 3.0 coughs in the CS-exposed group, 
which was accompanied by a statistically significant increase in Penh units from 7.5 ± 
0.5 to 11.2 ± 1.1. Furthermore, the responses to CAPS were again largely augmented 
from 5.5 ± 2.8 coughs to 21.0 ± 2.9 coughs in the air-exposed and CS-exposed groups 
respectively, which was associated with a statistically significant increase in airflow 
obstruction from 3.5 ± 1.2 to 10.1 ± 1.5 Penh units (Figure 4.8). Challenge with 
aerosols of the vehicle solutions confirmed that the air-exposed and CS-exposed 
animals do not cough spontaneously in the plethysmograph chambers (Figures 4.7 & 
4.8). This evidence indicates that coughs evoked in previous CS-enhanced cough 
experiments were in response to tussive stimuli challenge and not due to spontaneous 
coughing from previous exposure to smoke.  
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Figure 4.7: The effect of cigarette smoke exposures, once a day for 8 days, on 
citric acid-induced cough and airflow obstruction in the conscious guinea-pig  
Guinea-pigs were exposed to smoke generated from 4 cigarettes, once daily for 8 
days. Control guinea-pigs were exposed to air for the same length of time. 24 hours 
after the final exposure, the A) number of coughs and B) airflow obstruction (Penh) 
induced by the vehicle (saline) or citric acid (0.3M) were measured. Data are 
presented as A) individual data points and mean ± sem; B) mean ± sem.  *p<0.05 
compared with time-matched controls. n = 4 in the vehicle groups and n = 10 in the 
citric acid groups. 
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Figure 4.8: The effect of cigarette smoke exposures, once a day for 8 days, on 
capsaicin-induced cough and airflow obstruction in the conscious guinea-pig  
Guinea-pigs were exposed to smoke generated from 4 cigarettes, once daily for 8 
days. Control guinea-pigs were exposed to air for the same length of time. 24 hours 
after the final exposure, the A) number of coughs and B) airflow obstruction (Penh) 
induced by the vehicle (saline) or capsaicin (10µM) were measured. Data are 
presented as A) individual data points and mean ± sem; B) mean ± sem.  *p<0.05 
compared with time-matched controls. n = 4 in the vehicle groups and n = 12 in the 
capsaicin groups. 
 
 
 
 
 
 
 
 
 121
4.3.5. The effect of cigarette smoke exposures on bradykinin, PGE2 or hypertonic 
saline-induced cough and airflow obstruction in the conscious guinea-pig 
As the effect of CS exposure on cough induced by CA and CAPS had been 
established, further studies were carried out in order to determine whether CS 
exposure modulated the cough response induced by sub-maximal concentrations of 
the tussive stimuli bradykinin, PGE2 and hypertonic saline.  
 
As the impact of CS on bradykinin and PGE2-induced cough had not previously been 
evaluated, two separate studies were designed in order to obtain an initial result prior 
to confirmation with a second repeat experiment. Therefore, the results have been 
depicted as two separate studies followed by the combined results of both 
experiments. Based on the concentration-response experiments described in chapter 3, 
a sub-maximal concentration of 1mg/ml bradykinin was initially chosen, in order to 
determine the impact of CS on the tussive response and level of Penh. However, at 
this concentration, neither the control group nor the CS exposed groups were 
coughing adequately to determine a result (data not shown, n = 4). Therefore, a higher 
concentration of 3mg/ml was selected for the remainder of the bradykinin cough 
study, which proved a suitable concentration to evoke coughing.  
 
The effect of CS exposures, once a day for 8 days, has an interesting effect on the 
tussive response to bradykinin by altering the type of cough that is evoked. There was 
no significant difference in the number of typical Type 2 coughs following 8 days CS 
exposure (Figures 4.9A). However, the 8 day CS exposed groups do display Type 1 
coughs, which are not characteristically produced following bradykinin exposure but 
are characteristic of the type of cough produced following CA or CAPS exposure 
(Figure 4.9B). In order to confirm this interesting initial finding, the experiment was 
repeated at the 8 day time point to total 10 animals in each group. There was a 
statistically significant increase in the number of Type 1 coughs from zero coughs 
produced in the time-matched controls to 4.6 ± 1.6 coughs in the CS group (Figure 
4.10B). Furthermore, there were no significant changes in airflow obstruction 
between groups (Figure 4.10C). 
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Figure 4.9: The effect of cigarette smoke exposures, once a day for 8 days, on 
bradykinin-induced cough and airflow obstruction in the conscious guinea-pig  
Guinea-pigs were exposed to smoke generated from 4 cigarettes, once daily for 8 
days. Control guinea-pigs were exposed to air for the same length of time. 24 hours 
after the final exposure, the A & D) number of Type 2 coughs, B & E) number of 
Type 1 coughs and C & F) airflow obstruction (Penh) induced by bradykinin 
(3mg/ml) were measured. Data are presented as A & B & D & E) individual data 
points and mean ± sem; C & F) mean ± sem. *p<0.05 compared with time-matched 
controls. n = 4 in each group of the first study (A & B & C) and n = 6 in each group 
of the second study (D & E & F). 
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Figure 4.10: The effect of cigarette smoke exposures, once a day for 8 days, on 
bradykinin-induced cough and airflow obstruction in the conscious guinea-pig; 
combined studies  
Guinea-pigs were exposed to smoke generated from 4 cigarettes, once daily for 8 
days. Control guinea-pigs were exposed to air for the same length of time. 24 hours 
after the final exposure, the A) number of Type 2 coughs and B) number of Type 1 
coughs and C) airflow obstruction (Penh) induced by bradykinin (3mg/ml) were 
measured. Data are presented as A & B) individual data points and mean ± sem; C) 
mean ± sem. *p<0.05 compared with time-matched controls. n = 10 in each group. 
 
 
Having demonstrated that CS exposure exacerbated the cough response to CA and 
CAPS and results in both a change and enhancement in the cough response to 
bradykinin, the effects of CS exposure on cough induced by the endogenous 
prostanoid PGE2 were investigated. Again, an initial study was performed to assess 
the effects of CS on the PGE2-induced cough response before proceeding with a 
repeat experiment to establish the effects. Interestingly, the tussive Type 2 cough 
response induced by PGE2 is abolished after 8 days of CS exposure (Figure 4.11A). 
The experiment was repeated, resulting in a less robust inhibition of the cough 
response, but a 60% inhibition nonetheless (Figure 4.11C).  Therefore, when the two 
studies are combined to total 14 animals in each group, there is a clear attenuation of 
the cough response from 21.1 ± 4.7 coughs in the control group to 1.7 ± 1.7 coughs in 
the smoke group (Figure 4.12A). Exposure to PGE2 did not evoke any Type 1 coughs. 
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Interestingly, the absence of the PGE2-induced Type 2 cough response following 8 CS 
exposures is associated with a small but statistically significant increase in Penh from 
0.87 ± 0.04 to 1.3 ± 0.14 (Figure 4.12B).  
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Figure 4.11: The effect of cigarette smoke exposures, once a day for 8 days, on 
PGE2-induced cough and airflow obstruction in the conscious guinea-pig  
Guinea-pigs were exposed to smoke generated from 4 cigarettes, once daily for 8 
days. Control guinea-pigs were exposed to air for the same length of time. 24 hours 
after the final exposure, the A & C) number of coughs and B & D) airflow obstruction 
(Penh) induced by PGE2 (0.1mg/ml) were measured. Data are presented as A & C) 
individual data points and mean ± sem; B & D) mean ± sem. n = 8 in each group of 
the first study (A & B) and n = 6 in each group of the second study (C & D). 
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Figure 4.12: The effect of cigarette smoke exposures, once a day for 8 days, on 
PGE2-induced cough and airflow obstruction in the conscious guinea-pig; 
combined studies  
Guinea-pigs were exposed to smoke generated from 4 cigarettes, once daily for 8 
days. Control guinea-pigs were exposed to air for the same length of time. 24 hours 
after the final exposure, the A) number of coughs and B) airflow obstruction (Penh) 
induced by PGE2 (0.1mg/ml) were measured. Data are presented as A) individual data 
points and mean ± sem; B) mean ± sem. *p<0.05 compared with time-matched 
controls. n = 14 in each group. 
 
 
A robust cough response induced by hypertonic saline was not achieved during the 
model development stage; the responses that did result were termed respiratory 
events. In order to determine the effects of CS on the response induced by hypertonic 
saline, the concentration previously known to evoke coughs as described in the 
literature (7% NaCl) was chosen. Exposure of guinea-pigs to CS, once a day for 8 
days, followed by challenge with hypertonic saline did not result in reproducible and 
defined Type 1 or Type 2 coughs, therefore the reactions to hypertonic saline were 
consistent with the respiratory events defined during the concentration-response 
studies. There was no significant difference in the number of hypertonic saline-
induced respiratory events or in the level of airflow obstruction between the two 
groups (Figure 4.13). 
 
 
 
 
 126
0
2
4
6
8
Control
Smoke
Days of Exposure
8 8
A) Hypertonic Saline
R
es
pi
ra
to
ry
 ev
en
ts
 in
 1
5 
m
in
ut
es
0.00
0.25
0.50
0.75
Control
Smoke
Days of Exposure
8 8
B) Hypertonic Saline
Pe
nh
 A
ve
ra
ge
 
 
Figure 4.13: The effect of cigarette smoke exposures, once a day for 8 days, on 
hypertonic saline-induced respiratory events and airflow obstruction in the 
conscious guinea-pig  
Guinea-pigs were exposed to smoke generated from 4 cigarettes, once daily for 8 
days. Control guinea-pigs were exposed to air for the same length of time. 24 hours 
after the final exposure, the A) number of respiratory events and B) airflow 
obstruction (Penh) induced by hypertonic saline (7% NaCl) were measured. Data are 
presented as A) individual data points and mean ± sem; B) mean ± sem. n = 8 in each 
group. 
 
 
4.3.6. The effect of cigarette smoke exposures on sensory nerve activation using 
the in vitro isolated vagus nerve preparation 
In addition to investigating the effect of CS on the cough response in vivo, studies 
were performed to examine whether similar effects were observed by utilising the 
isolated vagus nerve preparation taken from guinea-pigs exposed to CS once a day for 
8 days. The experiments utilising the vagus nerve were performed on vagi taken from 
two separate in vivo studies, in order to establish and confirm the findings on separate 
occasions. The modulation of sensory nerve activation by CS depicted the same 
results on both occasions. Therefore, Figure 4.14 shows the combined results of the 
two equal studies. The results illustrate that there is indeed an effect of smoke on 
sensory nerve activation, which closely parallel the effects seen in vivo. The 
application of a low pH solution onto the vagus nerve results in a statistically 
significant increase in depolarisation in vagi taken from CS exposed animals 
compared to controls (from 0.10 ± 0.01 to 0.14 ± 0.01 mV). Similarly, a statistically 
significant increase in depolarisation following stimulation with CAPS was recorded 
in vagi taken from CS exposed guinea-pigs (0.26 ± 0.03 mV) compared to controls 
(0.14 ± 0.01 mV). There was no significant difference in depolarisation between the 
two groups following stimulation with bradykinin or hypertonic saline. However, the 
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depolarisation induced by PGE2 is abolished in vagi taken from guinea-pigs exposed 
to CS for 8 consecutive days. 
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Figure 4.14: The effect of cigarette smoke exposures, once a day for 8 days, on 
sensory nerve activation using the in vitro isolated vagus nerve preparation  
Guinea-pigs were exposed to smoke generated from 4 cigarettes, once daily for 8 
days. Control guinea-pigs were exposed to air for the same length of time. 24 hours 
after the final exposure, the vagus nerves were dissected. Depolarisation of the 
isolated vagi were then monitored and recorded during separate 2 minute exposures to 
A) low pH solution (pH 5.0), B) capsaicin (1µM), C) bradykinin (3µM), D) PGE2 
(10µM) and E) hypertonic saline solution (2% NaCl). n = 12-14 in each group. Data 
are presented as mean ± sem. *p<0.05 compared with time-matched controls. 
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4.4. Discussion 
 
The results described in this chapter provide evidence that repeated exposure of 
guinea-pigs to CS results in an enhancement of the in vivo cough response induced by 
the tussive agents CA and CAPS. In 1991, Karlsson and colleagues published work 
describing an acute model of CS-enhanced cough. They found that acute exposures of 
CS for two weeks induced a tussive hyper-responsiveness to CA and CAPS in the 
conscious guinea-pig, which was attributed to the effects of CS on CAPS-sensitive 
CGRP containing sensory nerves (Karlsson et al., 1991).  Work by Joad et al found 
that guinea-pigs exposed to smoke from one to six weeks of age demonstrate an 
enhanced CA-induced cough response and augmented airways obstruction (Joad et 
al., 2004). Recently, Lewis and colleagues published work using an acute CS model 
in the guinea-pig and showed exacerbated conscious cough in response to the tussive 
agents CA and CAPS (Lewis et al., 2007). 
 
Interestingly, the results in Figures 4.2 and 4.3 shows that CA-induced cough is 
enhanced following CS exposure at every time-point investigated, whereas enhanced 
cough to CAPS only occurs after 8 CS challenges. Furthermore, challenge with CA 
evoked approximately three times the numbers of coughs compared to CAPS 
challenge; this was evident in both the control treated animals and following smoke 
exposure. Therefore, the differing sensitivities of the two tussive stimuli and their 
capacity to evoke cough following CS exposure warrants further investigation. 
Previously, Lalloo and colleagues found that the TRPV1 antagonist capsazepine  
inhibited both CA and CAPS evoked coughs in a guinea-pig cough model, indicating 
that both tussive agents stimulate the cough reflex via activation of TRPV1 (Lalloo et 
al., 1995). Similarly, Trevisani et al documented the inhibition of CA and CAPS-
induced cough using the TRPV1 antagonist IRTX (Trevisani et al., 2004).  However, 
the results described in this chapter indicate that perhaps CA and CAPS have differing 
mechanisms of cough-provocation. Therefore it is possible that exposure to CAPS is 
initiating cough specifically via stimulation of the TRPV1 receptors located on 
nociceptive sensory nerves, whereas CA may have multiple mechanisms of action 
including the activation of TRPV1. Extracellular recordings of single jugular and 
nodose vagal ganglion neurons demonstrated that CA not only activated C-fibres but 
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also elicited TRPV1-independent actions, which were hypothesised to be via 
activation of ASICs (Kollarik and Undem, 2002). Furthermore, acid is believed to 
activate the recently identified ‘cough receptors’, whereas this airway afferent sub-
type is insensitive to CAPS exposure (Canning et al., 2004; Mazzone, 2005). Further 
evidence is required to expand on these interesting findings and the role of TRPV1 in 
eliciting a cough response will be investigated and discussed in more detail in chapter 
6 of the thesis.  
 
In addition to an augmented cough response, the level of airflow obstruction, between 
the CS and time-matched control groups exposed to CA or CAPS was significantly 
increased after 8 CS challenges. This is consistent with evidence utilising a chronic 
CS model, which describes a significant increase in airway reactivity (measured as 
Penh) between the air and CS groups exposed to CAPS (Bergren, 2001b). However, 
work published by Karlsson found the tussive hyper-responsiveness to CA and CAPS 
in the conscious guinea-pig  to be accompanied by an unchanged sensitivity of the 
bronchoconstrictor response (Karlsson et al., 1991). Clinical research to investigate 
the prevalence of cough in airway diseases, describes an increase in cough 
responsiveness to CAPS challenge in patients with COPD and asthma, which was 
unrelated to airflow limitation measured as forced expiratory volume in 1 second 
(FEV1). Thus, the authors suggest the mechanisms producing enhanced cough were 
different to those causing airways obstruction (Doherty et al., 2000). Comparisons of 
the associated airflow obstruction between guinea-pig and man should nonetheless be 
treated with caution since comparative cough studies have shown that guinea-pig and 
man evoke comparable cough responses to CAPS and CA but the bronchoconstriction 
induced by these tussive agents is more prolonged in the guinea-pig compared to the 
transient effects seen in man  (Laude et al., 1993). The effects of smoking and also 
smoking cessation on cough response in the clinic have also been documented. A 
study published in 2003 by Dicpinigaitis found that young healthy smokers had a 
diminished cough reflex sensitivity following challenge with CAPS, compared to 
non-smokers. The mechanism of the diminished cough response is unknown but is 
proposed to involve long-term smoke-induced desensitisation of the receptors causing 
cough (Dicpinigaitis, 2003a). Interestingly, more recently two reports have been 
published detailing the effects of cessation and subsequent resumption of cigarette 
smoking in man, on the sensitivity to CAPS challenge. They found that cough 
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sensitivity to CAPS is enhanced as early as 2 weeks after smoking cessation and that 
resumption of smoking after 2-12 weeks of abstinence resulted in a diminished cough 
response once more (Dicpinigaitis et al., 2006; Sitkauskiene et al., 2007).  
 
As well as investigating the effect of acute CS exposures on the production of cough, 
studies were also carried out to characterise the acute inflammatory changes in the 
airways at the chosen time-points by assessing the BAL fluid and lung tissue. By 
profiling the inflammatory changes, this acute CS model provides additional evidence 
to add to existing information gained from previous work, which have focussed on 
chronic exposures to CS in order to develop an emphysema-type guinea-pig model 
(Wright and Churg, 1990; Churg et al., 2007). The results show that CS exposure 
induces a significant increase in mucus production in the guinea-pig, which is 
consistent with previous findings (Kuo et al., 1992; Komori et al., 2001; Stevenson et 
al., 2005; Lewis et al., 2007). Examination of the lung tissue sections, which have 
been stained specifically for detection of mucus, show both visually (by viewing the 
representative cross-sections) and quantitatively (using a histological image-analysis 
programme) an increase in the area of mucus staining in the airways of guinea-pigs 
exposed to CS compared to air-exposed controls. Assessment of the leukocyte 
infiltration into the airways indicates that an inflammatory response occurred 
following acute insult to the airways with smoke. It is accepted that an inflammatory 
insult such as CS exposure promotes the accumulation of neutrophils at the 
inflammatory site (Traves et al., 2002; Beeh et al., 2003; Barnes, 2007). Furthermore, 
mucus hypersecretion in the lung and neutrophilia are known characteristics of COPD 
in man and patients with COPD have elevated numbers of neutrophils in the BAL 
fluid (Keatings et al., 1996; Barnes, 2004). Activated neutrophils subsequently release 
mediators and proteases, which promotes further inflammation and tissue damage 
(Barnes, 2004). The results in this chapter demonstrate a statistically significant 
increase in neutrophil infiltration into the airway lumen at 5 and 8 days of CS 
exposure. Characterisation of the airway inflammatory changes associated with the 8 
CS exposures showed that there was no significant change in the numbers of 
eosinophils between groups but that LMN cell numbers were statistically significantly 
increased in CS exposed groups compared to time-matched controls. The 
characterisation of acute CS effects described in this chapter are consistent with that 
of Stevenson and colleagues, who characterised the inflammatory and mucus changes 
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in rat BAL fluid and lung following acute CS exposures. They found that as few as 2 
exposures to CS caused a robust neutrophilic and mucus hypersecretory response 
(Stevenson et al., 2005). These results are also in agreement with Lewis at al, who 
describe a small but significant increase in neutrophils in the guinea-pig BAL fluid 
and significant mucus staining in the lung following CS exposure, once a day for 10 
days (Lewis et al., 2007).  
 
It is known that inhalation of CS alone can cause cough in humans, therefore it was 
important to determine that the guinea-pigs were coughing in response to stimulation 
with tussive agents and not spontaneously due to previous exposure to CS. Therefore, 
studies were carried out to confirm that the CS-exposed animals do not cough in the 
plethysmograph chambers when exposed to aerosols of the vehicle solutions. The 
results confirm that the tussive activity seen was in response to challenge with stimuli 
as no coughs were evoked during the control experiments. In addition, another 
interesting route of investigation would be to examine the effects of CS exposure 
directly on the initiation of cough. Unfortunately, it was not possible to carry out these 
studies as the chambers for CS challenge were not designed for simultaneous 
assessment of cough. However by observing the animals during the CS exposure 
periods, I did note the production of cough, in particular during the initial encounters 
with smoke on days 1 and 2 of challenge. In addition, by monitoring the guinea-pigs 
immediately after exposure to CS, there were no spontaneous coughs identified.  
Previously, Bergren published data using a chronic smoke model of enhanced cough, 
which involved exposing guinea-pigs to smoke once a day for up to 120 days. The 
author describes that spontaneous coughing did occur during and immediately after 
the smoke exposures and with increased frequency as the chronic study progressed 
(Bergren, 2001b).  
 
By utilising the in vitro isolated vagus nerve taken from guinea-pigs, the results show 
that CS exposure, once a day for 8 days, impacts on the sensory nerve activity. 
Interestingly, the results show that depolarisation induced by the low pH solution or 
by CAPS was significantly higher in vagus taken from CS exposed animals compared 
to time-matched controls, which correlates with the exacerbated tussive responses 
using CA and CAPS in vivo. The agreement of outcomes using the in vivo and in vitro 
models confirms that the vagus nerve preparation is an accurate and useful model to 
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use alongside the in vivo work for confirmation of theories and mechanisms 
associated with cough. Potential antitussive treatments have previously been shown to 
inhibit the vagus nerve depolarisation and to also inhibit the number of coughs in the 
conscious guinea-pig, which has been further validated following studies using human 
vagus nerve (Patel et al., 2003; Usmani et al., 2005).  
 
At the chosen time-point, the effect of CS exposure, once a day for 8 days, on 
bradykinin-induced cough was particularly interesting. Rather than simply an increase 
in the number of coughs as seen previously with CA and CAPS, there was also a 
change in the type of cough induced by bradykinin. There was no significant 
difference in the number of typical Type 2 coughs in response to bradykinin, however 
the CS exposed group do display Type 1 coughs, which are not characteristically 
produced following bradykinin exposure in the absence of CS, but are characteristic 
of the Type 1 coughs evoked by CA or CAPS. Furthermore, stimulation of the 
isolated vagi with a sub-maximal concentration of bradykinin displays no significant 
difference in depolarisation between the air-exposed and CS-exposed groups. The in 
vitro results are seemingly not in agreement with the in vivo cough findings, however 
if the 2 types of bradykinin-induced coughs were counted collectively, this would 
have resulted in no significant difference in cough numbers between the CS and air 
exposed groups. The mechanisms underlying the alteration in exogenous bradykinin-
induced cough response following exposure to CS is unknown. Since the mechanism 
of bradykinin receptor activation and production of a cough is not clear, it is possible 
that CS exposure is acting to sensitise the sensory nerves to the subsequent cough-
provocation with bradykinin. Certainly, the concept of airway sensory nerve 
sensitisation is established, since inflammatory mediators such as bradykinin and 
PGE2 are not only able to activate airway sensory nerves, but can themselves also 
induce sensitisation to other tussive agents (Choudry et al., 1989; Stone et al., 1992; 
Fox et al., 1996).  
 
As described previously in chapter 3, there are very few references describing 
bradykinin-induced cough in the conscious guinea-pig and in man. Work by Canning 
et al in 2004 shows that bradykinin induces cough in their conscious guinea-pig 
model of cough which appear to have characteristic traces and cough responses 
similar to those of the Type 2 variety described in this thesis (Canning et al., 2004). 
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However, Bergren did publish findings detailing the effects of chronic smoke 
exposure on cough evoked by bradykinin. The work showed that the control guinea-
pigs, which had been exposed to air, did not cough following challenge with the 
chosen concentration of bradykinin, whereas those exposed to smoke, once a day for 
90 days, did cough in response to bradykinin challenge. Furthermore, there was a 
positive correlation between the bradykinin-induced coughs and the increase in Penh 
units in this chronic smoke study. By studying the representative trace in the 
publication by Bergren, the coughs that were counted appear to be of the Type 1 
category and there was no indication of Type 2 coughs. This could be explained by 
the concentration of bradykinin used in the study and also the short 30 second 
exposure time to bradykinin may not have been optimal to initiate a Type 2 cough 
response. Alternatively the methods of cough detection did not identify the alternative 
type of cough during the experiments. However, by focusing on the Type 1 coughs, 
the results described in the paper by Bergren are in agreement with the findings in this 
chapter, since there were no Type 1 coughs evoked in the air exposed groups but a  
significant production of Type 1 coughs in the chronic smoke-exposed group 
(Bergren, 2001b). There are few clinical references comparing the direct effect of 
bradykinin on the cough response between healthy subjects and those with respiratory 
disease. Fuller et al found that bradykinin inhalation caused cough and retrosternal 
discomfort in both healthy and asthmatic subjects, whereas bronchoconstriction 
occurred only in the asthmatics (Fuller et al., 1987). A clinical trial investigating 
bradykinin-induced bronchoconstriction in asthmatic patients documented that 3 out 
of 10 asthmatic subjects coughed in response to bradykinin inhalation (Ichinose et al., 
1992). More recently, Hope-Gill and colleagues describe a clinical trial to investigate 
the cough response to inhaled bradykinin in 10 healthy control subjects and 10 
patients with IPF. They found that bradykinin did not cause cough in the control 
subjects, whereas 2 out of 10 patients with IPF coughed in response to bradykinin 
inhalation (Hope-Gill et al., 2003).  Therefore, by concluding on the experimental and 
clinical data utilising bradykinin, some data suggest that differences are emerging 
between the cough response to bradykinin between healthy subjects and those with 
airway inflammatory diseases.   
 
Having established robust guinea-pig models of enhanced cough, the impact of CS on 
cough induced by PGE2 was determined, which produced an unanticipated result. 
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Interestingly, rather than an enhanced cough or change in type of cough as previously 
experienced with bradykinin, exposure to CS inhibited the Type 2 cough response 
induced by PGE2. The diminished PGE2-induced cough following 8 days of CS 
exposure in the in vivo conscious model of cough is also apparent in vitro. Here there 
is complete inhibition of the PGE2-induced sensory nerve activation in the vagi taken 
from the CS group compared to controls. Similarly to bradykinin, there is little 
reference in the literature comparing the effect of cough provocation in healthy 
subjects and those with airway inflammatory disease. In the early 1970’s, a clinical 
trial aiming to investigate the bronchodilator properties of inhaled PGE2 described the 
production of cough both in normal subjects as well as those with asthma and chronic 
bronchitis. This indicated that PGE2 initiated cough equally as well in healthy subjects 
as those with airway inflammatory disease. Furthermore, the authors deduced that the 
cough and increase in pulmonary resistance observed were not correlated and 
therefore it was unlikely that the coughing itself provoked the bronchoconstriction 
(Kawakami et al., 1973). The independent effects of PGE2 on cough and 
bronchoconstriction are in agreement with results in this chapter as the complete 
inhibition of the PGE2-induced cough response was accompanied by a small but 
significant increase in airflow obstruction, indicating independent mechanisms of 
action. It is known that PGE2 is an agonist that acts with different specificities on the 
nine prostanoid receptor sub-types (EP1-4, DP1-2, TP, FP or IP) although it is 
believed that the EP subtypes bind most selectively with PGE2. Therefore, perhaps the 
prostanoid receptor(s) mediating the initiation of cough are independent to the 
receptor(s) responsible for the associated airflow obstruction. Certainly, there is 
information in the literature regarding the roles of EP receptor subtypes in various 
aspects of airway inflammatory disease. Moreover, the ability of PGE2 to act on more 
than one receptor type has been shown by its ability to both relax and constrict airway 
smooth muscle as demonstrated in both animal and human ex vivo experiments 
(Gardiner and Collier, 1980; McKenniff et al., 1988; Norel et al., 1999). Using 
selective antagonists, the contractile effects of prostanoid agonists such as PGE2 are 
believed to act via the EP1 and TP receptors in guinea-pig trachea (McKenniff et al., 
1988). As the CS exposure regime used for these experiments was acute, it would be 
interesting to investigate the effects of chronic exposure to CS on cough induced by 
PGE2 to determine if the inhibition of cough remains. Since the specific prostanoid 
receptor responsible for the PGE2-induced cough has not yet been identified, the 
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mechanisms surrounding the inhibition of PGE2–induced cough following exposure to 
CS is also unknown. Perhaps the key prostanoid receptor(s) or signalling pathway(s) 
that are responsible for the PGE2-induced cough are down-regulated or inactivated 
following CS exposure. Additionally the inhibition of response to PGE2 could be 
caused by lack of accessibility to the target receptor, caused by excess mucus or 
oedema in the airways. Alternatively the threshold for activation of the cough reflex 
may be increased following CS exposure, requiring a greater concentration of PGE2 in 
order to evoke the reflex response. Based on this preliminary observation, this field of 
research requires further investigation. 
 
There is still debate in the literature regarding precisely which airway afferent 
receptors are responsible for the initiation of a cough in both the ‘hard-wired’ state 
and in the hyper-responsive disease state. Most research in the literature has focussed 
on stimuli that directly activate the cough reflex, whereas there is relatively little 
information on the mechanisms of sensitisation of the cough reflex. Perhaps CS 
exposure alters the cough threshold by inducing an increased sensitivity of just one 
type of sensory receptor or alternatively multiple types of sensory receptors in the 
airways are involved. However, the theory that a single type of airway afferent sub-
type is mediating all types of coughing is believed to be too simplistic, given the 
various causes and different nature of cough that exists. The initial work described in 
this chapter is in favour of an increased CAPS-sensitive fibre or chemosensitive fibre 
reactivity as there was an augmented number of coughs and level of airflow 
obstruction demonstrated following challenge with the chemical stimulants CAPS and 
CA and a change as well as an increase in coughs induced by bradykinin. CAPS, CA 
and bradykinin are accepted stimulants of nociceptors and in the conscious state are 
believed to mediate sensory nerve function and initiate cough via the activation of 
TRPV1 (Kollarik and Undem, 2004). Indeed, antagonism of the TRPV1 receptor 
attenuates the sensory nerve activity and/or tussive response to these stimulants 
(Lalloo et al., 1995; Fox et al., 1995b; Carr et al., 2003; Trevisani et al., 2004). The 
identification of different airway afferent nerve sub-types, each with unique 
characteristics, has allowed differentiation of properties including conduction 
velocity, location within the airways and expression of certain receptors (Canning et 
al., 2004; Mazzone, 2005). Based on the given evidence, it seems unlikely that the 
predominantly mechanosensitive RARs or SARs are primarily involved in the sensory 
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hyper-reactivity seen following smoke as these airway afferents, which do not express 
TRPV1, are unresponsive to direct chemical stimulation with CAPS or bradykinin. 
Furthermore, the involvement of the recently identified ‘cough receptors’ requires 
further investigation, as this airway afferent sub-type is thought to be activated by 
acid but not by CAPS exposure (Canning et al., 2004). It is possible that the sensory 
nerve sub-types that are modulated following exposure to CS are the CAPS-sensitive 
nociceptors; C-fibres and Aδ-nociceptors (Undem et al., 2004; Yu et al., 2005). 
 
Previous studies have also supported the theory that sensitisation of CAPS-sensitive 
fibres occurs following exposure to CS. Chronic smoke exposure enhanced airway 
reactivity and cough in guinea-pigs exposed to CAPS and bradykinin, which was 
accompanied by an increased release of tachykinins. (Bergren, 2001a; Bergren, 
2001b). Furthermore, electrophysiological recordings of C-fibre impulse reactivity 
were increased in guinea-pigs which had been chronically exposed to smoke (Mutoh 
et al., 1999). Evidence has also described direct activation of both RARs (Bergren and 
Sampson, 1982) and C-fibres (Lee et al., 1989) in animal models following direct 
stimulation with CS. Lee et al utilised a technique to stimulate the vagus nerve in 
anaesthetised dogs and found that a single breath of CS resulted in stimulation of 
pulmonary C-fibres (Lee et al., 1989). Further evidence in favour of a nociceptor-
fibre dependent enhanced cough pathway is derived from the results using hypertonic 
saline, as the number of hypertonic saline-induced respiratory events were unaltered 
following CS exposure and this was not accompanied by a significant change in Penh 
values between the two groups. Stimulation of the isolated vagus nerve with 
hypertonic saline also displayed no significant difference in depolarisation between 
the air and CS exposed groups. This is an interesting finding as hypertonic saline-
induced single fibre stimulation innervates Aδ-fibres and the excitatory response is 
unaffected following application of the TRPV1 antagonist capsazepine (Fox et al., 
1995b). Additionally, the use of the TRPV1 antagonists capsazepine and IRTX in vivo 
has further corroborated that hypertonic saline-induced cough is believed to act 
independently of chemosensitive TRPV1-positive airway afferents (Lalloo et al., 
1995; Trevisani et al., 2004; Gatti et al., 2006).  
 
As described previously, patients suffering from airway inflammatory diseases can 
often present with an exacerbated cough reflex and the cough can present as chronic 
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(Irwin and Madison, 2002; Morice et al., 2004). Furthermore, cough reflex sensitivity 
to inhaled CA and CAPS is augmented in patients with airway disease compared to 
healthy subjects (Wong and Morice, 1999; Doherty et al., 2000). These studies in man 
have substantiated the effects observed in animal models. However, the clinical 
studies are unable to indicate specifically which fibre type is involved in reflex 
coughing in the healthy and the disease state, although valuable information can be 
gathered from pharmacological modulation of the tussive response during clinical 
trials and from analysis of tissue biopsies. Groneberg and colleagues detected a 
significant increase in expression of TRPV1-positive nerves in the airway epithelium 
of chronic coughers, which correlated with the cough response induced by CAPS 
challenge (Groneberg et al., 2004a). Mitchell et al found the expression of TRPV1 to 
be more abundant in the airway smooth muscle of chronic coughers compared to 
healthy controls (Mitchell et al., 2005).  Therefore, these clinical studies add valuable 
evidence in favour of an enhanced modulation of airway chemosensor activity in 
chronic cough. However, the mechanisms of enhanced cough sensitivity following CS 
exposure are not defined. Perhaps increased accessibility of inhaled tussive agents 
potentiates the activation of CAPS-sensitive fibres. Furthermore, CS may alter the 
sensitivity of the peripheral nociceptive fibres by promoting the increased expression 
of TRPV1 receptors in the cell membranes, or decrease the threshold of activation of 
the TRPV1 receptor. The role of TRPV1 in cough will be discussed further in chapter 
6 of the thesis.  
 
Even though mechanosensors are insensitive to the direct actions of chemicals such as 
CAPS on nerve terminals, chemical stimuli may activate airway mechanosensors 
secondary to reflex changes such as airway smooth muscle contraction, mucus 
secretion and oedema formation, which result from the release of neuropeptides such 
as SP and NKA from sensory C-fibre endings (Widdicombe, 1998). In vivo studies in 
anaesthetised animals have demonstrated that RARs are activated by chemical stimuli 
including CS, ammonia, CAPS, PGE2 and histamine (Bergren and Sampson, 1982; 
Matsumoto, 1988; Mohammed et al., 1993). However, the theory that CS exposure 
may result in a heightened activation of RARs secondary to C-fibre sensitisation is 
not corroborated with evidence derived from conscious animal studies. In particular, 
RAR stimulants such as histamine, leukotriene C4 and D4, SP and NKA have been 
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ineffective at causing cough in the conscious state (Barnes et al., 1984; Joos et al., 
1987; Canning et al., 2004; El Hashim and Amine, 2005). 
 
In conclusion, the results in this chapter have shown that exposure of guinea-pigs to 
CS results in an enhancement of cough induced by CA and CAPS. The response to 
these two tussive agents differs, as CA-induced cough is significantly enhanced after 
2, 5 and 8 days of CS exposure, whereas CAPS-induced cough is only exacerbated 
after 8 CS exposures. By further characterising this model of CS-enhanced cough, 
there was an increase in mucus production after 5 and 8 CS exposures. Furthermore, 
there was a neutrophilic inflammatory response in the BAL fluid. Profiling the effects 
of CS exposure on the cough response induced by various tussive agents has produced 
intriguing results. It has revealed distinct patterns of response dependent on the 
tussive stimulus used, ranging from a change in type of cough for bradykinin, an 
inhibition of cough response for PGE2 and a lack of effect on hypertonic saline. 
Furthermore, parallel studies using the isolated vagus nerve have correlated with the 
in vivo results and shown an equivalent and corresponding profile of effects.  The 
differing effect of CS on tussive stimuli-induced cough indicates a distinct mechanism 
of cough-provocation between the various cough provoking agents. Understanding the 
mechanisms driving these in vivo guinea-pig cough models and determining the 
changes that occur in the ‘disease’ state will provide valuable knowledge. Research 
focussing on understanding the mechanisms of sensitisation of the cough reflex may 
prove particularly important in understanding chronic cough in man. 
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CHAPTER 5 
 
 
 
 
 
 
NEUROTROPHINS MODULATE COUGH AND 
SENSORY NERVE ACTIVITY IN THE GUINEA-PIG 
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5.1. Aims and rationale 
 
The aim of these studies was to investigate whether the neurotrophins, NGF and 
BDNF, play a role in enhanced sensory nerve function and sensitisation of the cough 
reflex.  
 
The role of neurotrophins such as NGF and BDNF in modulating sensory innervation 
has previously been described. However, little is known regarding the involvement of 
NGF and BDNF in the enhanced cough reflex, a symptom often associated with 
airway inflammatory disease. Valuable knowledge will be gained from research 
focussing on understanding the mechanisms driving sensitisation of the cough reflex 
and could be particularly important in understanding chronic cough in man.  
 
The work in chapter 4 showed that exposure of guinea-pigs to CS results in airway 
inflammation and an enhanced cough response to inhalation of CA and CAPS. 
Therefore, the hypothesis was that the production of NGF or BDNF played a role in 
the sensitisation of airway sensory nerves and the exacerbated cough response 
associated with exposure to CS. The in vivo studies were designed to mimic the 
enhanced cough reflex response seen following exposure to CS. In these studies this 
would be achieved by exposing guinea-pigs to aerosolised NGF or BDNF, once a day 
for 8 days, and then assessing the number of coughs and level of airflow obstruction 
induced by CA or CAPS. This would establish whether exposure to NGF or BDNF 
acts to sensitise airway sensory nerves resulting in an increase in cough reflex 
sensitivity to tussive stimuli. Furthermore, the vagus nerves were dissected free from 
guinea-pigs that had been exposed to NGF or BDNF and modulation of sensory nerve 
activity was investigated in vitro. The BAL fluid was assessed for inflammatory cell 
influx. In addition, samples taken during the CS studies in chapter 4 were analysed for 
protein expression of NGF and BDNF.  
 
As the neurotrophins are costly, particularly in the quantities required for in vivo 
administration, I was kindly provided with a large quantity of human recombinant 
NGF and BDNF, sufficient for in vivo studies. It was stated upon receipt of the gift of 
BDNF that a bioassay would be required in order to confirm the bioactivity. 
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Therefore, an in vitro primary cell culture assay was developed, in order to establish 
that the neurotrophins were eliciting effects to the same degree as commercially 
available NGF and BDNF and secondly that these human recombinant neurotrophins 
exhibited species cross-reactivity in the guinea-pig. The bioassay was developed 
based on an established method, described in the literature. The chosen technique 
utilised TGs taken from the rat to show that the addition of neurotrophins to the 
culture media influenced the survival of the neurons in culture. Therefore, this 
bioassay was developed using TGs taken from rats and then subsequently repeated 
with guinea-pig tissues, prior to examining the bioactivity and species cross-reactivity 
of NGF and BDNF. It was deemed important to determine this information prior to 
using the NGF or BDNF for the in vivo cough experiments, which would require the 
use of animals and also large quantities of the compound. For the purpose of 
comparison and to aid the interpretation in the results section, the commercially 
available NGF and BDNF will be referred to as NGF(1) and BDNF(1) and the gifts of 
NGF and BDNF will be referred to as NGF(2) and BDNF(2).     
 
5.2. Methods 
 
5.2.1. Animals (NHLI) 
Male Dunkin-Hartley guinea-pigs (300-500g), purchased from Charles River 
(France), were used for the in vivo cough experiments. For the in vitro primary cell 
culture experiments, male Dunkin-Hartley guinea-pigs (200-300g) and male Sprague-
Dawley rats (200-300g) were purchased from Harlan-Olac (Bicester, UK). Animals 
were housed for at least 7 days before being used for experimental procedures. Food 
and water were supplied ad libitum. United Kingdom Home Office guidelines for 
animal welfare based on the Animals (Scientific Procedures) Act 1986 were strictly 
followed. In vivo studies performed at the NHLI were carried out under a Home 
Office license, which received approval from the Imperial College Ethical Review 
Process.    
 
5.2.2. Trigeminal ganglion dissection and cell culture (NHLI) 
Animals were killed by cervical dislocation and the TGs were rapidly dissected. TGs 
were cultured to generate cell suspensions as described in the methods chapter 
(Chapter 2.4.3). Neuronal cultures of TGs were plated on culture slides. The culture 
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media was treated with vehicle, NGF(1), BDNF(1), NGF(2) or BDNF(2) (1, 10 or 
100ng/ml) prior to plating. The culture media containing the desired concentrations of 
vehicle or neurotrophin were changed after 48 hours. On day 5, ICC and image 
acquisition was performed as described below.  
 
5.2.3. Immunocytochemistry and image acquisition on trigeminal ganglion 
cultures (NHLI) 
Five days after plating, TG cultures were fixed using 3.7% formaldehyde in PBS and 
immunocytochemistry was performed as described in detail in the methods (Chapter 
2.4.3.1). Briefly, TG cultures were incubated with a primary antibody directed against 
200kD neurofilament (NF-H) and the detection was visualised using a secondary 
antibody fluorescently labelled with Alexa-Fluor 488. Images were acquired using an 
Olympus BX51 system microscope equipped with a Quicam Q-imaging Fast1394 
camera, linked to a computer with Media Cybernetics Image Pro-plus image analysis 
software. In order to capture the complete cellular area for neuron counts, twenty 
images (x20 magnification) were taken of each well. The photos were analysed and 
the number of surviving neurons counted using the image analysis software. A 
threshold setting was determined so that all neurons displaying fluorescence above 
background were counted as positive. 
 
5.2.4. NGF or BDNF exposure (NHLI) 
Guinea-pigs were exposed to aerosolised NGF(2) or BDNF(2) (0.1, 1 or 10 µg/ml) 
once daily for 8 days, as described in chapter 2.2.5. Control guinea-pigs were exposed 
to vehicle in an identical chamber, for the same length of time. The animal behaviour 
and welfare was monitored throughout the exposure periods and thereafter during the 
study. 
 
5.2.5. Tussive agent-induced cough (NHLI) 
Guinea-pigs were exposed to vehicle, NGF(2) or BDNF(2) as described above in 
section 5.2.4. 24 hours after the final exposure, the conscious and unrestrained 
animals were placed in individual plastic transparent whole body plethysmograph 
chambers (Buxco, USA). The tussive agents used to evoke cough were either a 
nebulised aqueous solution of CA (0.3M for 10 minutes) or CAPS (30µM for 5 
minutes). The number of coughs and level of airflow obstruction were recorded as 
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described in the methods chapter 2.2.3.  
 
5.2.6. Bronchoalveolar lavage fluid sampling and processing (NHLI) 
Guinea-pigs were exposed to vehicle, NGF(2) or BDNF(2) as described above in 
section 5.2.4. 24 hours after the final exposure, guinea-pigs were euthanised with an 
overdose of sodium pentobarbitone (200mg/kg i.p). The trachea was exposed by blunt 
dissection and then cannulated in order to obtain BAL fluid as described previously 
(Chapter 2.3.1). Total cell counts for BAL fluid recovered from the airway lumen 
were quantified using an automated Sysmex cell counter (Sysmex UK Ltd, Milton 
Keynes, UK). Differential cell counts of neutrophils, eosinophils and LMN cells 
recovered from the airway lumen were determined by light microscopy (x40 
magnification) from cytospin preparations, which were prepared as described 
previously (Chapter 2.3.2.1). The numbers of leukocytes were expressed as number of 
cells/ml. 
 
5.2.7. Sensory nerve activation in isolated guinea-pig vagus nerve preparations 
(NHLI) 
Guinea-pigs were exposed to vehicle, NGF(2) or BDNF(2) as described in section 
5.2.4. 24 hours after the final exposure, guinea-pigs were killed by cervical 
dislocation and the vagus nerve dissected as previously described in methods chapter 
2.4.1. Nerve depolarisations were induced by perfusion of the vagus with sub-
maximal concentrations of either low pH solution (pH 5.0), CAPS (1µM), BK (3µM), 
PGE2 (10µM) or hypertonic saline (2% NaCl). A solution containing one of the five 
stimulants was applied to a section of vagus nerve for a period of two minutes at 
which point the tissue was washed until the baseline returned to the resting state. This 
was then repeated in turn using one of the other five stimuli until the nerve had been 
exposed to each of the stimuli in turn. The five stimuli were applied in the same order 
for each experiment in order to keep the conditions identical for comparison of vagus 
nerve taken from the different groups. Depolarising responses were recorded in 
response to stimulation with the sensory nerve stimuli and the data are expressed as an 
increase in mV from baseline.  
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5.2.8. Protein expression measured by ELISA (NHLI) 
ELISAs were performed on guinea-pig BAL and lung tissue supernatant samples. The 
samples were taken from guinea-pigs which had been exposed to air or CS, once a 
day for 8 days, as described in chapter 4.2.2. Cells were obtained from the lung 
tissues as described in the methods chapter 2.3.3. Lung homogenates and BAL fluid 
samples were assayed for NGF and BDNF levels using human pre-designed ELISA 
kits from R & D systems as described in chapter 2.3.3. The sensitivity of the assays is 
such that protein expression can be detected between 31.25 and 2000pg/ml. 
 
5.2.9. Monitoring animal health (NHLI) 
Guinea-pigs were monitored throughout procedures and during recovery. Animals 
were checked for signs of adverse events such as withdrawal with lack of mobility 
and respiratory distress. If such events occurred, the individual experiment would be 
terminated and the animal euthanised.  
 
5.3. Results 
 
5.3.1. Development of a rat trigeminal ganglion bioassay in order to determine 
the bioactivity of human recombinant NGF and BDNF  
Evidence has shown that rat TG neuronal cultures, which are treated with BDNF, 
demonstrate an increase in neuronal number compared with no growth factor controls 
(Price et al., 2005).  The initial studies for this chapter aimed to reproduce this 
technique, in order to develop an in vitro primary cell culture bioassay in the rat. Once 
established, the TG bioassay could subsequently be reproduced to determine the 
bioactivity of the neurotrophins using guinea-pig tissues.  
 
The results in Figure 5.1 show that treatment of rat TGs with NGF(1) does not 
significantly increase the number of surviving neurons in culture, whereas rat TG 
cultures treated with BDNF(1) demonstrate a statistically significant increase in the 
number of surviving neurons compared to controls. These findings are consistent with 
previous results (Price et al., 2005). 
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Figure 5.1: The effect of NGF or BDNF treatment on rat trigeminal ganglion 
neuronal survival  
Rat TG cultures were treated with DMEM containing 0, 1, 10 or 100ng/ml of A) 
NGF(1) or B) BDNF(1). On day 5, ICC was performed for 200kD NF-H present in 
the sensory neurons to determine if treatment with NGF(1) or BDNF(1) affected the 
neuronal survival.  Twenty images (x20 magnification) were captured for each well 
and immunoreactive neurons were counted using image acquisition. n = 6 in each 
group. Data are presented as mean ± sem. *p<0.05 compared with control. 
 
5.3.2. Further development of the bioassay in order to determine the bioactivity 
of human recombinant NGF and BDNF using guinea-pig trigeminal ganglion 
The next experiments aimed to reproduce the established methodology using TGs 
taken from the guinea-pig. This would allow the determination that commercially 
available NGF(1) and BDNF(1) were bioactive in the guinea-pig, which is the species 
of choice for the subsequent cough experiments. Figure 5.2A shows that treatment of 
guinea-pig TG cultures with NGF(1) (100ng/ml) results in a statistically significant 
increase in neuronal survival compared to vehicle treatment. Furthermore, there was 
an increase in the number of neurons in guinea-pig TG cultures treated with 
BDNF(1), which reached statistical significance following treatment with 10ng/ml 
and 100ng/ml BDNF(1) (Figure 5.2B). 
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Figure 5.2: The effect of NGF or BDNF treatment on guinea-pig trigeminal 
ganglion neuronal survival  
Guinea-pig TG cultures were treated with DMEM containing 0, 1, 10 or 100ng/ml of 
A) NGF(1) or B) BDNF(1). On day 5, ICC was performed for 200kD NF-H present in 
the sensory neurons to determine if treatment with NGF(1) or BDNF(1) affected the 
neuronal survival.  Twenty images (x20 magnification) were captured for each well 
and immunoreactive neurons were counted using image acquisition. n = 6 in each 
group. Data are presented as mean ± sem. *p<0.05 compared with control. 
 
5.3.3. Utilising the guinea-pig trigeminal ganglion bioassay to compare the 
activity of NGF(1) with NGF(2) and BDNF(1) with BDNF(2)  
As I had been provided with a quantity of NGF(2) and BDNF(2) sufficient for in vivo 
administration, it was important to determine that the activity of these were 
comparable to the commercially available neurotrophins. Therefore, the next guinea-
pig TG bioassay studies were designed in order to determine that the activity of 
NGF(2) was comparable to that of NGF(1) and that the activity of BDNF(2) was 
comparable to that of BDNF(1). The concentration of 100ng/ml was chosen for 
comparative purposes as this dose significantly altered the number of neurons in 
culture as shown in Figure 5.2. The results in Figure 5.3 show that treatment of 
guinea-pig TG cultures with 100ng/ml of NGF(2) results in an increase in neuronal 
survival compared to control, which is consistent and of similar magnitude to that 
obtained following treatment with 100ng/ml NGF(1).  Similarly, treatment of guinea-
pig TG cultures with 100ng/ml of BDNF(2) resulted in a statistically significant 
increase in the number of neurons, which is comparable to the effects of 100ng/ml of 
BDNF(1). Figure 5.4 displays representative images of guinea-pig TG cultures, which 
had been treated with vehicle or 100ng/ml BDNF(2), followed by labelling for NF-H 
immunoreactivity to identify the neurons. 
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Figure 5.3: Comparison of the effects of NGF(1) with NGF(2) and BDNF(1) with 
BDNF(2) on guinea-pig trigeminal ganglion neuronal survival  
Guinea-pig TG cultures were treated with DMEM containing 0 or 100ng/ml of A) 
NGF(1) or NGF(2) or B) BDNF(1) or BDNF(2). On day 5, ICC was performed for 
200kD NF-H present in the sensory neurons to determine if treatment with NGF or 
BDNF affected the neuronal survival.  Twenty images (x20 magnification) were 
captured for each well and immunoreactive neurons were counted using image 
acquisition. White bars represent the vehicle and black bars represent the treated 
group. n = 6 in each group. Data are presented as mean ± sem. *p<0.05 compared 
with control. 
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Figure 5.4: Representative images of guinea-pig trigeminal ganglion neurons  
Guinea-pig TG neurons were cultured and treated with DMEM containing either A) 
vehicle (PBS and 0.1% BSA) or B) 100ng/ml BDNF(2). On day 5, guinea-pig TG 
cultures were fixed and labelled for NF-H immunoreactivity. Images were taken at 
x20 magnification.  
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5.3.4. The effect of NGF or BDNF exposures on citric acid or capsaicin-induced 
cough and airflow obstruction in the conscious guinea-pig 
The in vivo cough studies were designed in two halves. The aim of the first study was 
to determine a preliminary result, investigating the effect of exogenous NGF or 
BDNF exposure on the cough response. The results from the first study were analysed 
before pursuing a further second study. The first cough experiment (n=6) examined 
the effects of NGF(2) or BDNF(2) exposure on the number of coughs and level of 
airflow obstruction induced by the tussive agents CA and CAPS. The coughs counted 
in response to stimulation with the tussive stimuli were all recognised as ’Type 1’. 
Guinea-pigs exposed to NGF(2), once a day for 8 days, did not demonstrate a 
significantly modulated cough reflex or level of airflow obstruction, in response to 
either CA or CAPS challenge (Figure 5.5). Furthermore, exposure to BDNF(2) did 
not have a significant effect on the number of coughs or extent of airflow obstruction 
induced by CA, but did cause a dose-related increase in CAPS-induced coughs, which 
displays a bell-shaped phenomenon. CAPS-induced airflow obstruction subsequent to 
BDNF(2) exposure, displays a similar bell-shaped profile and a statistically 
significant increase in the number of Penh units from 2.11 ± 0.65 in the control group 
to 6.81 ± 1.53 in the 1µg/ml BDNF(2) group (Figure 5.6). 
 
 
 
 
 
 
 
 150
0 0.1 1 10
0
10
20
30
A) Citric Acid
Vehicle
NGF (μg/ml)
C
ou
gh
s (
Ty
pe
 1
) i
n 
10
 m
in
ut
es
0 0.1 1 10
0.0
0.5
1.0
1.5
B) Citric Acid
Vehicle
NGF (μg/ml)
Pe
nh
 A
ve
ra
ge
0 0.1 1 10
0
5
10
15
20
C) Capsaicin
Vehicle
NGF (μg/ml)
C
ou
gh
s (
Ty
pe
 1
) i
n 
10
 m
in
ut
es
0 0.1 1 10
0.0
2.5
5.0
7.5
D) Capsaicin
Vehicle
NGF (μg/ml)
Pe
nh
 A
ve
ra
ge
 
 
Figure 5.5: The effect of NGF exposures, once a day for 8 days, on citric acid or 
capsaicin-induced cough and airflow obstruction in the conscious guinea-pig  
Guinea-pigs were exposed to aerosolised vehicle or NGF(2) (0.1, 1 or 10 µg/ml) for 
30 minutes, once daily for 8 days. 24 hours after the final exposure, the A) number of 
coughs and B) airflow obstruction (Penh) induced by citric acid (0.3M), or C) number 
of coughs and D) airflow obstruction (Penh) induced by capsaicin (30µM) were 
measured. Data are presented as A & C) individual data points and mean ± sem; B & 
D) mean ± sem. n = 6 in each group. 
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Figure 5.6: The effect of BDNF exposures, once a day for 8 days, on citric acid or 
capsaicin-induced cough and airflow obstruction in the conscious guinea-pig  
Guinea-pigs were exposed to aerosolised vehicle or BDNF(2) (0.1, 1 or 10 µg/ml) for 
30 minutes, once daily for 8 days. 24 hours after the final exposure, the A) number of 
coughs and B) airflow obstruction (Penh) induced by citric acid (0.3M), or C) number 
of coughs and D) airflow obstruction (Penh) induced by capsaicin (30µM) were 
measured. Data are presented as A & C) individual data points and mean ± sem; B & 
D) mean ± sem. *p<0.05 compared with control. n = 6 in each group. 
 
 
Since exposure to NGF(2) or BDNF(2) did not significantly alter the number of 
coughs or Penh induced by CA, studies utilising this tussive agent were not repeated. 
Rather, the second study was designed to further investigate the effects of NGF(2) or 
BDNF(2) exposure on the response to CAPS-induced cough and sensory nerve 
function. The results of the second cough study using CAPS (n=8) have been 
combined with the first study to total 14 in each group.   
 
Exposure to aerosols of NGF(2) did not result in a statistically significantly altered 
number of coughs or level of airflow obstruction compared to control, although the 
mean number of coughs does increase from 4.43 ± 0.86 coughs in the control group to 
7.79 ± 1.52 coughs in the 1µg/ml NGF(2) group (Figure 5.7). Guinea-pigs exposed to 
aerosols of 1µg/ml BDNF(2) coughed statistically significantly more to CAPS (from 
4.77 ± 1.31 coughs to 10.64 ± 1.06 coughs) and experienced a statistically significant 
increase in airflow obstruction compared to guinea-pigs previously exposed to 
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aerosols of the vehicle. In addition, the effects of BDNF(2) on cough and airway 
reactivity display a bell-shaped curve (Figure 5.8).    
 
0 0.1 1 10
0
5
10
15
20
A) Capsaicin
Vehicle
NGF (μg/ml)
C
ou
gh
s (
Ty
pe
 1
) i
n 
10
 m
in
ut
es
0 0.1 1 10
0.0
2.5
5.0
7.5
B) Capsaicin
Vehicle
NGF (μg/ml)
Pe
nh
 A
ve
ra
ge
 
 
Figure 5.7: The effect of NGF exposures, once a day for 8 days, on capsaicin-
induced cough and airflow obstruction in the conscious guinea-pig  
Guinea-pigs were exposed to aerosolised vehicle or NGF(2) (0.1, 1 or 10 µg/ml) for 
30 minutes, once daily for 8 days. 24 hours after the final exposure, the A) number of 
coughs and B) airflow obstruction (Penh) induced by capsaicin (30µM) were 
measured. Data are presented as A) individual data points and mean ± sem; B) mean ± 
sem. n = 14 in each group. 
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Figure 5.8: The effect BDNF exposures, once a day for 8 days, on capsaicin-
induced cough and airflow obstruction in the conscious guinea-pig  
Guinea-pigs were exposed to aerosolised vehicle or BDNF(2) (0.1, 1 or 10 µg/ml) for 
30 minutes, once daily for 8 days. 24 hours after the final exposure, the A) number of 
coughs and B) airflow obstruction (Penh) induced by capsaicin (30µM) were 
measured. Data are presented as A) individual data points and mean ± sem; B) mean ± 
sem. *p<0.05 compared with control. n = 14 in each group. 
 
 
5.3.5. The effect of NGF or BDNF exposures on sensory nerve activation using 
the in vitro isolated vagus nerve preparation 
In addition to investigating the effect of NGF and BDNF on the cough response in 
vivo, studies were performed to examine the in vitro modulation of sensory nerve 
activity of the isolated vagus nerve. The vagus nerves were dissected from guinea-
pigs that had been exposed to aerosolised NGF(2) or BDNF(2) (1µg/ml for 30 
minutes, once a day for 8 days) as this exposure regime had elicited an exacerbated 
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cough response following challenge with CAPS. The impact of the two different 
neurotrophins, NGF and BDNF, on sensory nerve activation was comparable, as a 
parallel profile of modulation was observed in response to stimulation by a range of 
tussive stimuli. Exposure to NGF(2) or BDNF(2) did not significantly modify the 
level of depolarisation induced by application of a low pH solution to the isolated 
vagus nerves. This in vitro finding is in agreement with the earlier in vivo cough 
results, showing that the numbers of CA-induced coughs are not significantly altered 
following challenge with either NGF or BDNF. Furthermore, the application of CAPS 
solution to the vagus nerves was also in agreement with the in vivo findings, resulting 
in a statistically significant increase in sensory nerve activation in vagus taken from 
NGF(2) and BDNF(2) exposed guinea-pigs compared to controls. Similarly, a 
statistically significant increase in bradykinin and PGE2–induced depolarisation was 
apparent in vagi taken from NGF(2) and BDNF(2) exposed guinea-pigs. There was no 
significant difference in hypertonic saline-induced depolarisation between the two 
groups (Figures 5.9 & 5.10).   
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Figure 5.9: The effect of NGF exposures, once a day for 8 days, on sensory nerve 
activation using the in vitro isolated vagus nerve preparation  
Guinea-pigs were exposed to aerosolised vehicle or NGF(2) (1 µg/ml) for 30 minutes, 
once daily for 8 days. 24 hours after the final exposure, the vagus nerves were 
dissected. Depolarisation of the isolated vagi were then monitored and recorded 
during separate 2 minute exposures to A) low pH solution (pH 5.0), B) capsaicin 
(1µM), C) bradykinin (3µM), D) PGE2 (10µM) and E) hypertonic saline solution (2% 
NaCl). n = 10 in each group. Data are presented as mean ± sem. *p<0.05 compared 
with time-matched controls. 
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Figure 5.10: The effect of BDNF exposures, once a day for 8 days, on sensory 
nerve activation using the in vitro isolated vagus nerve preparation  
Guinea-pigs were exposed to aerosolised vehicle or BDNF(2) (1 µg/ml) for 30 
minutes, once daily for 8 days. 24 hours after the final exposure, the vagus nerves 
were dissected. Depolarisation of the isolated vagi were then monitored and recorded 
during separate 2 minute exposures to A) low pH solution (pH 5.0), B) capsaicin 
(1µM), C) bradykinin (3µM), D) PGE2 (10µM) and E) hypertonic saline solution (2% 
NaCl). n = 12 in each group. Data are presented as mean ± sem. *p<0.05 compared 
with time-matched controls. 
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5.3.6. The effect of NGF or BDNF exposures on bronchoalveolar lavage fluid 
leukocyte infiltration 
BAL fluid samples were obtained during the second NGF(2) and BDNF(2) cough 
studies and analysed for expression of neutrophils, eosinophils and LMN cells by 
differential cell counts. Figure 5.11 displays the cell count data analysed from the 
BDNF study, which displays no significant change in leukocyte infiltration between 
BAL fluid taken from control groups and BAL taken from guinea-pigs exposed to 
BDNF(2). Similarly, exposure to NGF(2) did not result in a significant change in 
inflammatory cell influx compared to control (data not shown).   
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Figure 5.11: The effect of BDNF exposures, once a day for 8 days, on 
bronchoalveolar lavage fluid leukocyte infiltration  
Guinea-pigs were exposed to aerosolised vehicle or BDNF(2) (0.1, 1 or 10 µg/ml) for 
30 minutes, once daily for 8 days. 24 hours after the final exposure, lungs were 
lavaged and cytospin slides prepared for A) neutrophil, B) eosinophil and C) 
lymphomononuclear cell numbers to be determined by differential counting. n = 12 in 
each group. Data are presented as mean ± sem.  
 
 
5.3.7. Investigating the expression of NGF and BDNF in bronchoalveolar lavage 
fluid and lung tissue taken from guinea-pigs exposed to cigarette smoke or air 
Analysis of NGF and BDNF protein expression using pre-designed human ELISA 
kits from R & D systems, were performed on BAL fluid and lung homogenate 
supernatants taken from guinea-pigs exposed to CS or air (as described in chapter 4). 
There is evidence in the literature that these particular ELISA kits have been utilised 
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successfully for detection of NGF in guinea-pig BAL, resulting in a detectable level 
of NGF expression and the quantification of significant differences between treatment 
groups (de Vries et al., 2006). The sensitivity of the assays are such that protein 
expression can be detected between 31.25 and 2000pg/ml. NGF and BDNF 
expression in the samples were either very low or not detected by ELISA, therefore 
quantification to compare the levels of NGF and BDNF between groups was not 
possible with this technique.  
 
5.4. Discussion 
 
There is an increasing body of evidence that neurotrophins mediate effects on sensory 
nerve function in inflammatory diseases. However, there is little data in the literature 
directly associating neurotrophins with the modulation of airway afferent nerves 
leading to chronic cough.  The work in chapter 4 showed that exposure of guinea-pigs 
to CS results in airway inflammation and an enhancement of the cough response 
induced by inhalation of CA and CAPS. Patients with airway inflammatory disease 
also demonstrate a greater cough sensitivity to inhalation of these tussive agents, 
when compared to healthy subjects (Wong and Morice, 1999; Doherty et al., 2000). 
The guinea-pig model of CS-enhanced cough can be used as a pre-clinical 
experimental model by which to profile the effects of potential antitussives and can 
also be utilised to further expand our knowledge of the mechanisms driving enhanced 
cough.  Therefore, investigating the mechanisms underlying the sensitisation of the 
cough reflex is an important field of research, which could lead to a greater 
understanding of the pathophysiology of chronic cough. 
 
The results in this chapter provide evidence that BDNF and possibly also NGF 
modulate sensory nerve function and the cough reflex in guinea-pigs. The 
neurotrophins are protein molecules that are essential for the differentiation and 
survival of neurons. The first studies in this chapter utilised the characteristic actions 
of the neurotrophins in the development of a functional bioassay. It should be noted 
that this bioassay utilised TGs and not nodose or jugular ganglion, as the aim was to 
replicate the methods in the literature to establish the required end-points. The 
published work has shown that the addition of neurotrophins to the culture media of 
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rat TG neuron cultures, acts to increase the neuronal survival compared to cell 
cultures which did not receive exogenous neurotrophins (Price et al., 2005). 
Therefore, this evidence provided a basis for the development of an in vitro functional 
bioassay.  
 
The primary sensory neurons of the TG innervate the face, oral cavity and nasal 
cavity and provide a suitable cell culture model to investigate the activity of the 
neurotrophins, as they are comprised of large diameter and small diameter sensory 
neurons from placodal and neural crest origin (D'Amico-Martel and Noden, 1980). 
The discovery of NGF more than 50 years ago provided the framework for 
understanding the functions of neurotrophins (Levi-Montalcini et al., 1996) and since 
then there have been extensive tissue culture studies described in the literature which 
have established that neurotrophins promote the survival and differentiation of 
sensory neurons (Lindsay, 1996; Lewin and Barde, 1996). The dependence of sensory 
neurons on NGF was also demonstrated in an in vivo study utilising transgenic mice, 
which showed that mice that have a deletion in the coding sequence of the NGF gene 
are born with a profound loss of DRG neurons (Crowley et al., 1994). The 
identification of other members of the neurotrophin family has led to the discovery 
that the neurotrophins have defined and overlapping specificities for sensory neuronal 
sub-types. In vitro studies to investigate the ability of neurotrophins to elicit neurite 
outgrowth or to promote neuronal survival throughout embryonic development, have 
documented that the neural crest derived sensory neurons are responsive to NGF and 
that the placode derived sensory ganglia show little response to NGF (Lindsay et al., 
1985). The identification and subsequent interest in BDNF confirmed the distinct 
biological specificity of this neurotrophin, as not only did it act on neural crest 
neurons, but unlike NGF was found to promote the survival of placode derived 
nodose ganglia (Lindsay et al., 1985; Barde et al., 1987).  
 
Prior to utilising NGF and BDNF for the in vivo cough experiments, the bioassay was 
utilised to determine the bioactivity of the human recombinant neurotrophins in the 
guinea-pig. Once the bioassay had been established using TGs taken from the guinea-
pig, analysis of the in vitro neuronal cell culture studies established that the 
neurotrophins were significantly influencing the number of surviving neurons, 
although this model does not indicate whether the surviving cells were functional. 
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Furthermore, the NGF and BDNF that had been provided as gifts were eliciting 
neuronal survival to the same extent as commercially available NGF and BDNF and 
therefore were suitable for future utilisation in the in vivo studies. Additionally, the 
NGF and BDNF exhibited species cross-reactivity in the guinea-pig. This anticipated 
cross-reactivity is in agreement with publications in the literature describing the 
effects of human recombinant neurotrophins in the guinea-pig, including exogenous 
administration of neurotrophins, functional blocking using anti-neurotrophin 
antibodies and detection of endogenous neurotrophins in guinea-pig samples (de Vries 
et al., 1999; Hunter et al., 2000; Friberg et al., 2001; de Vries et al., 2002; Gillespie et 
al., 2003; de Vries et al., 2006).  
 
The immunocytochemical detection of neurons in the TG cell culture model utilised 
an antibody targeting at 200kD neurofilament protein. Neurofilaments are found 
almost exclusively within nerve cells and these intermediate (10nm diameter) 
filaments are composed of three major proteins of molecular weights 68kD, 160kD 
and 200kD. The neurofilaments comprise a major type of protein of the cytoskeleton 
framework, which acts to support the cytoplasm in the axon and are found particularly 
abundantly in the axons of large-diameter neurons (Ricco et al., 1996; Chuaychoo et 
al., 2005a). As described in the introduction, there are functionally and anatomically 
distinct airway afferent phenotypes present in the vagal sensory ganglion, which are 
distinguished according to a number of characteristics including conduction velocity, 
anatomical location and response to chemical and mechanical stimulation. 
Interestingly, characterisation of the nodose and jugular ganglion in the guinea-pig 
has included information as to whether the neurons are positive for neurofilaments or 
neuropeptide expression (Ricco et al., 1996). Studies to detect SP have shown that 
they and the other related neuropeptides are exclusively found in the small diameter 
unmyelinated C-fibres and are not present in the other sensory nerve sub-types 
(Kummer et al., 1992; Ricco et al., 1996). Studies investigating the properties of 
guinea-pig airways taken from animals that were injected with the neuronal tracer 
Fast Blue, found that neurofilament-positive neurons accounted for approximately 
49% of the Fast Blue-labelled cells found within the neural crest derived jugular 
ganglion, whereas in the placode derived nodose ganglion neurofilament-positive 
neurons accounted for about 98%. Furthermore, SP-positive neurons were never 
observed in the same cell as neurofilament-positive immunostaining, suggesting that 
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distinct populations of airway afferents were present (Ricco et al., 1996).  However, 
more recent studies have determined that the distinct expression profile of the vagal 
sensory neurons can be modulated under experimental conditions. In particular, the 
application of exogenous NGF into the trachea of guinea-pigs changes the phenotype 
of large diameter, fast conducting, mechanically sensitive Aδ-fibres such that a 
proportion of these neurofilament-positive neurons also express the neuropeptide SP 
(Hunter et al., 2000). This phenomenon has also been observed in the mouse, 
documented by an induction of SP in large-diameter, CAPS-insensitive neurons 
following NGF treatment (Dinh et al., 2004b). Similarly, allergic inflammation in the 
guinea-pig airways also modulates the expression profile of the neuropeptides, such 
that they are produced by Aδ-mechanosensors in the nodose ganglion, which do not 
constitutively express neuropeptides under normal conditions (Fischer et al., 1996; 
Undem et al., 1999; Myers et al., 2002; Dinh et al., 2005).  Therefore, evidence in the 
literature suggests that the neurotrophins can alter the expression profiles in sensory 
nerve ganglia.    
 
As described in the introduction, the role of neurotrophins such as NGF and BDNF in 
modulating sensory innervation leading to allergic airway inflammation has been 
documented (Woolf et al., 1996; Braun et al., 1999a). It is believed that inflammatory 
mediators promote increased neurotrophin expression in both structural and 
inflammatory cells, which when released can stimulate sensory nerve endings via 
activation of Trk receptors. The airway epithelium, which lies in close proximity to 
airway sensory nerve endings, has been proposed as the source of neurotrophins (Fox 
et al., 2001). However, little is known regarding the role of neurotrophins in the 
enhanced cough response associated with respiratory disease. The results described in 
this chapter provide evidence that repeated exposure of guinea-pigs to aerosolised 
NGF or BDNF results in modulation of sensory nerve function and could provide 
information leading to a greater understanding of the mechanism of enhanced cough. 
The specificity of the modulation of sensory nerve function by NGF and BDNF could 
be investigated with specific Trk receptor decoys or inhibitors (de Vries et al, 2006; 
Nassenstein et al, 2006). The results in this chapter show that the number of coughs 
induced in the conscious animal by CA and the extent of depolarisation of the isolated 
vagus nerves induced by a low pH-solution, were unaffected by pre-exposure to NGF 
or BDNF. Furthermore, the numbers of CAPS-induced coughs were not significantly 
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enhanced following NGF exposure although there was an increase in the mean 
number of coughs in the 1µg/ml NGF group compared to controls.  However, 
exposure to BDNF resulted in a significant augmentation of CAPS-induced coughs 
and there was a significant increase in CAPS-induced sensory nerve activation in the 
vagus nerves taken from NGF and BDNF treated guinea-pigs. Therefore, analysis of 
the overall results suggests that exposure to exogenous NGF or BDNF can both act to 
sensitise the cough reflex to subsequent stimulation with CAPS. As described in the 
introduction, there is evidence in the literature describing the mechanisms of cough 
reflex initiation by CA and CAPS. CAPS has been found to stimulate sensory nerves 
via the activation of TRPV1 receptors, which are located on nociceptive airway 
afferent nerve terminals (Caterina and Julius, 2001). CA is also believed to mediate 
cough via TRPV1 but also acts through a TRPV1-independent pathway, hypothesised 
to be the activation of ASICs (Kollarik and Undem, 2004) or the activation the 
recently identified ‘cough receptors’ (Canning et al., 2004; Mazzone, 2005). The 
results in this chapter indicate that the mechanisms of tussive hyper-responsiveness 
following CA challenge, does not involve the overproduction of endogenous 
neurotrophins or that the parameters utilised in these studies were not optimal to 
initiate enhanced cough to this tussive agent. The augmentation of CAPS-induced 
cough in the guinea-pig, following exposure to neurotrophins, is an interesting 
finding. Clinically, an association has previously been documented between CAPS-
induced cough sensitivity and the relationship to endogenous neurotrophins. Patients 
with IPF had a heightened cough sensitivity to inhaled CAPS, which was associated 
with a significant increase in NGF and BDNF detected in the patients sputum (Hope-
Gill et al., 2003). Furthermore, investigation into patients who had a sensitivity to 
scents and chemicals showed that a significant increase in NGF in the nasal lavage 
fluid was associated with cough sensitivity to CAPS challenge (Millqvist et al., 2005). 
 
Interestingly, BDNF exposure not only augmented the cough response and sensory 
nerve activation induced by CAPS, but also caused a significant increase in CAPS-
induced airway reactivity, measured as Penh. This finding agrees with previous 
animal studies, which show that NGF over-expressing mice are more sensitive to the 
bronchoconstrictive effects of inhaled CAPS, compared to wild type mice (Hoyle et 
al., 1998; Path et al., 2002). The simultaneous modulation of sensory nerve activity 
and enhanced airway reactivity indicates that the neurotrophins are significantly 
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altering the multiple actions of CAPS on sensory nerve mediated function. As 
exposure to NGF or BDNF significantly modulated the tussive stimuli-induced 
sensory nerve activity, it was of interest to examine whether this effect was 
accompanied by an increase in inflammatory cells in the airways. The analysis of 
leukocytes in the BAL fluid shows that the guinea-pigs exposed to neurotrophins do 
not present with a significant increase in airway inflammation compared to controls, 
thereby suggesting that the modulation of the cough reflex by NGF and BDNF in this 
experimental setting occurs independently of airway inflammation. The over-
production of NGF has been postulated to occur secondary to airway inflammation, 
resulting in exacerbated sensory nerve activity (Ji et al., 2002). Therefore, one would 
not necessarily expect that exposure to NGF or BDNF would initiate inflammation. 
These results are in agreement with published reports by Braun et al, who found that 
treatment of mice with NGF induced airway hyper-responsiveness to a similar extent 
as that seen in mice sensitised with allergen. Furthermore, mice which overexpress 
NGF in the airways, demonstrated enhanced airway hyper-reactivity compared to 
wild type mice. The authors suggest that NGF by itself alters airway hyper-
responsiveness in the absence of airway inflammation (Braun et al., 2001).    
 
The augmentation of CAPS-induced cough and airflow obstruction following BDNF 
exposure displays a bell shaped profile. This is present as a significant increase in 
CAPS-induced cough numbers following challenge with 1µg/ml BDNF, which then 
decreased back to levels consistent with control values in the group exposed to 
10µg/ml BDNF. There is a precedent in the literature for this phenomenon; in 
particular in studies describing the in vitro effects of neurotrophins on cell cultures 
(Freund-Michel et al., 2006; Rende et al., 2000; Hu et al., 2006; Pyle et al., 2006). 
Freund-Michel et al documented the effect of NGF on proliferation of human airway 
smooth muscle cells in culture and found that the concentration-dependent effect 
displayed a bell-shaped curve (Freund-Michel et al., 2006). Additionally, the potent 
concentration-dependent effects of BDNF on human embryonic stem cell survival 
also displays a bell-shaped profile (Pyle et al., 2006). The mechanisms underlying the 
bell-shaped effect of neurotrophins are unknown. As the biological effects of 
neurotrophins are mediated by binding to two different receptor types, the Trk family 
of receptor tyrosine kinases and the p75 receptor, a member of the tumour necrosis 
factor receptor superfamily, perhaps the bell-shaped effect is a consequence of 
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activation of two different receptor types. This field of research would require further 
investigation in order to verify the mechanisms of action.  
 
The in vitro studies were designed to determine whether exposure to NGF or BDNF 
modulated the tussive stimuli-induced depolarisation of the isolated vagus nerve. 
Furthermore, it was of interest to compare whether the profile of response was 
comparable to the results obtained during the in vivo cough experiments. The low pH-
induced depolarisation did not significantly differ between groups, whereas CAPS-
induced depolarisation was significantly increased in vagus nerves taken from guinea-
pigs exposed to NGF or BDNF. Therefore, the in vivo and in vitro models show a 
comparable profile of effects, indicating that the in vitro model of sensory nerve 
activation is a valuable model for confirmation of theories and mechanisms associated 
with cough. Although it was not possible to perform in vivo cough studies to 
determine the effects of NGF or BDNF exposure on the cough response induced by 
other tussive agents (bradykinin, PGE2 and hypertonic saline), experiments were 
carried out to determine whether modulation of sensory nerve activation induced by 
these tussive stimuli were affected by NGF and BDNF. As the profile of effects 
between the in vivo and in vitro results have previously correlated, it is possible that 
the outcome of the vagus nerve preparation studies would be representative of the 
response had the in vivo studies using bradykinin, PGE2 and hypertonic saline been 
performed. Neither NGF nor BDNF significantly altered the hypertonic saline-
induced level of depolarisation. Conversely, both bradykinin and PGE2 induced 
sensory nerve activation were significantly augmented in vagus taken from NGF or 
BDNF exposed guinea-pigs compared to controls. This interesting profile of effects 
indicates that the neurotrophins are modulating specific sensory nerve sub-types, 
which is demonstrated by the distinct responses induced by the different tussive 
stimuli. CAPS, bradykinin and PGE2 are all chemical stimuli shown to stimulate 
airway sensory nerves via activation of nociceptors originating from the vagal sensory 
ganglia (Canning et al., 2004; Mazzone, 2005). Therefore, the results in this chapter 
suggest that exposure to NGF or BDNF sensitises the nociceptive fibres, either the C-
fibres and/or the nociceptive Aδ-fibres, rendering them more sensitive to chemical 
stimulation. However, CA is also a tussive agent known to act on the chemosensitive 
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airway afferents. Therefore, the reason for the apparent lack of effect of NGF or 
BDNF exposure on the actions of CA in this experimental setting is unknown.  
 
As described in chapter 4, guinea-pigs exposed to CS, once a day for 8 days, 
demonstrate an enhanced cough reflex sensitivity induced by CA and CAPS, a 
neutrophilic inflammatory response in the BAL fluid and mucus hypersecretion in the 
lung. The mechanisms underlying the sensitisation of the cough reflex following CS 
exposure are unknown, although as described previously, the evidence in chapter 4 is 
in favour of an increased CAPS-sensitive fibre or chemosensitive fibre reactivity. The 
work in this chapter was derived from the hypothesis that the production of 
neurotrophins under inflammatory conditions played a role in the sensitisation of 
airway sensory nerves and the exacerbated cough response seen in the CS model. Ji et 
al proposed a theory regarding how the production of NGF in inflammatory 
conditions may contribute to the development of hyperalgesia. They found that NGF 
administered to rats induced an increase in TRPV1 protein expression in the DRG. 
Inflammation also increases protein expression of TRPV1 in the soma of C-fibre 
nociceptors, which is then transported to peripheral C-fibre terminals. The authors 
suggest that p38 mitogen-activated protein kinase activation in the DRG is secondary 
to peripheral production of NGF in primary sensory neurons during inflammation. 
This results in an NGF-induced increase in TRPV1 and contributes to the 
maintenance of inflammatory heat hypersensitivity (Ji et al., 2002). Therefore, it is 
possible that NGF and BDNF may act similarly on the vagal sensory ganglia, 
inducing an increased expression of TRPV1 and contributing to the tussive hyper-
responsiveness seen in inflammatory airway disease. Further studies are required to 
explore these ideas, which will be described in the future works chapter of the thesis 
(chapter 7). 
 
The results in this chapter demonstrate that exposure to NGF or BDNF act to sensitise 
airway sensory nerves resulting in an increase in cough reflex sensitivity to tussive 
stimuli. This is an interesting finding and provides evidence that the production of 
neurotrophins may be involved in the mechanisms underlying enhanced cough.  In the 
clinic, analysis of BAL and serum taken from patients with airway inflammatory 
diseases show greater levels of NGF compared to healthy subjects (Bonini et al., 
1996; Sanico et al., 1999; Sanico et al., 2000). Therefore, it was of interest to 
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investigate whether the guinea-pig CS model of airway inflammation and exacerbated 
cough was associated with an increased protein expression of NGF and BDNF. 
Utilisation of ELISA did not result in adequate protein detection in the BAL fluid or 
lung supernatant samples. The reason behind the lack of detection of either 
neurotrophin using this technique is unknown. De Vries et al previously utilised this 
ELISA to measure NGF in guinea-pig BAL and found that protein expression of NGF 
was significantly higher in ovalbumin sensitised and challenged guinea-pigs 
compared to controls (de Vries et al., 2006). The samples from the CS studies were 
taken 24 hours after the final challenge as this was the established time-point for 
measurement of an enhanced conscious cough response. It is possible that the 24 hour 
time-point was not optimal for detection of neurotrophins in this experimental setting. 
Therefore, optimisation of the experimental parameters or the use of another 
technique to detect and quantify NGF and/or BDNF protein expression, such as 
immunohistochemistry, would be important for confirmation of these theories. The 
work in this chapter has not proved or disproved whether NGF and/or BDNF are 
driving the sensitisation of the cough reflex seen in the CS model. However, by 
comparing the effect on sensory nerve activation of exposure to CS with exposure to 
NGF or BDNF, a differing profile of effects is revealed. CS exposure elicited distinct 
effects on the cough in conscious guinea-pigs and on sensory nerve activity measured 
in vitro; enhanced cough induced by CA, CAPS and bradykinin, an inhibition of 
PGE2–induced cough and no effect on the response to hypertonic saline. However, 
NGF and BDNF appear to have a different profile of actions, enhancing the response 
to CAPS, BK and PGE2 but having no effect on the response induced by CA or 
hypertonic saline. Although every effort was made to keep the experimental 
conditions as close as possible, comparison of these studies should be interpreted with 
some caution as they were carried out at different establishments and using different 
equipment; the CS studies at Novartis and the neurotrophin studies at the NHLI. 
Therefore, further experiments are required to determine whether there is a direct link 
between the CS model of enhanced cough and the production of endogenous 
neurotrophins. Suggestions for potential future studies to continue these investigations 
will be described in chapter 7 of the thesis.   
  
In summary, the mechanisms linking neurotrophins and enhanced airway responses 
such as cough and airway hyper-responsiveness are not understood, although there is 
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evidence in the literature that may contribute to our understanding. Neurotrophins 
may contribute to the sensitisation of sensory nerve endings, thus reducing the 
threshold for activation of these nerves. This could result from neurotrophin-induced 
upregulation of TRPV1 expression, as described above (Ji et al., 2002). 
Neurotrophins have also been shown to alter the expression profiles in sensory 
ganglia by increasing the expression of neuropeptides such as substance P. This 
finding has been observed both in the guinea-pig and in the mouse, as administration 
of NGF into the airways induced an increase in the expression of SP and also the 
expression of TrkA receptors in large-diameter mechanosensitive fibres  (Hunter et 
al., 2000; Dinh et al., 2004b). In addition, treatment with Trk receptor inhibitors has 
been shown to inhibit allergen induced upregulation of SP expression in the nodose 
ganglia and lung tissue as well as attenuating airway hyper-responsiveness in a 
guinea-pig model of allergic asthma (de Vries et al., 2006). Furthermore, it has also 
been shown that there is an enhanced innervation of SP-positive sensory nerves, in the 
airways of mice overexpressing NGF and that these transgenic mice are more 
sensitive to the constrictive effects of inhaled CAPS compared to wild types (Hoyle et 
al., 1998; Path et al., 2002). This increase in sensory innervation and neuropeptide 
expression, along with the ability of neurotrophins to sensitise sensory nerves could 
ultimately lead to enhanced sensory nerve mediated effects seen in airways diseases 
such as asthma and COPD, so that a response to a given tussive stimulus would 
become deleterious (see Figure 5.12).  
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Figure 5.12: Schematic diagram showing the hypothesised mechanisms of 
neurotrophin-induced sensitisation of airway sensory nerves leading to enhanced 
cough 
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CHAPTER 6 
 
 
 
 
 
 
INVESTIGATING THE ROLE OF TRPV1 IN SENSORY 
NERVE ACTIVATION AND THE COUGH REFLEX 
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6.1. Aims and rationale 
 
The first aim of the studies described in this chapter was to establish whether the CS-
induced model of enhanced cough and airway inflammation was associated with an 
increased expression of TRPV1 in the sensory nerve ganglia. Secondly, the studies 
aimed to investigate the potential antitussive activity of TRPV1 antagonists on the 
cough reflex.  
 
There is a need to develop novel, safe and efficacious antitussive therapies as 
currently available cough suppressants have been shown to possess little clinical 
efficacy. There is an interest in the role of TRPV1 in the cough reflex since it was 
discovered that this receptor is activated by numerous exogenous and endogenous 
ligands, which can induce cough in experimental animal models and also in man. 
Furthermore, as described in the introduction chapter of this thesis, there is increasing 
evidence that TRPV1 could be implicated in the mechanisms underlying cough reflex 
sensitisation in experimental conditions aimed at mimicking enhanced sensory nerve 
function and chronic cough.  
 
In order to establish whether the CS-induced inflammatory model of enhanced cough 
was associated with an increased expression of TRPV1, an immunohistochemical 
technique to distinguish TRPV1 protein expression in the vagal sensory nerve 
ganglion was developed. As the work in this thesis has analysed the response to a 
variety of tussive stimuli, believed to activate the cough reflex via differing 
mechanisms including the activation of TRPV1, it was of interest to investigate the 
potential antitussive activity of TRPV1 antagonists on the cough reflex. 
Pharmacological modulation using two TRPV1 antagonists; capsazepine and 
SB366791, was profiled in the in vitro isolated guinea-pig vagus nerve preparation, in 
order to elucidate the contribution of TRPV1 in sensory nerve activation. The 
pharmacological modulation of human vagus nerve was also investigated. Further in 
vitro studies were performed to determine and compare the antagonist affinity of 
capsazepine and SB366791 on CAPS-induced contraction of isolated guinea-pig 
trachea. Subsequently, pharmacokinetic analyses were performed in guinea-pigs in 
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order to optimise the experimental conditions prior to the in vivo cough study to 
determine the effect of TRPV1 antagonism on the cough response.   
 
6.2. Methods 
 
6.2.1. Animals (Novartis & NHLI) 
Male Dunkin-Hartley guinea-pigs (300-500g), purchased from Charles River 
(France), were used for the in vivo cough experiments performed at Novartis and the 
NHLI. For the in vitro functional studies carried out at the NHLI and the 
pharmacokinetic studies performed at Novartis, male Dunkin-Hartley guinea-pigs 
(300-500g) were purchased from Harlan-Olac (Bicester, UK).  
 
Animals were housed for at least 7 days before undergoing experimental procedures. 
Food and water were supplied ad libitum. United Kingdom Home Office guidelines 
for animal welfare based on the Animals (Scientific Procedures) Act 1986 were 
strictly followed. In vivo studies performed at the NHLI were carried out under a 
Home Office license, which received approval from the Imperial College Ethical 
Review Process. In vivo studies performed at Novartis were carried out under a Home 
Office license and reviewed and approved by the Novartis Ethical Review Process. 
 
6.2.2. Immunohistochemical staining of Substance P in the guinea-pig vagal 
sensory nerve ganglion (NHLI) 
Naïve guinea-pigs were killed by cervical dislocation and the left and right nodose 
and jugular ganglia were removed and immersion fixed in NBF for histological 
assessment. 24 hours later, the nodose or jugular ganglia were processed as separate 
wax tissue blocks. Sections of ganglion (9µm) were cut, placed onto Polysine slides 
and were immuno-stained for detection of SP as described in the methods chapter 
2.3.5. As the technique of immunohistochemical staining in sensory ganglia had not 
been utilised previously by our group, these methods were developed and optimised. 
Utilisation of ganglia from naïve guinea-pigs allowed comparison of the expression of 
SP between the two ganglia phenotypes; nodose and jugular. This serves as a positive 
control to show that a) the ganglia have been identified correctly and b) the 
immunohistochemistry technique is working suitably. 
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6.2.3. Immunohistochemical staining of PGP9.5 and TRPV1 in the guinea-pig 
vagal sensory nerve ganglion (Novartis & NHLI) 
Immunohistochemistry was performed on samples taken from guinea-pigs used in 
studies described in chapter 4. As described previously; guinea-pigs were exposed to 
CS from 4 standard filtered cigarettes (2R4F, University of Kentucky, KY) once daily 
for 8 days. Control guinea-pigs were exposed to air only (500ml/min) in identical 
chambers, for the same length of time. The animal behaviour and welfare was 
monitored throughout the CS exposure periods and thereafter during the study. Full 
details of the CS exposure methodology are described in the methods chapter 2.2.4 
and in chapter 4.2.2. 
 
24 hours after the final CS or air exposure, the left and right nodose and jugular 
ganglia were excised from guinea-pigs and immersion fixed in NBF for histological 
assessment. 24 hours later, the nodose and jugular ganglia were processed as separate 
wax tissue blocks. Consecutive sections of ganglion (9µm) were cut, placed onto 
Polysine slides and alternate slides were immuno-stained for detection of PGP9.5 or 
TRPV1 as described in the methods (Chapter 2.3.5). The immunoreactivity of PGP9.5 
and TRPV1 was determined in consecutive ganglion sections using specific rabbit 
polyclonal antibodies. Control staining was performed for PGP9.5 and TRPV1 (and 
SP as described above) using two separate control measures. Firstly, the primary 
antibody was substituted by using a rabbit IgG control (as this must be from the same 
species as the primary antibodies were raised in); to show that there is no non-specific 
staining. Secondly, the primary antibody was omitted and blocking peptide was used 
alone, in order to confirm that this did not cause non-specific binding. 
 
Although measures were taken to try to obtain a similar section and therefore stain a 
similar field within the individual ganglion, visual comparisons of TRPV1 positive 
staining between groups were difficult as the sections taken from the two different 
groups may have been cut from different areas of the ganglion and therefore differed 
according to surface area and expression of positively identified fields. Therefore, 
consecutive sections were obtained from each ganglion within the air-exposed or CS-
exposed groups and PGP9.5 and TRPV1 detection were performed on the consecutive 
sections. This allowed numerical quantification as described below in section 6.2.4. 
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6.2.4. Quantification of TRPV1 staining in the guinea-pig vagal sensory nerve 
ganglion (NHLI) 
Images of the ganglion were acquired using an Olympus BX51 system microscope 
equipped with a Quicam Q-imaging Fast1394 camera, linked to a computer with 
Image Pro-plus Version 5.1 image analysis software (Media Cybernetics, UK). In 
order to compare and quantify the consecutive sections stained for detection of 
PGP9.5 and TRPV1, images were taken of each slide (x10 magnification), ensuring 
that images of the same field were obtained from consecutive sections. The images 
were analysed by counting 200 PGP9.5 immuno-positive cell bodies in total (100 
PGP9.5-positives were counted in two distinct fields) and specifying the areas 
containing the 200 PGP-positively identified cell bodies within the field. The numbers 
of TRPV1-positive cell bodies were expressed as a percentage of PGP-positive cell 
bodies, by counting the immuno-positive cell bodies for TRPV1 within the specified 
areas. 
 
6.2.5. Effect of capsazepine or SB366791 on sensory nerve activation in the in 
vitro isolated vagus nerve (NHLI) 
Guinea-pigs were killed by cervical dislocation and the vagus nerve dissected as 
previously described in chapter 2.4.1. Nerve depolarisations were induced by 
superfusion of the vagus with sub-maximal concentrations of either low pH solution 
(pH 5.0), CAPS (1µM), BK (3µM), PGE2 (10µM) or hypertonic saline (2% NaCl). A 
solution containing one of the five stimulants was applied to a section of vagus nerve 
for a period of two minutes at which point the tissue was washed until the baseline 
returned to the resting state. After two reproducible depolarisation responses to the 
sub-maximal concentration of the sensory nerve stimulant, a solution of the vehicle 
(0.1% methanol) or capsazepine (0.1 - 10µM) or SB366791 (0.01 - 1µM) superfused 
the nerves for 10 minutes. Immediately following the 10 minutes incubation, the 
tissue was exposed to the sensory nerve stimulant in the presence of vehicle, 
capsazepine or SB366791 for two minutes, followed by washing until the baseline 
response of the nerve was regained. The final depolarisation response to the stimulant 
alone was important to ensure that the tissue was still viable and responsive by the 
end of the experiment. Only one experiment was performed per vagus preparation.  
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When available, human trachea with branches of the vagus nerve attached, were 
obtained from patients undergoing heart-lung transplantation, which were surplus to 
requirement. Nerve depolarisations were induced by superfusion of the human vagus 
nerve sections with CAPS (100µM) and the effect of SB366791 (1µM) was 
determined, as described above by following the same protocol as had been used 
previously for the guinea-pig isolated vagus studies. 
 
6.2.6. Effect of capsazepine on sensory nerve activation of the isolated vagus 
nerves taken from guinea-pigs exposed to cigarette smoke or air (Novartis & 
NHLI) 
Guinea-pigs were exposed to CS or air, once a day for 8 days, as described in chapter 
2.2.4. 24 hours after the final exposure, guinea-pigs were killed by cervical 
dislocation and the vagus nerve dissected as previously described in the methods 
chapter 2.4.1. The effect of capsazepine (10µM) was investigated on nerve 
depolarisations in response to stimulation with sub-maximal concentrations of the 
sensory nerve stimulants, as described above in section 6.2.5. 
 
6.2.7. Effect of capsazepine on capsaicin or citric acid-induced cough and airflow 
obstruction in the conscious guinea-pig (NHLI) 
Guinea-pigs were intraperitoneally (i.p.) dosed with vehicle (20% ethanol plus 20% 
Cremaphor EL in saline) or capsazepine (30mg/kg), split across two injection sites 
(dosing volume was 1ml/kg). 
 
60 minutes after treatment, the conscious and unrestrained animals were placed in 
individual plastic transparent whole body plethysmograph chambers (Buxco, USA). 
The tussive agents used to evoke cough were either a nebulised aqueous solution of 
CA (0.3M for 10 minutes) or a nebulised aqueous solution of CAPS (60µM for 5 
minutes). The number of coughs and level of airflow obstruction were recorded as 
described in the methods (Chapter 2.2.3). 
 
6.2.8. Effect of capsazepine or SB366791 on capsaicin-induced contraction of the 
isolated guinea-pig trachea (NHLI) 
Guinea-pigs were killed by cervical dislocation and the trachea dissected as 
previously described in chapter 2.4.2. Tracheal segments were mounted in organ baths 
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and incubated for 1 hour with capsezepine (10µM), SB366791 (0.1µM, 1µM or 
10µM) or vehicle (0.1% DMSO). One concentration of antagonist was tested per 
tissue. Cumulative concentration response curves were subsequently generated 
following incubation with CAPS (10-9 – 10-4M).  Contractile responses were 
measured and expressed as absolute values in milligrams tension. Concentration-
response curves were analysed by least-squares, non-linear iterative regression 
(GraphPad Prism software, San Diego, USA) and pEC50 values were subsequently 
interpolated from curves of best-fit. Estimates of antagonist affinity were calculated 
using the equation pKB = log (CR-1) – log [B] (Schild, 1949), where CR is the 
concentration ratio calculated from the EC50 of agonist in the presence of the 
antagonist divided by the EC50 of the agonist alone, KB is the equilibrium dissociation 
constant and [B] is the concentration of antagonist. In the experiments described, the 
term pA2 is substituted for pKB as data were obtained using one concentration of the 
antagonist. 
 
6.2.9. Pharmacokinetic analysis of the concentration of SB366791 in guinea-pig 
blood plasma (Novartis)  
The jugular vein of each guinea-pig was cannulated 36 hours prior to SB366791 
administration to allow serial blood sampling. Guinea-pigs were i.p. dosed with 
SB366791 (1, 10 or 30mg/kg). The vehicle in the first PK study was 20% ethanol plus 
20% Cremaphor EL in saline. The dose volume in the first PK study was 1ml/kg and 
formulation concentrations were 1 and 10mg/ml for the 1 and 10mg/kg doses 
respectively. The 1mg/ml formulation was a clear solution and the 10mg/ml 
formulation was a suspension. The vehicle in the second PK study was DMSO plus 
Cremaphor EL in 20% aqueous ß-cyclodextrin (1:4:15 v/v). The dose volume in the 
second PK study was 10ml/kg and formulation concentrations were 1 and 3mg/ml for 
the 10 and 30mg/kg doses respectively. The 1mg/ml and 3mg/ml formulations were 
clear solutions; however the 3mg/ml solution precipitated at this concentration and so 
was dosed within 30 minutes of preparation.  
 
Serial blood samples (150µl) were removed at 5, 15, 45, 90, 150, 240, 360 and 1440 
minutes after i.p. administration of SB366791. An equal volume of heparinised saline 
was administered to the animal after removal of each blood sample. Plasma was 
separated from blood samples and analysed for SB366791 by LC-MS/MS analysis.  
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6.2.10. Effect of SB366791 on capsaicin-induced cough and airflow obstruction in 
the conscious guinea-pig (Novartis) 
Guinea-pigs were i.p. dosed with vehicle or SB366791 (1, 3, 10 or 30mg/kg), split 
across two injection sites. The vehicle was DMSO plus Cremaphor EL in 20% 
aqueous ß-cyclodextrin (1:4:15 v/v). The dosing volume was 10ml/kg and the 
formulation concentrations were 0.1, 0.3, 1 or 3mg/ml for the 1, 3, 10 or 30 mg/kg 
doses respectively. All formulations formed a solution. 
 
15 minutes post vehicle or SB366791 treatment, the conscious and unrestrained 
animals were placed in individual plastic transparent whole body plethysmograph 
chambers (Buxco, USA). Aerosolisation of CAPS (15µM for 7 minutes) was used to 
evoke cough. The number of coughs and level of airflow obstruction were recorded 
for a total of 15 minutes as described in the methods chapter 2.2.2.  
 
Immediately following the end of the cough experiment, animals were euthanised 
with an overdose of sodium pentobarbitone (200mg/kg i.p) and blood was taken via 
cardiac puncture. The blood was centrifuged and the plasma was removed and stored 
at -80ºC for PK analysis. The plasma was analysed to determine the concentration of 
SB366791 achieved during the cough studies using the same methodology as 
described above in section 6.2.9.  
 
6.2.11. Monitoring animal health (Novartis & NHLI) 
Guinea-pigs were monitored throughout procedures and during recovery. Animals 
were checked for signs of adverse events such as withdrawal with lack of mobility 
and respiratory distress. If such events occurred, the individual experiment would be 
terminated and the animal euthanised.  
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6.3. Results  
 
6.3.1. Development of an immunohistochemical technique to determine protein 
expression in guinea-pig sensory nerve ganglia  
The nodose and jugular ganglia comprise distinct phenotypes derived from a number 
of distinguishing features. One such characteristic difference is based on the 
neuropeptide content as jugular C-fibres are more likely to express neuropeptides 
such as SP, whereas nodose C-fibres have been found to be SP-negative or express 
significantly fewer SP-containing neurons (Kummer et al., 1992; Undem et al., 2004). 
Figure 6.1 clearly shows a difference in SP-immunoreactivity between the vagal 
ganglion phenotypes as there are few cell bodies positive for SP in the nodose 
ganglion and an abundance of cell bodies positive for SP in the jugular ganglion, 
which is in agreement with previous findings (Kummer et al., 1992; Undem et al., 
2004).  
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Figure 6.1: Expression of Substance P protein measured by 
immunohistochemistry in nodose and jugular ganglion taken from naïve guinea-
pigs  
Nodose and jugular ganglion were dissected from naïve guinea-pigs, stored in 
formalin and processed into sections. Localisation of Substance P expression was 
assessed in A) nodose ganglion and B) jugular ganglion using immunohistochemistry. 
(Scale bar = 200µm). Images were taken at x10 magnification. 
 
 
 
 
 
 
 
A 
B 
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6.3.2. The effect of cigarette smoke exposure on immunohistochemical detection 
of TRPV1 in the vagal sensory nerve ganglia  
The results in chapter 4 describe an increased sensitivity of the guinea-pig cough 
reflex following exposure to CS. The conscious cough response following CS 
exposure was exacerbated when cough was induced by the tussive agents CA, CAPS 
and bradykinin. Evidence in the literature suggests that the stimulation of sensory 
nerves by these three tussive agents is mediated via the activation of TRPV1 (Fox et 
al., 1995b; Lalloo et al., 1995; Carr et al., 2003; Trevisani et al., 2004; Kollarik and 
Undem, 2004). Therefore, by utilising the immunohistochemical technique, analysis 
of TRPV1 protein expression in the vagal sensory ganglia, taken from CS-exposed or 
air-exposed guinea-pigs, were performed. In order to quantify the results and ensure 
that the samples and sections were viable, consecutive sections from the ganglia were 
evaluated for expression of PGP9.5, which is a ubiquitin-protein hydrolase that stains 
all of the cell bodies and axons of neurons (Figure 6.2). 
 
The sections taken from the air-exposed and CS-exposed nodose and jugular ganglion 
depicts PGP9.5 immunoreactivity of the neuronal cell bodies. The intensity of the 
chromagenic staining for PGP9.5 is relatively uniform across the population and 
appears to stain all of the cell bodies within the sections. The sections taken from the 
air-exposed nodose and jugular ganglion showed positive staining for TRPV1 in a 
selection of neuronal cell bodies within the section. In the nodose and jugular 
ganglion taken from the CS-exposed group, there was also a clear detection of TRPV1 
within the cell bodies. There was no positive staining observed in any of the control 
sections. 
 
Quantification of the TRPV1-positive staining shows that the expression of TRPV1 in 
the nodose and jugular ganglion is similar and represents approximately 30% of the 
PGP9.5-positive cell bodies. Exposure of guinea-pigs to CS (once a day for 8 days), 
which is associated with a functional enhancement of the cough response to CAPS, 
resulted in a significant increase in TRPV1 protein expression in both the nodose and 
jugular ganglion. TRPV1 expression in the nodose ganglion increased from 28.6 ± 3.5 
% in the air group to 41.0 ± 3.6 % in the CS group, whereas there was a slightly more 
marked increase in the jugular ganglion from 30.3 ± 0.9% in the air-exposed group to 
47.3 ± 3.7% in the CS-exposed group (Figure 6.3).  
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Figure 6.2: Expression of PGP9.5 and TRPV1 protein measured by 
immunohistochemistry in jugular ganglion taken from guinea-pigs exposed to 
cigarette smoke or air  
Guinea-pigs were exposed to smoke generated from 4 cigarettes, once daily for 8 
days. Control guinea-pigs were exposed to air for the same length of time. 24 hours 
after the final exposure, the jugular ganglion were dissected, stored in formalin and 
processed into sections. Localisation of PGP9.5 (A & C) and TRPV1 (B & D) protein 
expression were assessed in consecutive sections of jugular ganglion taken from air-
exposed (A & B) or cigarette smoke-exposed (C & D) guinea-pigs, using 
immunohistochemistry. (Scale bar = 200µm). Images were taken at x10 
magnification. 
 
 
 
 
 
  
 
A) Air-exposed & PGP9.5  B) Air-exposed & TRPV1  
C) Cigarette smoke-
exposed & PGP9.5  
 
D) Cigarette smoke-
exposed & TRPV1  
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Figure 6.3: The effect of cigarette smoke exposure, once a day for 8 days, on 
TRPV1 protein expression in the cell bodies of nodose and jugular ganglia  
Guinea-pigs were exposed to smoke generated from 4 cigarettes, once daily for 8 
days. Control guinea-pigs were exposed to air for the same length of time. 24 hours 
after the final exposure, the nodose and jugular ganglion were dissected, stored in 
formalin and processed into sections. Localisation of PGP9.5 and TRPV1 protein 
expression were assessed in consecutive sections of A) nodose and B) jugular 
ganglion taken from air-exposed or cigarette smoke-exposed guinea-pigs, using 
immunohistochemistry. Images were captured and positive expression of TRPV1 was 
quantified as a percentage of PGP9.5-positive cell bodies in the consecutive section. n 
= 6 in each group. Data are presented as mean ± sem. *p<0.05 compared with 
controls. 
 
 
6.3.3. Investigating the effect of capsazepine on tussive stimuli-induced 
depolarisation of the in vitro isolated guinea-pig vagus nerve  
The isolated vagus nerve preparation has proved a useful in vitro model to investigate 
the activation of sensory nerves. Therefore, this in vitro model can be used as a 
screening system to profile pharmacological agents and potential cough suppressants 
of interest, prior to testing them in vivo. Furthermore, the results obtained with the 
isolated vagus nerve have complimented and correlated with clinical cough data 
(Usmani et al., 2005). A functional enhancement of the number of CAPS-induced 
coughs evoked in the conscious guinea-pig following CS exposure, coupled with the 
finding that TRPV1 protein expression is upregulated in sensory nerve ganglion, 
suggests that TRPV1 is a suitable target for further research. Therefore, it was of 
interest to investigate the effect of TRPV1 antagonism on the tussive stimuli-induced 
activation of sensory nerves in vagi taken from naïve guinea-pigs, prior to 
investigating if the response is sensitive to TRPV1 inhibition in the enhanced cough 
response. Incubation of the isolated vagus nerve with capsazepine concentration-
dependently and statistically significantly inhibits sensory nerve activation in 
response to stimulation with CAPS. Maximal inhibition of CAPS-induced 
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depolarisation was achieved following incubation with the 3µM and 10µM 
concentrations of capsazepine. Concentration-response studies were also carried out 
to determine the effects of capsazepine treatment on depolarisation induced by low 
pH, which resulted in approximately 50-60% inhibition at the highest doses. The 
maximal inhibition of CAPS-induced depolarisation was achieved following 
incubation with 10µM capsazepine; therefore this concentration was chosen to test 
against stimulation with PGE2 and bradykinin, which resulted in 46.4% and 50.5% 
inhibition respectively. Stimulation of the nerves with hypertonic saline was not 
significantly inhibited following incubation with capsazepine (Figure 6.4). 
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Figure 6.4: The effect of capsazepine on tussive stimuli-induced depolarisation of 
the guinea-pig isolated vagus nerve  
Vagus nerves were dissected from naïve guinea-pigs. The effect of vehicle or 
capsazepine (0.1 - 10µM), on depolarisation induced by A) capsaicin (1µM) or B) 
low pH solution (pH 5) were determined. In subsequent experiments, the effect of 
vehicle or capsazepine (10µM) on depolarisation induced by C) bradykinin (3µM), D) 
PGE2 (10µM) or E) hypertonic saline (2%) were determined. n = 4-6 in each group. 
Data are presented as mean ± sem. *p<0.05 compared with controls. 
 
 
 
 183
6.3.4. Comparing the effect of capsazepine on tussive stimuli-induced 
depolarisation of the isolated vagus nerve taken from naïve, air-exposed or 
cigarette smoke-exposed guinea-pigs 
Previous results utilising the isolated vagus nerve have demonstrated that exposure to 
CS once a day for 8 days resulted in enhanced sensory nerve activity in response to 
CAPS and low pH solution, a block of sensory nerve activation in response to 
stimulation with PGE2 and no change in response to hypertonic saline or bradykinin 
stimulation, compared to time-matched controls.  The aim of the next set of 
experiments was to investigate the inhibitory effect of capsazepine on the sensory 
nerve activation induced by tussive stimuli by comparing vagi taken from either 
naïve, air-exposed or CS-exposed guinea-pigs. Therefore, the following preliminary 
in vitro studies will determine whether capsazepine is as effective at abolishing the 
response in tissues that have demonstrated a functional modulation of the response.  
 
As there were a limited supply of vagal tissue and the studies were time-critical, the 
vagi from the CS and air groups were all incubated with capsazepine, in order to 
maximise the experimental output generated from these tissues. Therefore, the control 
group; incubating the tissue with vehicle rather than capsazepine, was not performed. 
As the concentration-response studies had previously been carried out to determine 
the effect of capsazepine on depolarisation in naïve tissues, the control group results 
were utilised as a comparison in this instance. Therefore, the graphs displaying these 
results are from two separate studies and are presented beside each other to form a 
comparison. 
 
The concentration of capsazepine (10µM) that maximally inhibits CAPS-induced 
depolarisation in naive guinea-pig vagus nerve also completely blocks the response in 
the CS and control vagi taken from guinea-pigs exposed once a day for 8 days. 
Furthermore, the extent of depolarisation following stimulation with bradykinin, 
PGE2 or a low pH solution are all inhibited to a similar level after treatment with 
capsazepine in both vagus taken from naïve guinea-pigs and from the two treatment 
groups. Stimulation of the nerves with hypertonic saline was not inhibited by 
capsazepine in any of the groups (Figure 6.5). 
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Figure 6.5: The effect of capsazepine on tussive stimuli-induced depolarisation of 
the isolated vagus nerve taken from naïve, air-exposed or cigarette smoke-
exposed guinea-pigs  
Vagus nerves were dissected from naïve guinea-pigs. In a separate group, guinea-pigs 
were exposed to smoke generated from 4 cigarettes, once daily for 8 days. Control 
guinea-pigs were exposed to air for the same length of time. 24 hours after the final 
exposure, the vagus nerves were dissected. The effect of capsazepine (10µM) on 
depolarisation of the isolated vagi induced by the following tussive stimuli was 
recorded; A) capsaicin (1µM), B) low pH solution (pH 5.0), C) bradykinin (3µM), D) 
PGE2 (10µM) and E) hypertonic saline solution (2%). n = 5-6 in each group. Data are 
presented as mean ± sem.  
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6.3.5. The effect of capsazepine treatment on capsaicin or citric acid-induced 
cough and airflow obstruction in the conscious guinea-pig  
Capsazepine dosed i.p. did not significantly inhibit cough or airflow obstruction 
induced by either CAPS or CA challenge. The number of coughs to CAPS was 
reduced from 6.67 ± 2.18 coughs to 3.17 ± 0.76 coughs, which was not a statistically 
significant inhibition (Figure 6.6).  
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Figure 6.6: The effect of capsazepine treatment on capsaicin or citric acid-
induced cough and airflow obstruction in the conscious guinea-pig  
Guinea-pigs were dosed intraperitoneally with vehicle (20% ethanol plus 20% 
Cremaphor EL in saline) or capsazepine (30 mg/kg). 60 minutes post-administration, 
guinea-pigs were either exposed to capsaicin (60µM for 5 minutes) or citric acid 
(0.3M for 10mins).The A & C) number of coughs and B & D) airflow obstruction 
(Penh) were determined. Data are presented as A & C) individual data points and 
mean ± sem; B & D) mean ± sem. n =12 in each group. 
 
The response to capsazepine on tussive-stimuli induced depolarisation has been 
profiled in the vagus, suggesting that TRPV1 may play a role in CAPS, CA, PGE2 and 
bradykinin-induced cough. Unfortunately the guinea-pig in vivo conscious cough 
study using capsazepine did not result in a significant inhibition of either the CA-
induced or CAPS-induced cough response. Furthermore, evidence suggests that at 
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higher doses, capsazepine may have non-specific effects (Docherty et al., 1997; Liu 
and Simon, 1997). Therefore, studies were performed to profile the effects of a novel 
TRPV1 antagonist, SB366791 in vitro. 
 
6.3.6. The effect of capsazepine and SB366791 on capsaicin-induced contraction 
of the isolated guinea-pig trachea 
The next experiments aimed to determine and compare the antagonist affinity of 
SB366791 and capsazepine on CAPS-induced contraction of the isolated guinea-pig 
trachea. CAPS produced a concentration-dependent contraction of isolated guinea-pig 
tracheal segments. SB366791 produced a concentration-dependent rightward shift of 
the CAPS concentration-response curve compared to vehicle control (pEC50 values of 
vehicle; 6.81 ± 0.13, 0.1µM; 6.18 ± 0.28, 1µM; 5.88 ± 0.21 and 10µM; 5.22 ± 0.13). 
SB366791 did not significantly suppress the maximal level of CAPS-induced 
contraction. Capsazepine also shifted the curve to the right and did not significantly 
reduce the maximal contraction to CAPS (Figure 6.7). Therefore, the results suggest 
that SB366791 and capsazepine are competitive antagonists at the TRPV1 receptor. 
The pA2 for SB366791 (0.1µM) derived from these studies is 7.51, which is slightly 
lower than previously published values (pA2 = 7.71; (Gunthorpe et al., 2004)).  The 
pA2 for capsazepine (10µM) derived from these studies is 6.77, which is higher than 
previously published in the literature (pA2 = 6.04; (Ellis and Undem, 1994)). 
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Figure 6.7: The effect of SB366791 or capsazepine on capsaicin-induced 
contraction of isolated guinea-pig trachea  
Trachea were dissected from naïve guinea-pigs.  The effect of vehicle (0.1% DMSO) 
or A) SB366791 (0.1, 1 or 10µM) or B) capsazepine (10µM) on capsaicin-induced 
contraction was determined. n = 8-16 in each group. Data are presented as mean ± 
sem. Study was performed by Dr Deborah Clarke at the NHLI.  
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6.3.7. The effect of SB366791 on tussive stimuli-induced depolarisation of the in 
vitro isolated guinea-pig vagus nerve  
The TRPV1 antagonist SB366791 concentration-dependently inhibited CAPS-
induced depolarisation of the isolated vagus nerve and is approximately 10 times 
more potent than capsazepine as complete inhibition was achieved following 
incubation with the 1µM dose. This maximal concentration was used to determine the 
contribution of TRPV1 to sensory nerve activation generated by hypertonic saline, 
low pH solution, bradykinin and PGE2. Similarly, the effect of SB366791 correlated 
with the results previously obtained using capsazepine as treatment with SB366791 
resulted in no inhibition of vagus nerve depolarisation to hypertonic saline, however 
did cause 45.9% inhibition of the response following stimulation with low pH 
solution and 41.1% and 40.1% inhibition following stimulation with bradykinin or 
PGE2 respectively (Figure 6.8).  
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Figure 6.8: The effect of SB366791 on tussive stimuli-induced depolarisation of 
the guinea-pig isolated vagus nerve  
Vagus nerves were dissected from naïve guinea-pigs. The effect of vehicle or 
SB366791 (0.01 - 3µM) on depolarisation induced by A) capsaicin (1µM) was 
determined. In subsequent experiments, the effect of vehicle or SB366791 (1µM) on 
depolarisation induced by B) low pH solution (pH 5), C) hypertonic saline (2%), D) 
PGE2 (10µM) or E) bradykinin were determined. n = 4-6 in each group. Data are 
presented as mean ± sem. *p<0.05 compared with controls. 
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6.3.8. The effect of SB366791 on capsaicin-induced depolarisation of the in vitro 
isolated human vagus nerve  
SB366791 (1µM) abolished CAPS-induced depolarisation of the human vagus nerve 
(Figure 6.9). The in vitro results using SB366791 suggest that this compound would 
be a good tool to use in vivo as it has exhibited greater potency than capsazepine, the 
ability to completely inhibit the effects of CAPS in vitro, and also shown efficacy in a 
human tissue preparation. 
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Figure 6.9: The effect of SB366791 on capsaicin-induced depolarisation of the 
isolated human vagus nerve  
Human trachea with branches of the vagus nerve attached, were obtained from 
patients undergoing heart-lung transplantation. Vagus nerves were dissected free and 
the effect of SB366791 (1µM) on depolarisation induced by capsaicin (100µM) was 
determined. n = 3. Data are presented as mean ± sem.  
 
6.3.9. Pharmacokinetic analysis of SB366791 
The in vitro evaluation suggests that SB366791 may be a suitable TRPV1 antagonist 
to profile in vivo. The plans for the in vivo cough studies were designed in a parallel 
manner to the vagus nerve experiments. Therefore, the aim was to establish a dose of 
SB366791 that completely blocks CAPS-induced activation of the ‘hard-wired’ cough 
reflex. This dose of SB366791 would then be utilised in subsequent cough studies to 
establish the effect of TRPV1 antagonism on cough induced by the other tussive 
agents CA, bradykinin, PGE2 and hypertonic saline. Finally, the plan was to examine 
the effect of SB366791 treatment in a model presenting with airway inflammation and 
enhanced cough (i.e. following CS exposures).  
 
Prior to the first CAPS-induced cough study, two sets of PK analysis were carried out 
in the guinea-pig, in order to determine and optimise peak plasma concentrations 
following treatment with SB366791. Figure 6.10 depicts the results from the first PK 
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study following 1mg/kg and 10mg/kg SB366791 dosed i.p. in the guinea-pig. The PK 
analysis shows that this compound is rapidly absorbed and is also quickly cleared and 
that the plasma concentration is at its highest at 15 minutes post-administration. The 
maximum plasma concentration following the 10mg/kg dose is only approximately 
two-fold higher than the 1mg/kg dose. The reason for this poor linearity in peak 
plasma concentration may be a consequence of the compound formulation, as 1mg/kg 
was dosed as a solution and 10mg/kg was dosed as a suspension (Figure 6.10).  
 
In order to design the first in vivo cough experiment with the intention of blocking 
CAPS-induced cough, it was important to ensure that sufficient compound exposure 
was achieved. By looking at the data generated using the isolated vagus nerve 
preparations, the concentration-response relationship showed that 1µM SB366791 is 
required to achieve 100% inhibition of CAPS-induced depolarisation (Figure 6.8). 
The first set of PK studies showed that the maximal plasma concentration achieved 
using the 10mg/kg dose was 0.287µM (Table 6.2 & Figure 6.10). It is difficult to 
predict the peak plasma concentrations necessary to inhibit cough. However, by 
extrapolating that the concentrations required in vivo will be related to the results 
obtained with the vagus nerve and isolated trachea preparation, it will be necessary to 
obtain approximately 3-fold more compound exposure in order to achieve 1µM 
plasma concentrations and the potential maximal inhibition of cough. Therefore, a 
second PK study was performed in order to determine the guinea-pig plasma 
concentrations following i.p. administration of 10mg/kg and 30 mg/kg SB366791. 
The compound was dosed at 10ml/kg and formulated with a different vehicle, which 
had been suggested by the pharmacokinetic experts to achieve maximum compound 
exposure.  
 
Analysis of the second PK study showed that 10 and 30 mg/kg SB366791 were 
rapidly absorbed in guinea-pigs following i.p. dosing and were also quickly cleared. 
The plasma concentration is maximal between 15 and 45 minutes post-administration. 
The peak plasma concentration achieved using the 30mg/kg dose was 1.068µM, 
which when compared to values obtained using the vagus preparation, indicates that 
sufficient compound exposure has been achieved at this dose (Figure 6.11A & Table 
6.4). Figure 6.11B depicts a comparison of the two sets of PK analysis utilising the 
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different vehicle formulations at 10mg/kg, showing no difference in the plasma 
concentrations between the two different experimental parameters.     
 
SB366791 concentration (µM) Time 
(Minutes)  Subject 1 Subject 2 Subject 3 
Mean SD 
5 0.054 0.146 0.052 0.084 0.054 
15 0.046 0.210 0.102 0.119 0.083 
45 0.020 0.042 0.021 0.028 0.013 
90 0.010 0.009 0.006 0.008 0.002 
150 0.005 - - - - 
240 0.004 - - - - 
360 - - - - - 
1440 - - - - - 
Table 6.1: Plasma concentrations of SB366791 after a 1mg/kg i.p. administration 
to guinea-pigs. The vehicle was 20% ethanol plus 20% Cremaphor EL in saline 
and the dosing volume was 1ml/kg.  
 
 
SB366791 concentration (µM) Time 
(Minutes) Subject 1 Subject 2 Subject 3 
Mean SD 
5 0.241 0.126 0.140 0.169 0.063 
15 0.244 0.308 0.309 0.287 0.037 
45 0.209 0.312 0.275 0.265 0.052 
90 0.273 0.261 0.267 0.267 0.006 
150 0.95 0.150 0.093 0.113 0.032 
240 0.033 0.035 0.051 0.039 0.010 
360 0.011 0.014 0.012 0.012 0.001 
1440 - - - - - 
Table 6.2: Plasma concentrations of SB366791 after a 10 mg/kg i.p. 
administration to guinea-pig. The vehicle was 20% ethanol plus 20% Cremaphor 
EL in saline and the dosing volume was 1ml/kg. 
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Figure 6.10: Concentration-time profile for SB366791 (1 or 10 mg/kg) in guinea-
pig plasma after i.p. administration  
Guinea-pigs were i.p. dosed with SB366791 (1mg/kg or 10mg/kg). The vehicle was 
20% ethanol plus 20% Cremaphor EL in saline. The dose volume was 1ml/kg. The 
1mg/ml formulation was a solution and the 10mg/ml formulation was a suspension. 
Serial blood samples (150µl) were removed at 5, 15, 45, 90, 150, 240, 360 and 1440 
minutes after i.p. administration of SB366791. Plasma was separated from blood 
samples and analysed for SB366791 by LC-MS/MS analysis. n = 3 in each group. 
Study was performed by the MAP group at Novartis. 
 
 
SB366791 concentration (µM) Time 
(Minutes) Subject 1 Subject 2 Subject 3 
mean SD 
5 0.097 0.143 0.127 0.122 0.024 
15 0.151 0.219 0.245 0.205 0.049 
45 0.101 0.266 0.260 0.209 0.094 
90 0.074 0.208 0.230 0.171 0.084 
150 0.039 0.169 0.205 0.138 0.087 
240 0.018 0.116 0.128 0.087 0.060 
360 0.009 0.070 0.046 0.042 0.031 
1440 - - - - - 
Table 6.3: Plasma concentrations of SB366791 after a 10 mg/kg i.p. 
administration to guinea-pigs. The vehicle was DMSO plus Cremaphor EL in 
20% aqueous ß-cyclodextrin (1:4:15 v/v) and the dosing volume was 10ml/kg. 
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Figure 6.11: Concentration-time profile for SB366791 (10 or 30 mg/kg) in 
guinea-pig plasma after i.p. administration  
A) Guinea-pigs were i.p. dosed with SB366791 (10mg/kg or 30mg/kg). The vehicle 
was DMSO plus Cremaphor EL in 20% aqueous ß-cyclodextrin (1:4:15 v/v). The 
dose volume was 10ml/kg. The 1mg/ml and 3mg/ml formulations were solutions. 
Serial blood samples (150µl) were removed at 5, 15, 45, 90, 150, 240, 360 and 1440 
minutes after i.p. administration of SB366791. Plasma was separated from blood 
samples and analysed for SB366791 by LC-MS/MS analysis. B) Concentrations of 
SB366791 in plasma following i.p. administration at 10 mg/kg; a comparison between 
suspension formulation and solution formulation (data taken from Tables 6.2 and 6.3). 
Studies were performed by the MAP group at Novartis.  
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SB366791 concentration (µM) Time 
(Minutes) Subject 1 Subject 2 Subject 3 
mean SD 
5 0.353 0.588 0.725 0.555 0.188 
15 0.598 1.358 1.250 1.068 0.411 
45 0.678 1.508 0.990 1.058 0.419 
90 0.435 1.790 0.530 0.918 0.756 
150 0.253 1.283 0.343 0.626 0.570 
240 0.129 0.870 0.248 0.416 0.398 
360 0.034 0.285 0.069 0.129 0.136 
1440 - - - - - 
Table 6.4: Plasma concentrations of SB366791 after a 30 mg/kg i.p. 
administration to guinea-pigs. The vehicle was DMSO plus Cremaphor EL in 
20% aqueous ß-cyclodextrin (1:4:15 v/v) and the dosing volume was 10ml/kg. 
 
 
6.3.10. The effect of SB366791 treatment on capsaicin-induced cough and airflow 
obstruction in the conscious guinea-pig  
A dose-response study was carried out to investigate the potential antitussive activity 
of SB366791 on CAPS-induced coughs in the conscious guinea-pig (the coughs were 
all classified as ‘Type 1’ coughs). Treatment with SB366791 did not significantly 
modulate the number of CAPS-induced coughs or the level of airflow obstruction 
compared to controls. There is a reduction in the average number of coughs from 12.3 
± 2.3 coughs in the control group to 6.1 ± 1.8 in the 1mg/kg group. However, this 
50.7% inhibition does not reach statistical significance and as the higher doses of 
compound had no effect, this is not likely to be a pharmacological effect of the 
compound (Figure 6.12). Furthermore, the cough response in this control group of 
animals was higher than the average numbers of coughs usually obtained following 
exposure to 15µM CAPS. An average of 12.3 ± 2.3 coughs in the vehicle group of 
this study is over 2-fold higher than the number of coughs (5.7 ± 1.2 coughs) achieved 
during the dose-response studies (Figure 3.1, chapter 3). 
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Figure 6.12: The effect of SB366791 on capsaicin-induced cough and airflow 
obstruction in the conscious guinea-pig  
Guinea-pigs were dosed intraperitoneally with vehicle (DMSO plus Cremaphor EL in 
20% aqueous ß-cyclodextrin (1:4:15 v/v)) or SB366791 (1, 3, 10 or 30 mg/kg). 15 
minutes post-administration, guinea-pigs were exposed to capsaicin (15µM) and the 
A) number of coughs and B) airflow obstruction (Penh) were measured. Data are 
presented as A) individual data points and mean ± sem; B) mean ± sem. n = 12 in 
each group. 
 
6.3.11. Pharmacokinetic analysis of SB366791 in plasma taken from guinea-pigs 
during the capsaicin-induced cough study 
A third PK analysis was performed in order to establish whether sufficient compound 
exposure was achieved during the cough study. Immediately following the cough 
experiment, blood was taken via cardiac puncture and plasma was obtained for 
analysis of SB366791 concentrations. Analysis of the plasma shows that there was a 
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dose-related increase in SB366791 detected, which corresponded to the increasing 
dose of compound administered. The mean plasma concentrations of SB366791 in the 
10 mg/kg and 30 mg/kg groups (n = 12 in each group) were 0.72 ± 0.11 µM and 1.90 
± 0.42 µM respectively (Figure 6.13). The concentrations of SB366791 previously 
shown to elicit approximately 75% and 100% inhibition of the CAPS-induced 
depolarisation of the in vitro isolated vagus nerve were 0.3µM and 1µM respectively. 
Therefore, by predicting that the concentrations required in vivo to inhibit the cough 
response, will be similar to the concentrations shown to be effective in the vagus 
preparation, the results from the PK analysis show that sufficient compound exposure 
was achieved.  
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Figure 6.13: Plasma concentrations of SB366791 during the capsaicin-induced 
cough study  
Guinea-pigs were dosed intraperitoneally with vehicle (DMSO plus Cremaphor EL in 
20% aqueous ß-cyclodextrin (1:4:15 v/v)) or SB366791 (1, 3, 10 or 30 mg/kg). 15 
minutes post-administration, guinea-pigs were exposed to capsaicin (15µM for 7 
minutes). Immediately after the cough experiment, guinea-pigs were euthanised with 
an overdose of sodium pentobarbitone (200mg/kg i.p) and blood samples were taken 
via cardiac puncture. Plasma was separated from blood samples and analysed for 
SB366791 by LC-MS/MS analysis. n = 12 in each group. Data are presented as mean 
± sem. *p<0.05 compared with controls. Analysis of the plasma samples was 
performed by the MAP group at Novartis.  
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6.4. Discussion 
 
The identification of a novel and efficacious antitussive therapy would fulfil an unmet 
clinical need in the treatment of cough. There are currently a number of antitussive 
targets, including TRPV1, aimed at specific ion channels, receptors or molecules that 
are expressed by airway sensory nerves or that modulate sensory nerve function. 
There is a wealth of evidence linking TRPV1 to the cough reflex rendering this 
receptor a good candidate for further research.  TRPV1 is a ligand gated ion channel 
that is expressed in a subpopulation of nociceptive primary sensory neurons, which 
are believed to be important in the activation of the cough reflex. Furthermore, 
TRPV1 can be activated and/or sensitised by a number of endogenous and exogenous 
ligands, including CAPS (Caterina and Julius, 2001), low pH solutions (Bevan and 
Geppetti, 1994; Jordt et al., 2000), bradykinin (Carr et al., 2003; Kollarik and Undem, 
2004) and prostaglandins (Moriyama et al., 2005). In vivo, TRPV1 agonists such as 
CAPS are potent tussive stimuli, which have been utilised extensively to investigate 
the cough reflex in animal models as well as in the clinical setting. The work 
described in this thesis aimed to investigate a role for TRPV1 in the cough reflex. The 
results in chapter 3 show that the conscious guinea-pig and the isolated vagus nerve 
preparation respond to stimulation with TRPV1 agonists. Interestingly, the studies in 
chapter 4 show that the inflammatory insult of the lungs, caused by exposure to CS, 
was accompanied by an increased sensitivity of the cough reflex in response to a 
number of tussive stimuli known to act via TRPV1. The hypersensitivity of airway 
afferent nerves in diseased and inflamed lungs has also been described in man, as 
patients with airway inflammatory diseases such as asthma and COPD demonstrate a 
heightened cough sensitivity following inhalation of CAPS (Fujimura et al., 1994; 
Wong and Morice, 1999; Doherty et al., 2000). 
 
During the cough experiments described in chapter 4, nodose and jugular vagal 
sensory ganglia were dissected from guinea-pigs that had been exposed to air or CS. 
The ganglia were processed and stored for potential future immunohistochemical 
detection of proteins of interest. This technique had not been utilised previously in-
house, therefore the methodology was developed and optimised by modifying 
elements of the protocol in order to obtain a suitable, reproducible and clear immuno-
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staining. The parameters that were optimised included determination of the thickness 
of the ganglion section to be placed on the glass slide, maximising the specificity of 
the stain with antigen retrieval and the addition of blocking steps, optimisation of the 
primary antibody dilution, the incubation times and selection of the chromagen and 
counter-stain. In guinea-pigs, the nodose and jugular ganglia lie in very close 
proximity but are distinguishable by the naked eye. Even though both ganglia project 
fibres to the lung, they comprise individual phenotypes derived from a number of 
distinguishing features. One such characteristic difference is based on the 
neuropeptide content as jugular C-fibres are more likely to express neuropeptides 
such as SP, whereas nodose C-fibres have been found to be SP-negative or express 
significantly fewer SP-containing neurons (Kummer et al., 1992; Undem et al., 2004). 
The immunohistochemistry results in this chapter show that ganglia taken from naïve 
guinea-pigs have few cell bodies positive for SP in the nodose ganglion and an 
abundance of cell bodies positive for SP in the jugular ganglion. This distinct 
phenotype of SP expression is in agreement with previous findings (Kummer et al., 
1992; Undem et al., 2004). The confirmation of the staining technique using vagal 
sensory ganglion taken from naive animals, was followed by immuno-staining to 
detect PGP9.5 and TRPV1 in the nodose and jugular ganglion taken from CS or air 
exposed guinea-pigs.  
 
Detection and quantification of PGP9.5 and TRPV1 protein expression reveals that 
the nodose and jugular ganglion dissected from CS-exposed guinea-pigs contain a 
higher expression of TRPV1 compared to the control group. This information adds 
strength to the current knowledge regarding the potential importance of TRPV1 in 
enhanced cough and also the possible use of TRPV1 antagonists as antitussive 
treatments. It is of importance to consider that the immuno-staining of the ganglion 
does not distinguish sensory nerves originating in the lungs. As airway sensory nerves 
make up only a proportion of the sensory nerves within the cell bodies of the nodose 
and jugular ganglion, it would be beneficial to utilise a technique whereby the guinea-
pig airways are initially injected with a neuronal tracer such as fast blue before 
extraction of the ganglion (Ricco et al., 1996; Dinh et al., 2005). Furthermore, 
additional evidence could be derived from detection of TRPV1 and PGP9.5 by 
immunohistochemistry within the lung tissue or the isolated vagus nerve. Staining of 
the lung or vagus nerve is less commonly utilised than the detection of protein in the 
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sensory nerve ganglion, possibly due to the lower expression profile and increased 
difficulty obtaining a quantifiable level of detection. However, Watanabe and 
colleagues carried out extensive immunohistochemical studies to map the anatomical 
location of TRPV1 and sensory neuropeptides within the guinea-pig airways and 
vagal sensory ganglion (Watanabe et al., 2005; Watanabe et al., 2006). Therefore, it 
would be worthwhile pursuing whether TRPV1 is upregulated in the lungs or vagus 
nerves of guinea-pigs presenting with exacerbated cough.  
 
Valuable clinical evidence has also described an association between enhanced cough 
in man and an increased expression of TRPV1 within the airways. Groneberg et al 
compared airway mucosal biopsies from healthy patients and from subjects with 
chronic cough and an associated enhanced CAPS responsiveness. The authors found 
that immuno-staining of airway biopsies detected no difference in the expression of 
PGP9.5 positive nerves in the airway epithelium between healthy volunteers and 
chronic coughers. Interestingly, there was a significant increase in TRPV1 expression 
in the lungs of chronic coughers, which correlated with the CAPS-induced cough 
response (Groneberg et al., 2004a). Furthermore, Mitchell et al found that the 
expression of TRPV1 is more abundant in the airway smooth muscle of chronic 
coughers compared to normal human airways (Mitchell et al., 2005). Thus, the 
guinea-pig model of CS-enhanced cough could be utilised as a relevant pre-clinical 
experimental screen in which to profile and compare the effects of potential 
antitussive therapies, such as TRPV1 antagonists.  
 
There is evidence in the literature that TRPV1 antagonists can functionally inhibit 
sensory nerve activation and the cough reflex in guinea-pigs. The antitussive activity 
of capsazepine and recently identified antagonists of TRPV1 has been demonstrated, 
thus supporting the potential for this therapy in the treatment of cough. Lalloo et al 
found that capsazepine administered via aerosol significantly inhibited cough induced 
by CAPS and CA in the conscious guinea-pig (Lalloo et al., 1995). More recently, 
Trevisani et al profiled and compared the effects of the potent TRPV1 antagonist, 
IRTX with capsazepine, on the CA and CAPS-induced cough response in the guinea-
pig. By also investigating the route of administration, they found that both of the 
TRPV1 antagonists, dosed either i.p. or via aerosol, dose-dependently inhibited 
cough, but that the activity of IRTX was 10-100 times more potent than capsazepine 
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in all the experimental conditions tested (Trevisani et al., 2004). Recent interest in the 
clinical potential of TRPV1 antagonists for various pain indications as well as 
potential antitussives, has led to the identification and development of novel TRPV1 
antagonists. The in vivo effects of a TRPV1 antagonist, 4-(3-trifluoromethyl-pyridin-
2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide 
(JNJ17203212), dosed i.p. in the guinea-pig, attenuated CAPS-induced coughs with a 
similar efficacy to codeine (Bhattacharya et al., 2007). There is limited data in the 
literature describing the utilisation of animal models of cough in which there are 
associated pathological changes in the lung representative of airway inflammatory 
disease. McLeod et al examined the antitussive effect of the TRPV1 antagonist, N-(4-
Tertiarybutylphenyl)-4(3-cholorphyridin-2-yl)-tetrahydro-pyrazine1(2H) - 
carboxamide (BCTC), on the ‘hard-wired’ cough reflex and in an ovalbumin 
sensitised guinea-pig model of enhanced cough. They found that BCTC dosed i.p. 
before CAPS inhalation, significantly inhibited cough and also attenuated antigen 
ovalbumin-induced cough in ovalbumin sensitized guinea pigs (McLeod et al., 2006). 
There is also little evidence surrounding the role of TRPV1 in bradykinin or PGE2-
induced cough.  Therefore, in order to build upon the current knowledge in the field, 
the work in this chapter aimed to study the effects of TRPV1 antagonism on sensory 
nerve activation and cough induced by the five tussive stimuli; CA, CAPS, 
bradykinin, PGE2 and hypertonic saline, thus allowing direct comparison of the 
potential antitussive effects. Furthermore, it would be valuable to utilise the model of 
CS-enhanced cough to examine whether the sensitised cough reflex is equally 
responsive to the potential antitussive activity of TRPV1 antagonists.  
 
There were only a limited number of commercially available TRPV1 antagonists 
which could be used for the studies in this thesis. Capsazepine, which is a synthetic 
analogue of CAPS, acts as a competitive antagonist of CAPS and is the original 
TRPV1 antagonist used historically to inhibit the actions of a TRPV1 ligand. Prior to 
investigating the effect of capsazepine on the conscious cough reflex, the effects of 
this antagonist were profiled on the tussive stimuli-induced depolarisation of the 
isolated vagus nerve. Previous work in this thesis has shown that the results obtained 
using the in vitro isolated vagus nerve preparation, correspond with the in vivo effects 
on conscious cough. Incubation of the isolated vagus nerve with capsazepine causes a 
concentration-related inhibition of CAPS-induced depolarisation, resulting in a 
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complete block of CAPS-induced sensory nerve activation at the highest 
concentration (10µM). The anticipated concentration-dependent effects of 
capsazepine on the sensory neurone excitant CAPS in the airways, are in agreement 
with evidence in the literature (Bevan et al., 1992). Belvisi et al found that 
capsazepine acts as a competitive antagonist to inhibit the contractile actions of CAPS 
in guinea-pig bronchi (Belvisi et al., 1992). Fox et al showed that capsazepine applied 
to sensory nerve single fibres produced a reversible inhibition of CAPS-induced 
excitation of C-fibres (Fox et al., 1995b). As described previously, capsazepine dosed 
either as an aerosol or i.p., has also been found to significantly inhibit the number of 
coughs in response to CAPS and CA challenge (Lalloo et al., 1995; Trevisani et al., 
2004; McLeod et al., 2006). Aerosolised capsazepine also significantly inhibited 
anandamide-induced cough in the conscious guinea-pig (Jia et al., 2002).  
 
The work in this chapter shows that capsazepine concentration-dependently inhibits 
low pH-induced sensory nerve activation of the isolated vagus nerve. Interestingly, 
the low pH-induced response was not completely abolished by capsazepine, resulting 
in approximately 60% maximal inhibition achieved. This finding suggests that an 
acidic solution such as CA may activate sensory nerves via TRPV1-dependent and 
also TRPV1-independent mechanisms. This hypothesis is in agreement with Kollarik 
et al, who published findings using an isolated guinea-pig airway nerve preparation to 
measure action potential discharge from single nodose or jugular vagal ganglion 
sensory neurons that projected sensory fibres into the airways. The authors utilise the 
TRPV1 antagonists capsazepine and IRTX and deduce that activation of guinea-pig 
sensory nerves by low pH is via TRPV1-dependent activation of C-fibres and also 
TRPV1-independent mechanisms, hypothesised to be the activation of ASICs on 
RARs (Kollarik and Undem, 2002). Expanding on these findings, Kollarik and 
colleagues found that acid activated C-fibres in wild type mice as well as TRPV1 
knock-out mice, further representing a TRPV1-independent mechanism of acid-
induced activation of airway sensory nerves (Kollarik and Undem, 2004). 
 
In order to elucidate the effect of TRPV1 antagonism on bradykinin, PGE2 and 
hypertonic saline-induced depolarisation, a maximal concentration of capsazepine 
(10µM) that completely blocked sensory nerve activation by CAPS was chosen. 
Interestingly, 10µM capsazepine had no effect on hypertonic saline-induced 
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depolarisation but did inhibit bradykinin and PGE2–induced depolarisation by 
approximately 40-50%. The TRPV1-independent actions of hypertonic saline on 
airway sensory nerves has been documented previously as hypertonic saline-induced 
activation of single Aδ-fibres was unaffected by pre-treatment with capsazepine (Fox 
et al., 1995b) and capsazepine and IRTX failed to inhibit the number of hypertonic 
saline-induced coughs in the conscious guinea-pig (Lalloo et al., 1995; Trevisani et 
al., 2004).  A role for TRPV1 in bradykinin-induced activation of airway sensory 
nerves has been documented, although exact mechanisms linking bradykinin and 
TRPV1 require further research. Capsazepine significantly inhibited bradykinin-
induced action potentials of C-fibre receptive fields in guinea-pig isolated airways 
(Carr et al., 2003). Furthermore, a proportion of bradykinin-induced action potentials 
were inhibited in TRPV1 knock-out mice (Kollarik and Undem, 2004). The effect of 
capsazepine on PGE2-induced depolarisation is a novel finding. There is limited 
evidence in the literature describing the mechanisms sub-serving the direct initiation 
of cough by PGE2, or the link with TRPV1 receptor activation. Rather, there is 
evidence that PGE2 sensitises the cough reflex such that subsequent exposure to 
CAPS results in a heightened response (Choudry et al., 1989). Therefore, these 
observations represent an interesting avenue for further investigation. 
 
The studies documented in chapter 4 describe the functional effect of CS exposure on 
the in vitro stimulation of the isolated vagus nerve and the in vivo cough reflex 
response. During the CS studies, vagus nerves were dissected free from guinea-pigs, 
which had been exposed once a day for 8 days to CS or air. The nerves were 
transported immediately from Novartis to the NHLI and experiments were performed 
to determine whether there was a modulation of sensory nerve activation induced by 
the five different tussive stimuli (results in chapter 4; figure 4.14). Additionally, 
experiments were performed to assess the effect of 10µM capsazepine on the response 
to tussive stimuli-induced depolarisation of vagus nerves.  By comparing the level of 
inhibition, it appears that capsazepine attenuates sensory nerve activation to the same 
extent in vagus taken from naïve animals, air-exposed guinea-pigs and CS-exposed 
guinea-pigs. Therefore, even though CAPS-induced depolarisation was significantly 
increased following CS exposure, the response is potentially still sensitive to TRPV1 
inhibition and can be blocked using a TRPV1 antagonist. 
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The results profiling the effects of capsazepine in the isolated vagus nerve suggests 
that this antagonist would be a useful tool to examine the role of TRPV1 in the in vivo 
cough model. Incubation of the whole vagus nerve with capsazepine significantly 
modulated the sensory nerve activation in response to CAPS and interestingly also 
inhibited the depolarisation following stimulation with CA, bradykinin and PGE2. 
Therefore, subsequent to the in vitro functional studies, the aim of the in vivo cough 
experiments was to parallel the work by investigating the role of TRPV1 in the ‘hard-
wired’ cough model and also in the CS-enhanced cough model. Similarly to the vagus 
nerve experiments, the aim was to completely inhibit CAPS-induced cough and then 
to choose this effective concentration of capsazepine to assess against the response to 
other tussive agents. A high dose of capsazepine was selected for the in vivo cough 
study in order to ensure maximal compound exposure. However, treatment of guinea-
pigs with 30mg/kg capsazepine i.p. did not significantly inhibit the cough response to 
CAPS or CA, even though capsazepine has been shown to attenuate cough at similar 
doses and route of administration (Trevisani et al., 2004). Unfortunately, capsazepine 
is not the ideal in vivo pharmacological tool as at higher concentrations capsazepine 
exhibits non-specific effects such as inhibition of voltage-gated calcium channels 
(Docherty et al., 1997) and nicotinic receptors (Liu and Simon, 1997). Therefore, a 
more potent, specific and efficacious TRPV1 antagonist was required to examine the 
role of TRPV1 in the cough reflex. IRTX, which is the structurally related analogue of 
resiniferatoxin, is a recently identified, potent and commercially available TRPV1 
antagonist (Wahl et al., 2001). IRTX has been effectively utilised in a number of in 
vivo and in vitro preparations to inhibit TRPV1-mediated responses (Undem and 
Kollarik, 2002; Rigoni et al., 2003; Trevisani et al., 2004). IRTX exhibited 10-30 
times higher potency than capsazepine in inhibiting contraction induced by CAPS and 
resiniferatoxin in guinea-pig trachea (Undem and Kollarik, 2002) and is effective at 
inhibiting CA and CAPS-induced cough (Trevisani et al., 2004). However, although 
several studies have validated a therapeutic rationale for TRPV1 antagonists such as 
capsazepine and IRTX, these agents are not fully efficacious as they have not been 
found to completely abolish the cough response, rather inhibit the effect to some 
degree (Lalloo et al., 1995; Trevisani et al., 2004). Furthermore, difficulties sourcing 
IRTX coupled with the extremely high cost for the quantities needed for in vivo 
administration in the guinea-pig meant that IRTX was no longer a viable option. 
Furthermore, there is evidence that IRTX may act as a partial agonist at the TRPV1 
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receptor (Shimizu et al., 2005). Therefore, a different TRPV1 antagonist was 
required, which could provide a useful tool to further study the biology of TRPV1. 
 
SB366791 is a commercially available, novel, potent and selective TRPV1 antagonist, 
which has recently been identified via high throughput screening (Gunthorpe et al., 
2004).  At the time of performing the studies for this thesis, there were few references 
in the literature describing the use of SB366791 in vivo and only a small number of 
publications describing the effects of this compound on CAPS-induced responses. 
Varga et al found that SB366791 (500µg/kg, dosed i.p.) significantly inhibited CAPS-
induced hypothermia, eye wiping movement and vasodilatation in the knee joint of 
the rat and was more potent and selective than capsazepine (Varga et al., 2005). 
Trevisani et al documented that SB366791 inhibited hydrogen sulphide induced 
contraction of guinea-pig isolated bronchi, providing evidence that this TRPV1 
antagonist may show efficacy in guinea-pig models (Trevisani et al., 2005). There 
was limited literature describing the use of SB366791 in the guinea-pig and no 
evidence to indicate that the effects of this compound had been determined on cough.  
Therefore, SB366791 posed a suitable and novel candidate to examine the role of 
TRPV1 in the cough reflex. As there was limited characterisation data available for 
SB366791, it was important to compare the effects of this novel compound with 
capsazepine. Furthermore, preliminary in vitro studies were necessary prior to using 
this compound in vivo in the guinea-pig. Therefore, the next experiments aimed to 
determine and compare the antagonist affinity of SB366791 and capsazepine on 
CAPS-induced contraction of the isolated guinea-pig trachea. Additionally, the effect 
of SB366791 on tussive stimuli-induced depolarisation of the vagus nerve was 
profiled. Furthermore, it was important to perform PK analysis to determine the 
optimal compound exposure parameters, as the effects on other species may not be 
representative of the profile of peak plasma concentration in the guinea-pig. The PK 
analysis would also provide the means to make a suitable judgement of the optimal 
time to dose the compound prior to exposure to tussive agent. Furthermore, the 
formulation of the compound was modified in order to optimise the exposure level 
and therefore the efficacy of the compound. 
 
Assessment of the functional pharmacology of capsazepine and SB366791 in a 
guinea-pig in vitro preparation showed that both of these agents are competitive 
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antagonists at the TRPV1 receptor as the maximal response to CAPS-induced 
contraction of guinea-pig trachea was not significantly reduced. Furthermore, 
SB366791 has greater affinity for TRPV1 than capsazepine. This relative increase in 
potency is also apparent by examining the results utilising the in vitro isolated vagus 
nerve preparation, as SB366791 acts in a similar manner to capsazepine but at 10-fold 
lower concentrations to elicit the same effects. Importantly, studies utilising human 
vagus nerve were performed, which showed that SB366791 completely inhibits the 
CAPS-induced depolarisation. This finding confirms the observations seen with 
guinea-pig vagus nerve and suggests that TRPV1 antagonists may have clinical 
relevance in the treatment of cough in man. With the intention of optimising exposure 
following compound administration, PK analysis was performed to measure plasma 
concentrations following administration by the i.p. route. Based on the results from 
the PK analysis, SB366791 was dosed 15 minutes prior to the cough experiment. 
Treatment with SB366791 did not significantly inhibit or modulate the CAPS-induced 
cough or airflow obstruction at any of the concentrations tested, which was an 
unexpected result, considering the body of evidence in favour of a positive outcome. 
Analysis of the plasma concentrations of SB366791 achieved during the cough 
experiment shows that the mean concentrations of compound detected in the plasma 
were dose-related and that ample compound exposure was achieved derived from 
required levels extrapolated from previous in vitro studies. Therefore, the reason for 
the apparent lack of effect of SB366791 on CAPS-induced coughs is unknown. The 
preliminary in vitro results indicate that the compound is capable of completely 
abolishing the depolarisation induced by CAPS both in the guinea-pig and human 
vagus nerve. Even though there was an abundance of SB366791 in the blood, this is 
not representative of the concentrations in the lung or at the sensory nerve endings, 
which raises the possibility that there may have been insufficient compound exposure 
in the target tissue or that the concentrations achieved were not optimal to achieve 
functional effects. In addition, the efficacy of SB366791 may be affected by the 
extent to which it binds to proteins within the blood plasma; therefore a low efficacy 
may be indicative of a high level of plasma-protein binding. Local delivery of the 
antagonist via aerosol may provide a more suitable route of administration and 
provide pre-clinical support for the use of TRPV1 antagonists in the treatment of 
cough. However, the studies described in the literature show that cough in the 
conscious guinea-pig has effectively been inhibited following i.p. treatment with 
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TRPV1 antagonists such as capsazepine, IRTX, JNJ17203212 and BCTC, albeit 
cough is not completely abolished. In fact, there is no evidence to suggest that a 
complete blockade of cough in vivo has been achieved; rather the number of coughs 
has been significantly reduced by 50-80%. Furthermore, Lewis et al document the 
lack of antitussive activity of capsazepine or IRTX on conscious cough in the guinea-
pig (Lewis et al., 2007). These findings may challenge the dogma that exposure to 
aerosolised CAPS induces cough in the conscious guinea-pig exclusively via the 
activation of TRPV1. Determing whether there are TRPV1-independent mechanisms 
associated with CAPS-induced cough would require further investigation. These 
findings also highlight the challenges when utilising the results obtained in vitro to 
perform experiments in an in vivo setting. These results may indicate that the isolated 
vagus nerve preparation is not representative of the cough response in vivo, or that 
further studies are required to translate the in vitro results to significant effects on the 
in vivo conscious cough response. Proposed experiments for future research will be 
described in chapter 7.  
 
In conclusion, the results in this chapter have shown that the CS model of airway 
inflammation and enhanced cough is associated with an increased expression of 
TRPV1 in the vagal sensory nodose and jugular ganglion. The utilisation of two 
TRPV1 antagonists has shown that the sensory nerve activation of the isolated vagus 
nerve is sensitive to inhibition. Furthermore, TRPV1 antagonism appears to attenuate 
sensory nerve activation of distinct tussive stimuli to varying degrees in vagus taken 
from naïve guinea-pigs, indicating distinct yet overlapping mechanisms of cough 
provocation.  In addition, vagus nerve taken from guinea-pigs previously exposed to 
CS, are equally sensitive to TRPV1 antagonism compared to naïve or control groups. 
Importantly, incubation of the human vagus nerve with a TRPV1 antagonist 
completely inhibits CAPS-induced depolarisation, which provides translational 
evidence in support of the use of TRPV1 antagonists to treat cough in man. Following 
a detailed in vitro assessment and optimisation of the PK parameters, treatment of 
guinea-pigs with SB366791 did not inhibit CAPS-induced cough in vivo. Therefore, 
further studies are required to expand upon the current findings and further examine 
the role of TRPV1 in the cough reflex.   
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CHAPTER 7 
 
 
 
 
 
 
SUMMARY AND FUTURE DIRECTIONS 
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7.1. Summary and future directions 
 
Animal models are vital in order to expand upon the current knowledge of disease 
pathology and to aid in the identification of novel therapies. Cough is the most 
common cause for patients to seek consultation from a doctor (Schappert and Burt, 
2006) and there is the need to develop novel, effective and safe antitussive therapies 
as current treatments have been shown to possess little clinical efficacy and are often 
associated with side-effects (Schroeder and Fahey, 2002; Smith et al., 2006). Animal 
models of cough are important experimental tools, which are necessary to aid 
understanding in this complex field of study. Furthermore, the utilisation of in vivo 
models is a crucial phase in scientific research, by linking in vitro experiments and 
clinical studies in man. The outcome of experiments using animal models may not 
always be predictive of the outcome in human disease, nevertheless the information 
gained from animal models is critical in the pursuit of novel therapies. Furthermore, 
modelling a complex system such as the reflex production of a cough would not be 
possible with cell-based assays. There is currently an abundance of information 
known about the cough reflex; however the mechanisms underlying the production of 
a cough are not fully understood. In addition, modulation of the cough reflex pathway 
in disease can lead to sensitisation of the cough reflex, which is a field of research that 
demands further attention. Therefore, elucidating the mechanisms underlying 
enhanced cough could lead to the identification of novel therapies for the treatment of 
chronic cough in man. 
 
In chapter 3, a conscious guinea-pig cough model, using different tussive stimuli, 
which are known to elicit cough in man (CA, CAPS, bradykinin, PGE2 and hypertonic 
saline), was established. The use of aerosolised tussive stimuli for the in vivo studies 
was essential as the cough provoking agent can be delivered directly to the lungs and 
the experimental approach mimics the techniques utilised in the clinic (Laude et al., 
1993). Careful observation of the type of response evoked by the different tussive 
agents has identified the distinct patterns of response when comparing the effect of 
exposure to the aerosolised stimuli. The response can differ according to the numbers 
of coughs evoked, the type of cough produced, the associated sound and posture of 
the animal and the level of airflow obstruction. It would be interesting to perform 
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more detailed analysis of the data generated in the concentration response studies by 
analysing the number of coughs within distinct time periods; i.e in the first or second 
10 minutes of the recording period. Furthermore, the data could be further analysed 
by focusing on whether the production of cough occurs independently or 
simultaneously to the changes in airflow obstruction. These findings emphasise the 
intricacy of modelling and understanding the mechanisms underlying the production 
of a cough in an experimental setting. Although there are different types of cough 
response, generated from different causes, the link between them is the stimulation of 
airway sensory nerves, activating the cough reflex. However, the specific mechanisms 
by which these tussive stimuli initiate cough requires further investigation. In 
addition, the tussive stimuli BK and PGE2 are endogenously produced, therefore may 
present a more clinically relevant and exciting direction for further investigation. To 
this end, it would be interesting to perform further analyses to decipher the receptors, 
located on the sensory nerve afferents, which are activated by these agents to initiate 
cough. This could be achieved using specific agonists and antagonists (for example 
PGE2 and the use of specific prostanoid receptor antagonists) to assess the impact on 
sensory nerve activation and the reflex induction of a cough response. The recognition 
of specific receptors involved in the cough pathway could potentially lead to the 
identification of novel targets aimed at inhibiting cough. Furthermore, CA and CAPS 
are two tussive stimuli which are routinely used in the clinic to determine cough 
sensitivity between healthy subjects and patients with disease, as well as determining 
the effectiveness of antitussive treatments on the induced cough response. Therefore, 
it would also be of interest to characterise the effect of other tussive stimuli (BK, 
PGE2 and hypertonic saline) during clinical studies.  
 
The work in chapter 3 also examined the importance of experimental design when 
performing conscious cough studies. The results suggest that pre-exposure of guinea-
pigs to CA may inhibit the cough response induced by CAPS in successive weeks; 
therefore in order to avoid any possible skewing of the data, ranking the guinea-pigs 
according to CA-induced cough response was not performed in subsequent 
experiments. Interestingly, the results from this study also suggest that CA and CAPS 
may initiate cough via distinct mechanisms.  Inhibition of the cough reflex did not 
occur when investigating the effect of repeated weekly exposures of guinea-pigs to 
CA, whereas exposure of guinea-pigs to CAPS results in a complete block of the 
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CAPS-induced cough response in the following week. These are intriguing results as 
evidence in the literature suggests that both CA and CAPS can act via TRPV1 to 
initiate cough (Lalloo et al., 1995; Trevisani et al., 2004). Furthermore, the results in 
chapter 6 show that both CAPS and low pH-induced sensory nerve activation of the 
guinea-pig isolated vagus nerve are inhibited by TRPV1 antagonists, albeit to varying 
degrees. Therefore, perhaps CA and CAPS induce cough via distinct yet overlapping 
mechanisms. Further studies could be performed to confirm this initial observation 
and to obtain samples for analyses of protein and gene expression in order to 
understand the underlying mechanisms. This could be achieved using a similar 
method as described by Watanabe et al, who examined the distribution of TRPV1, 
PGP9.5, SP and CGRP in the guinea-pig airways by immunohistochemistry. The 
authors found that animals chronically exposed to CAPS demonstrated a complete 
loss of TRPV1 positive axons and also a loss of bronchoconstriction induced by 
subsequent CAPS exposure (Watanabe et al., 2006). 
 
In addition to establishing in vivo models of conscious cough, an in vitro model of 
sensory nerve activation was characterised, by investigating the effect of tussive 
stimuli on the depolarisation of the guinea-pig isolated vagus nerve preparation. In 
vitro assays are often employed experimentally in the early stages of the drug 
screening process as they can be utilised for pharmacological proof of concept studies 
prior to evaluating the effects of a potential therapy in the whole animal. However, the 
results obtained in vitro should always be interpreted with some caution as the effects 
may not translate entirely to the effect of a drug in an in vivo model, which 
encompasses many different cell types and is a far more complex system. 
Nevertheless, the isolated vagus nerve preparation is a well-established and useful 
model in the study of sensory nerve activation, as previous work has shown that 
potential antitussive therapies inhibit the depolarisation of the isolated vagus nerve 
and comparably inhibit the number of coughs in the conscious guinea-pig (Patel et al., 
2003; Usmani et al., 2005). Furthermore, the guinea-pig vagus nerve responds 
comparably to the isolated human vagus nerve (Belvisi et al., 1998). Despite this, it 
would be advantageous to develop another in vitro model, which can be used 
specifically to examine distinct airway afferent subtypes in the guinea-pig. Use of 
single fibre preparations will allow evaluation of defined receptive fields by 
determining conduction velocities, location, and chemical or mechanical sensitivity of 
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single fibres (Fox et al., 1993; Fox et al., 1995b). In combination with the established 
in vivo models of cough and ‘enhanced cough’, utilisation of these preparations would 
allow detailed assessment of the functional physiology and pharmacology of single 
sensory nerve afferents.  
 
Most research in the field of cough has focussed on stimuli that activate airway 
sensory nerves to initiate cough, whereas there are fewer studies investigating 
sensitisation of the cough reflex. In addition, most of the information on the cough 
reflex comes from animal models of cough in which there is no airway inflammatory 
disease modelling. Therefore, the effect of pathological changes in the airways in 
modulating the cough reflex response is unknown and the pharmacological changes 
that are occurring in exacerbated cough are not well understood. The in vivo models 
of cough established in chapter 3, utilised different and pharmacologically distinct 
tussive stimuli. The development of these models provided the basis for selecting 
appropriate sub-maximal concentrations of tussive agents and optimal experimental 
parameters required for further research into the mechanisms underlying enhanced 
cough associated with airway inflammatory disease. The work in chapter 4 
demonstrated that exposure to CS, which is a disease relevant stimulus, results in an 
exacerbation of the CA and CAPS-induced cough responses in the conscious state. 
Further studies to assess the effect of CS on different concentrations of CA or CAPS 
may have provided conclusive evidence as to whether CS shifts the concentration 
response curve. Interestingly, patients with airway inflammatory diseases such as 
asthma and COPD demonstrate an increased cough sensitivity following inhalation of 
CAPS or CA (Fujimura et al., 1994; Wong and Morice, 1999; Doherty et al., 2000). 
This suggests that the guinea-pig CS model is a useful pre-clinical tool that can be 
utilised for the identification of efficacious and novel antitussive therapies as well as 
experimentally investigating mechanisms driving enhanced sensory nerve function. 
Interestingly, the utilisation of different tussive stimuli resulted in distinct patterns of 
response following exposure to CS. In particular, exposure to CS inhibited the PGE2-
induced cough response. The specific prostanoid receptor responsible for the PGE2-
induced cough has not yet been identified; therefore the mechanisms surrounding the 
inhibition of PGE2–induced cough following exposure to CS are unknown. It would 
be key to investigate if the prostanoid receptor(s) or signalling pathway(s) that are 
responsible for the PGE2-induced cough are down-regulated or inactivated following 
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CS exposure. Additionally, it would be worth pursuing whether the threshold for 
activation of the cough reflex is increased following CS exposure, requiring a greater 
concentration of PGE2 in order to evoke the reflex response. Based on this interesting 
preliminary observation, this field of research requires further investigation. 
Therefore, future work could focus on analysis and comparison of protein expression 
in target tissues such as sensory nerve ganglion, lung and vagus nerve, taken from CS 
or air exposed animals. This could be achieved using immunohistochemistry targeted 
at TRPV1 as well as SP, NKA, B2, prostanoid receptors, ASICs, ‘cough receptors’ 
and any other proteins of interest, which are believed to facilitate the modulation of 
the cough reflex following exposure to CS. The work in chapter 6 makes progress in 
this field of investigation by developing a technique for immunohistochemical 
detection of protein within the guinea-pig vagal sensory nerve ganglion, as described 
below.  
 
During the in vivo cough studies described in this thesis, every effort was made to 
dissect tissues and store them appropriately for future analysis in order to gain an 
abundance of information from these animal experiments. As well as keeping tissues 
for histological assessment and cytology, samples were flash frozen for analysis of 
gene expression.  Currently, our group utilises Taqman chemistry to measure gene 
expression by real time polymerase chain reaction (Birrell et al., 2006; Birrell et al., 
2007). However, this technique has only been performed on rat, mouse and human 
samples and cells. Therefore, it would be advantageous to translate and develop these 
techniques for the analysis of guinea-pig samples. Determination of gene expression 
in the guinea-pig is a more challenging task as the complete sequence for the guinea-
pig genome is not publicly available. Therefore, in order to amplify and detect 
specific products, the primers and probes for gene targets of interest need to be 
custom-designed. Using this technique will provide an interesting end-point to 
compare gene expression levels between different treatment groups of the cough 
studies. Furthermore, once the methodology is established, this technique will provide 
a higher throughput means by which to assess targets of interest, which can 
accompany the data generated from slower throughput experiments such as protein 
determination by immunohistochemistry. Providing suitable primers and probes can 
be designed, the gene expression profiling could parallel the targets explored for 
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protein expression, such as TRPV1, prostanoid receptors, Trk receptors, ‘cough 
receptors’ and any others of interest in the future. 
 
Investigating the mechanisms of cough reflex sensitisation is an important field of 
research, which requires wider attention. Determining the mechanisms underlying 
enhanced sensory nerve function could lead to a greater understanding of the 
pathophysiology of chronic cough and the development of efficacious antitussive 
therapies. The work in chapter 5 aimed to investigate whether the production of 
endogenous neurotrophins was involved in the mechanisms underlying enhanced 
sensory nerve function and exacerbated cough. The in vivo cough studies aimed to 
mimic the enhanced cough reflex response seen following exposure to CS, by treating 
guinea-pigs with aerosolised NGF or BDNF, once a day for 8 days. The results in 
chapter 5 provide evidence that treatment with neurotrophins can modulate sensory 
nerve function and the cough reflex and the most convincing data comes from the use 
of BDNF, which caused a significant increase in CAPS-induced coughs compared to 
controls. The specificity and mechanisms underlying the modulation of sensory nerve 
function by BDNF could be confirmed with specific Trk receptor decoys or inhibitors 
(de Vries et al, 2006; Nassenstein et al, 2006). However, whether NGF and/or BDNF 
are driving the sensitisation of the cough reflex following CS exposure, remains to be 
established. It appears that the modulation of sensory nerve activation of the isolated 
vagus nerve, in response to CS exposure is different compared to the responses seen 
following NGF or BDNF exposure. CS exposure resulted in an increased response to 
CA and CAPS, inhibition of PGE2 and no change in BK or hypertonic saline-induced 
depolarisation, whereas, exposure to NGF or BDNF resulted in an increase in CAPS, 
BK and PGE2-induced depolarisation, but had no effect on CA or hypertonic saline-
induced depolarisation. Examination and comparison of the gene and protein 
expression profiles in tissues taken from these two models may elucidate these 
distinctions.  
 
There are a number of pharmacological methods which could be utilised to investigate 
whether NGF and/or BDNF are involved in the sensitisation of the cough reflex 
following exposure to CS. Prior to performing the studies described in chapter 5, it 
would have been of particular benefit to determine if treatment of guinea-pigs with 
anti-NGF or anti-BDNF antibodies attenuated the increase in cough numbers 
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following exposure to CS. These agents, which have been utilised previously by other 
groups, demonstrate effective inhibition of airway hyper-reactivity in mouse and 
guinea-pig models of allergic airway inflammation (Braun et al., 1998; Braun et al., 
2004; de Vries et al., 2002). In addition, it would be of interest to assess the functional 
relevance of Trk receptors in the guinea-pig model of CS enhanced cough and airway 
inflammation. Nassenstein et al utilised a pan Trk receptor decoy to show that Trk 
receptor signalling plays an important role in a murine model of allergic asthma 
(Nassenstein et al., 2006). Therefore, the functional effects of inhibiting neurotrophins 
or their receptors could be investigated in vivo and may be further analysed by 
comparing different dosing regimens such as therapeutic versus prophylactic 
treatment.  
 
Providing suitable tools can be identified for analysis of guinea-pig samples, 
experiments could be performed to determine protein expression in the BAL and lung 
homogenate supernatant for targets of interest.  Experiments in chapter 5, to 
determine the protein expression of NGF and BDNF, measured by ELISA, did not 
result in detectable levels of protein in the BAL or lung samples taken from CS or air 
exposed guinea-pigs. As described previously, the reason behind the lack of detection 
of NGF or BDNF using this technique is unknown, as evidence suggests that this 
technique has been utilised successfully to measure NGF in the BAL taken from 
guinea-pigs (de Vries et al., 2006). It is possible that the cross-reactivity of this 
ELISA kit is not suitable for use with guinea-pig samples, or that the sampling would 
need to occur at a different time-point for the optimal expression and detection of 
neurotrophins. Therefore, it would be beneficial to develop and utilise other 
experimental techniques to detect and quantify NGF and/or BDNF expression in 
tissues taken from CS exposed animals. These could include immunohistochemistry 
for protein determination and real-time polymerase chain reaction for quantification 
of gene expression. By using histological sections taken from the lungs, vagus nerve 
and sensory nerve ganglion, immunohistochemistry would not only determine 
changes in expression but also specific localisation within the target tissue.  
 
As described previously, there is an interest in the role of TRPV1 in the cough reflex 
and TRPV1 receptors can be activated by a number of exogenous and endogenous 
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ligands, which are known to induce cough in animals and in man. Furthermore, there 
is increasing evidence that TRPV1 plays a role in the sensitisation of the cough reflex 
and in the mechanisms driving enhanced sensory nerve function and chronic cough. 
Following development and optimisation of an immunohistochemical technique, the 
results in chapter 6 show that there is a higher expression of TRPV1 in the nodose and 
jugular ganglion taken from CS exposed guinea-pigs compared to controls. It would 
be beneficial to refine the technique by initially injecting the guinea-pig airways with 
a neuronal tracer such as fast blue, prior to dissection of the ganglion (Kummer et al., 
1992; Ricco et al., 1996; Dinh et al., 2005). Additionally, analysis of the cell bodies 
could be distinguished according to size, thus differentiating the positively stained 
markers as either small or large diameter neurons. This would allow a more specific 
determination of the site of action and distinct sensory nerve afferent sub-types that 
are presenting with an upregulation of a target receptor such as TRPV1. Future studies 
will focus on confirming these findings by investigating the expression of TRPV1 in 
the lung and also in the vagal nerve tissue. Furthermore, if the immunohistochemical 
technique was optimised for detection of multiple targets, the co-localisation of 
TRPV1 receptors could be analysed alongside other proteins, such as Trk receptors. 
This could be achieved by substituting the use of a chromagen such as DAB for a 
fluorochrome, which could provide a sensitive detection of multiple targets in one 
section of tissue (Nassenstein et al., 2006; Dinh et al., 2004b). 
 
There is evidence in the literature that TRPV1 antagonists can functionally inhibit 
sensory nerve activation and the cough reflex in guinea-pigs (Lalloo et al., 1995; 
Trevisani et al., 2004). Therefore, the work in chapter 6 investigated the potential 
antitussive activity of TRPV1 antagonists on the guinea-pig cough reflex. Having 
established both models of tussive stimuli-induced cough as well as CS models of 
enhanced cough, future studies could profile and compare the effects of novel 
antitussive therapies in the normal and hyper-responsive state. This would determine 
whether the sensitised cough reflex is equally responsive to the potential antitussive 
activity of novel therapies. Preliminary studies to address this are described in chapter 
6, which showed that even though CAPS-induced depolarisation was significantly 
increased following CS exposures, the sensory nerve activation is potentially still 
sensitive to TRPV1 inhibition as the CAPS-induced response was blocked using 
capsazepine in vagus nerves from naïve, air exposed or CS exposed guinea-pigs. 
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Further pharmacological modulation using capsazepine and SB366791 showed that 
the sensory nerve activation of the guinea-pig and human isolated vagus nerve was 
sensitive to inhibition. Interestingly, the work in chapter 6 also showed that TRPV1 
may play a role in bradykinin and PGE2–induced sensory nerve activation, as the 
response to these tussive stimuli was inhibited by TRPV1 antagonists. Future work 
should focus on understanding the mechanisms linking bradykinin and PGE2–induced 
cough and the activation of TRPV1. 
 
Assessment of the functional pharmacology of capsazepine and SB366791 in a 
guinea-pig in vitro preparation showed that SB366791 has a greater affinity for 
TRPV1 than capsazepine. Following a detailed in vitro assessment and optimisation 
of the PK parameters, treatment of guinea-pigs with SB366791 did not inhibit CAPS-
induced cough in vivo, which was an unexpected result. This demonstrates the 
potential problems when translating the results obtained in vitro into experiments 
performed in vivo, as SB366791 completely abolished the CAPS-induced 
depolarisation with the simplistic in vitro vagus nerve preparation but these effects did 
not translate into positive effects on the in vivo conscious cough response. Analysis of 
concentrations of SB366791 from blood samples taken during the cough study 
showed that there was a dose-related detection of compound in the blood. As 
described in chapter 6, future studies will pursue an alternative route of 
administration, specifically aerosol delivery of SB366791, so that the compound is 
inhaled directly into the lungs. This should address whether the lack of functional 
effects in vivo were due to PK accessibility problems or insufficient compound 
exposure at the target tissue. In addition, it may be beneficial to compare the effects of 
another potent, well-characterised and commercially available antagonist, such as 
IRTX, on the sensory nerve activation and cough response induced by CAPS and the 
other tussive stimuli.   
 
In summary, the work in this thesis developed and characterised guinea-pig in vivo 
and in vitro models of cough and sensory nerve activation. Exposure to CS resulted in 
airway inflammation and altered the activity of the cough reflex in guinea-pigs, by 
modulating the responsiveness of the afferent fibres that mediate cough. Research 
focussing on understanding the mechanisms driving enhanced cough showed that the 
neurotrophins, NGF and BDNF, may play a role in sensitisation of the cough reflex. 
 218
Further characterisation of the CS model demonstrated an augmented expression of 
TRPV1 in the vagal sensory nerve ganglion. Sensory nerve activation of the isolated 
vagus nerve was pharmacologically modulated using TRPV1 antagonists and further 
work is required to establish the effects on the conscious cough response. Further 
insight into the neural mechanisms associated with these findings may help to guide 
the development of novel pharmacological approaches in the treatment of cough. 
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Appendix І 
 
Chemicals and reagents 
Below is a list of all of the reagents and vehicle or diluents which were used in the 
work described in this thesis. 
 
Drug/Reagent Source Vehicle or Diluent 
(where applicable) 
10% NBF Surgipath Europe Ltd - 
(2-hydroxypropyl)-β-
cyclodextrin 
Sigma-Aldrich - 
2R4F Research cigarettes University of Kentucky - 
37% Formaldehyde Sigma-Aldrich PBS 
5-Fluoro-2'-deoxyuridine Sigma-Aldrich - 
β-NGF human, 
recombinant  
Calbiochem 0.1% BSA in PBS (in 
vitro) 
β-NGF human, 
recombinant 
Genentech 20mM sodium acetate in 
saline with 1.8% ethanol 
(in vitro & in vivo) 
Acetylcholine chloride Sigma-Aldrich - 
Avidin/Biotin blocking kit Vector Laboratories - 
BDNF, human, 
recombinant 
Calbiochem 0.1% BSA in PBS (in 
vitro) 
BDNF, human, 
recombinant  
Novartis PBS (in vitro & in vivo) 
Bradykinin  Sigma-Aldrich 0.1% dH20 in KHS (in 
vitro) 
Sterile saline (in vivo) 
BSA powder Sigma-Aldrich - 
CA Sigma-Aldrich Sterile saline 
CaCl2 VWR - 
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CAPS  Sigma-Aldrich 0.1% DMSO in KHS (in 
vitro) 
10% ethanol in saline (in 
vivo) 
CAPS  Fluka Biochemika 1% ethanol and 1% Tween 
80 in saline (in vivo) 
Capsazepine  Sigma-Aldrich 0.1% methanol in KHS (in 
vitro) 
20% ethanol plus 20% 
Cremaphor EL in saline 
(in vivo) 
Collagenase Invitrogen - 
Cremophor EL Sigma-Aldrich - 
DAB Vector Laboratories - 
DMEM Invitrogen - 
DMSO Sigma-Aldrich - 
DNase Roche - 
Duoset ELISA (human) R&D Systems - 
Ethanol VWR - 
FCS Invitrogen - 
Glucose VWR - 
Hematoxylin Sigma-Aldrich - 
HBSS Invitrogen - 
H2SO4 VWR dH20 
Hydrogen peroxide Sigma-Aldrich - 
IMS Fisher Scientific - 
Indomethacin Sigma-Aldrich - 
KCl VWR - 
Lectin from Ulex 
europaeus, FITC 
conjugated 
Sigma-Aldrich - 
Methanol VWR - 
MgSO4 VWR - 
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Monoclonal Anti-
Neurofilament 200 
antibody produced in 
mouse 
Sigma-Aldrich - 
NaCl VWR - 
NaHCO3 VWR - 
NaH2PO4 VWR - 
NaH2PO4.2H2O VWR - 
Na2HPO4 VWR - 
NaN3 Sigma-Aldrich - 
Normal goat serum Invitrogen - 
PBS Sigma-Aldrich - 
Peroxidase conjugated 
anti-FITC antibody 
Dako - 
Penicillin-Streptomycin-
Glutamine (100x) 
Invitrogen - 
PGE2  Sigma-Aldrich 0.1% methanol in KHS (in 
vitro) 
0.1M phosphate buffer (in 
vivo) 
Polyclonal anti-PGP9.5 
antibody produced in 
rabbit 
Abcam - 
Polyclonal anti-SP 
antibody produced in 
rabbit 
Bachem - 
Polyclonal anti-rat TRPV1 
antibody produced in 
rabbit 
GSK - 
Polyclonal goat anti-rabbit 
immunoglobulins/ 
biotinylated 
Dako - 
RPMI 1640 Invitrogen - 
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SB366791  Tocris 0.1% methanol in KHS (in 
vitro) 
20% ethanol plus 20% 
Cremaphor EL in saline 
(in vivo) or DMSO plus 
Cremaphor EL in 20% 
aqueous ß-cyclodextrin 
(1:4:15 v/v) (in vivo) 
Sterile saline Fresenius Kabi - 
Sodium acetate VWR - 
Sodium citrate Sigma-Aldrich - 
Sodium pentobarbitone Merial Animal Health - 
Streptavidin-HRP Dako - 
Sucrose Sigma-Aldrich PBS 
TBS Sigma-Aldrich - 
TMB substrate BD Biosciences - 
Triton X-100 Amersham Pharmacia - 
Trypsin Sigma-Aldrich - 
Tween 20 Sigma-Aldrich - 
Tween 80 Sigma-Aldrich - 
Uridine Sigma-Aldrich - 
Wrights Giemsa stain Sigma-Aldrich - 
Xylene VWR - 
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Appendix ІІ 
 
Below is a list of figures in the thesis and the establishment (Novartis and/or NHLI) at 
which the studies were performed. 
 
Figure Establishment at which study was 
performed (Novartis and/or NHLI) 
Figure 3.1 Novartis 
Figure 3.2 NHLI 
Figure 3.3 NHLI 
Figure 3.4 Novartis 
Figure 3.5 Novartis 
Figure 3.6 Novartis 
Figure 3.7 Novartis 
Figure 3.8 NHLI 
Figure 3.9 NHLI 
Figure 4.2 Novartis 
Figure 4.3 Novartis 
Figure 4.4 Novartis 
Figure 4.5 Novartis 
Figure 4.6 Novartis 
Figure 4.7 Novartis 
Figure 4.8 Novartis 
Figure 4.9 Novartis 
Figure 4.10 Novartis 
Figure 4.11 Novartis 
Figure 4.12 Novartis 
Figure 4.13 Novartis 
Figure 4.14 Novartis and NHLI 
Figure 5.1 NHLI 
Figure 5.2 NHLI 
Figure 5.3 NHLI 
Figure 5.4 NHLI 
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Figure 5.5 NHLI 
Figure 5.6 NHLI 
Figure 5.7 NHLI 
Figure 5.8 NHLI 
Figure 5.9 NHLI 
Figure 5.10 NHLI 
Figure 5.11 NHLI 
Figure 6.1 NHLI 
Figure 6.2 Novartis and NHLI 
Figure 6.3 Novartis and NHLI 
Figure 6.4 NHLI 
Figure 6.5 Novartis and NHLI 
Figure 6.6 NHLI 
Figure 6.7 NHLI 
Figure 6.8 NHLI 
Figure 6.9 NHLI 
Figure 6.10 Novartis 
Figure 6.11 Novartis 
Figure 6.12 Novartis 
Figure 6.13 Novartis 
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